Office of Directorate General of Foreign Trade
New Delhi -0

Para 4.7 Decision

Minutes of the Norms Committee – 3 Meeting No. 2/82-ALC4/2020 dated 10.07.2020 (actually held on 10.07.2020 and 24.07.2020) for considering the cases/issues under Duty Exemption Scheme (Chapter-4) of Foreign Trade Policy, 2015-20 pertaining to Chemical and Allied products falling under Chapter 29 and 30, held under the Chairmanship of Shri Satyan Sharda, Addl. DGFT in Room No.11, Udyog Bhawan, New Delhi.

Following members were present in the Meeting:

(i) Shri Ajay Kumar, Assistant Director
(ii) Consultant, Technical Expert Pharmaceuticals
(iii) Consultant, Technical Expert Chemicals

The committee went through the minutes of earlier meeting No. 1/82-ALC4/2020 dated 17.04.2020 (actually held on 06.05.2020)

ONLINE CASES

1	**Case No.:820/15/82-ALC4/2018**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02277/AM19/	RLA File :09/24/040/00508/AM19/	Lic.No/Date:0910067061 16.01.2019	
	Decision: Deferred for comments of TE.			

2	**Case No.:1026/15/82-ALC4/2018**	Party Name:ANLON HEALTHCARE PRIVATELIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02483/AM19/	RLA File :24/24/040/00049/AM19/	Lic.No/Date:2410042628 16.01.2019	
	Decision: Deferred for comments of TE.			

3	**Case No.:829/15/82-ALC4/2018**	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02286/AM19/	RLA File :09/24/040/00499/AM19/	Lic.No/Date:0910067071 18.01.2019	
	Decision: Deferred for comments of TE.			

4	**Case No.:830/15/82-ALC4/2018**	Party Name:R CHEM (SOMANAHALLI) PVT.LTD,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02287/AM19/	RLA File :09/24/040/00516/AM19/	Lic.No/Date:0910067074 18.01.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. **13/82-ALC4/2019 dated 31.01.2020**, followed by Reminder on **20.03.2020**: **(i) Complete chemical name of the Export Product.** **(ii) Complete technical details as per Appendix 4E.** In view of above, the Committee decided to issue **<u>Final Reminder</u>** to firm to furnish its reply, failing which the case will be rejected.			

5	**Case No.:837/15/82-ALC4/2018**	Party Name:DANOPHARM CHEMICALS PRIVATE LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02294/AM19/	RLA File :03/94/040/00886/AM19/	Lic.No/Date:0310826539 22.01.2019	
	Decision: Deferred for comments of TE.			

6	**Case No.:842/15/82-ALC4/2018**	Party Name:S.M. HERBALS PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02299/AM19/	RLA File :05/24/040/00602/AM19/	Lic.No/Date:0510409465 24.01.2019	
	Decision: Deferred for comments of TE.			

7	**Case No.:845/15/82-ALC4/2018**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/02302/AM19/	RLA File :03/94/040/00925/AM19/	Lic.No/Date:0310826640 25.01.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	Bupivacaine with Adrenaline Injection 10 x 20ml Ampoules. Each ml contains Bupivacaine Hydrochloride 5.3175 mg. Net content - 8.811 Kgs.	1 Number Ampoule	1	Bupivacaine Hydrochloride	111.67 mg
2	Bupivacaine Hydrochloride and Dextrose Injection 10x4ml. Each ml contains Bupivacaine Hydrochloride 5.3175 mg. Net content - 8.811 Kgs.	1 Number Ampoule	1	Bupivacaine Hydrochloride	23.40 mg

RA concerned may take further necessary action as per above decision of NC.

Case No.:848/15/82-ALC4/2018	Party Name:VIVIMED LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
HQ File :01/82/050/02305/AM19/	RLA File :09/24/040/00505/AM19/	Lic.No/Date:0910067112 28.01.2019	

8

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No	Export Product	Qty.	Sl. No.	Import items	Qty.
1	Amlodipine Besylate USP - 2.5 Mg	90000000 Numbers	1	Amlodipine Besylate	312.3 kg
			2	Anhydrous dibasic calcium Phospahte (A-TAB)	1080.0 kg
			3	Microcrystalline Cellulose	7202.7 kg
			4	Sodium Starch Glycolate	180.0 kg
			5	Colloidal Silicon Dioxide(Aerosil 200)	45.00 kg
			6	Stearic Acid (Hystrene 5016 FG)	135.00 kg
			7	Magnesium Stearate	45.00 kg
2	Amlodipine Besylate USP – 5 Mg	180000000 Numbers	1	Amlodipine Besylate	1167.540 kg
			2	Anhydrous dibasic calcium Phospahte (A-TAB)	4039.200 kg
			3	Microcrystalline Cellulose	26938.560 kg
			4	Sodium Starch Glycolate	673.200 kg
			5	Colloidal Silicon Dioxide(Aerosil 200)	168.300 kg
			6	Stearic Acid (Hystrene 5016 FG)	504.900 kg
			7	Magnesium Stearate	168.300 kg
3	Amlodipine Besylate USP – 10 Mg	135000000 Numbers	1	Amlodipine Besylate	1167.540 kg
			2	Anhydrous dibasic calcium Phospahte (A-TAB)	4039.200 kg
			3	Microcrystalline Cellulose	26938.560 kg
			4	Sodium Starch Glycolate	673.200 kg
			5	Colloidal Silicon Dioxide(Aerosil 200)	168.300 kg
			6	Stearic Acid (Hystrene 5016 FG)	504.900 kg
			7	Magnesium Stearate	168.300 kg

RA concerned may take further necessary action as per above decision of NC.

9	**Case No.:851/15/82-ALC4/2018**	Party Name:SI GROUP - INDIA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02308/AM19/	RLA File :03/95/040/01108/AM19/	Lic.No/Date:0310826724 30.01.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. **9/82-ALC4/2019 dated 18.10.2019**, followed by Reminder on **20.03.2020**: **(i) Complete chemical reaction from raw material acetone to 3,3,5TRIMETHYLCYCLOHEXANONE showing molecular weights of each component with percentage yield on molar basis at each step of the reaction.** In view of above, the Committee decided to issue **Final Reminder** to firm to furnish its reply, failing which the case will be rejected.			

10	**Case No.:853/15/82-ALC4/2018**	Party Name:ALPHAMED FORMULATIONS P LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02310/AM19/	RLA File :09/24/040/00511/AM19/	Lic.No/Date:0910067120 31.01.2019	
	Decision: Deferred for comments of TE.			

11	**Case No.:855/15/82-ALC4/2018**	Party Name:SMS LIFESCIENCES INDIA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02312/AM19/	RLA File :09/24/040/00542/AM19/	Lic.No/Date:0910067122 31.01.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm vide its e-mail dated 04.05.2020 has furnished its reply. Deferred for comments of TE.			

12	**Case No.:861/15/82-ALC4/2018**	Party Name:INNOVARE LABS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02318/AM19/	RLA File :09/24/040/00535/AM19/	Lic.No/Date:0910067125 01.02.2019	
	Decision: Deferred for comments of TE.			

13	**Case No.:863/15/82-ALC4/2018**	Party Name:JAYANT AGRO ORGANICS LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02320/AM19/	RLA File :03/94/040/00948/AM19/	Lic.No/Date:0310826798 04.02.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm vide its e-mail dated 08.11.2019 has furnished its reply. Deferred for comments of TE.			

14	**Case No.:864/15/82-ALC4/2018**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02321/AM19/	RLA File :03/94/040/00944/AM19/	Lic.No/Date:0310826799 04.02.2019	
	Decision: Deferred for comments of TE.			

15	**Case No.:873/15/82-ALC4/2018**	Party Name:CADILA HEALTHCARE LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/02330/AM19/	RLA File :08/24/040/00379/AM19/	Lic.No/Date:0810144496 05.02.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
BROMOCRIPTINE MESYLATE CAPSULES USP 5 MG (ACTIVE INGREDIENT : BROMOCRIPTINE MESYLATE USP EQUIVALENT TO 8.633 KGS OF BROMOCRIPTINE)	1 Number	1	BROMOCRIPTINE MESYLATE USP	5.855 mg / capsule

RA concerned may take further necessary action as per above decision of NC.

16	**Case No.:874/15/82-ALC4/2018**	Party Name:CADILAHEALTHCARE LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/02331/AM19/	RLA File :08/24/040/00372/AM19/	Lic.No/Date:0810144497 05.02.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.
1	DESMOPRESSIN ACETATE INJECTION USP 4MCG/ML (1ML VIAL) (ACTIVE INGREDIENT : DESMOPRESSIN ACETATE USP - NET WT. 1.826 GMS.) & (PACKING MATERIAL IN FINISHED FORM - NET NOS. 456450)	456450.000 Vials
2	DESMOPRESSIN ACETATE INJECTION USP 4MCG/ML (10ML VIAL) (ACTIVE INGREDIENT : DESMOPRESSIN ACETATE USP - NET WT. 3.842 GMS.) & (PACKING MATERIAL IN FINISHED FORM - NET NOS. 96060)	96060.000 Vials

Sl. No.	Import Items	Qty.
1	DESMOPRESSIN ACETATE USP	6.235 Gram
2	2ML CLEAR USP TYPE I TUBULAR GLASS VIALS (AS PER GENERAL NOTE FOR CHEMICAL AND ALLIED PRODUCTS POINT NO. 5, WASTAGE ALLOWED @ 5%)	Relevant as per packing policy
3	13MM RFS FLUROTEC RUBBER STOPPERS (AS PER GENERAL NOTE FOR CHEMICAL AND ALLIED PRODUCTS POINT NO. 5, WASTAGE ALLOWED @ 1%)	Relevant as per packing policy
4	10ML CLEAR USP TYPE I TUBULAR GLASS VIALS (AS PER GENERAL NOTE FOR CHEMICAL AND ALLIED PRODUCTS POINT NO. 5, WASTAGE ALLOWED @ 5%)	Relevant as per packing policy
5	20MM RFS FLUROTEC RUBBER STOPPERS (AS PER GENERAL NOTE FOR CHEMICAL AND ALLIED PRODUCTS POINT NO. 5, WASTAGE ALLOWED @ 1%)	Relevant as per packing policy

RA concerned may take further necessary action as per above decision of NC.

17	**Case No.:1027/15/82-ALC4/2018**	Party Name:ANLON HEALTHCARE PRIVATELIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02484/AM19/	RLA File :24/24/040/00053/AM19/	Lic.No/Date:2410042653 05.02.2019	

Decision: Deferred for comments of TE.

18	**Case No.:880/15/82-ALC4/2018**	Party Name:DEEPAK NOVOCHEM TECHNOLOGIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02337/AM19/	RLA File :31/83/040/00162/AM19/	Lic.No/Date:3110067309 06.02.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. **13/82-ALC4/2019 dated 31.01.2020**, followed by Reminder on **19.03.2020**: **(i) A copy of 4.07 application of subject advance authorization alongwith all technical details as per Appendix 4E.** **(ii) Exact Chemical name of the Export Product.** In view of above, the Committee decided to issue **<u>Final Reminder</u>** to firm to furnish its reply, failing which the case will be rejected.			

19	**Case No.:881/15/82-ALC4/2018**	Party Name:SHILPA MEDICARE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02338/AM19/	RLA File :07/24/040/00263/AM19/	Lic.No/Date:0710114519 07.02.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

20	**Case No.:883/15/82-ALC4/2018**	Party Name:MAHESHRAJ CHEMICALS PVT.LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02340/AM19/	RLA File :08/24/040/00374/AM19/	Lic.No/Date:0810144562 08.02.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

21	**Case No.:885/15/82-ALC4/2018**	Party Name:ORTIN LABORATORIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02342/AM19/	RLA File :09/24/040/00538/AM19/	Lic.No/Date:0910067148 08.02.2019	
	Decision: Deferred for comments of TE.			

22	**Case No.:887/15/82-ALC4/2018**	Party Name:ENAL DRUGS PVT LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/02344/AM19/	RLA File :09/24/040/00543/AM19/	Lic.No/Date:0910067153 08.02.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 48/82-ALC4/2010 , dated 01.03.2011, it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl.No.	Import items	Qty.
2-CHLORO METHYL-3-METHYL-4-(2,2,2-TRIFLUOROETHOXY) PYRIDINE HCL	1 kg	1.	2,3, Lutidine	0.79 kg
		2.	2,2,2-Trifluoro Ethanol	0.915 kg

RA concerned may take further necessary action as per above decision of NC.

23	**Case No.:891/15/82-ALC4/2018**	Party Name:GELTEC PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02348/AM19/	RLA File :03/94/040/00970/AM19/	Lic.No/Date:0310826970 11.02.2019	

Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm:

(i) Copy of revised Advance Authorization.
(ii) Net weight of empty capsules to be exported.
(iii) Composition of soft gelatine capsule.

24	**Case No.:894/15/82-ALC4/2018**	Party Name:DEEPAK PHENOLICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02351/AM19/	RLA File :34/24/040/00328/AM19/	Lic.No/Date:3410044883 12.02.2019	

Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm:

(i) Quantity and commercial value of Co-Product Phenol obtained.
(ii) Percentage yield on molar basis.

25	**Case No.:896/15/82-ALC4/2018**	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02353/AM19/	RLA File :09/24/040/00555/AM19/	Lic.No/Date:0910067168 13.02.2019	

Decision: Deferred for comments of TE.

26	**Case No.:903/15/82-ALC4/2018**	Party Name:MATRIX FINE SCIENCES PVT.LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02360/AM19/	RLA File :03/95/040/01113/AM19/	Lic.No/Date:0310827030 14.02.2019	
	Decision: Deferred for comments of TE.			

27	**Case No.:905/15/82-ALC4/2018**	Party Name:JODAS EXPOIM PVT.LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02362/AM19/	RLA File :05/23/040/00508/AM19/	Lic.No/Date:0510409675 15.02.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

28	**Case No.:906/15/82-ALC4/2018**	Party Name:JODAS EXPOIM PVT.LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02363/AM19/	RLA File :05/23/040/00507/AM19/	Lic.No/Date:0510409676 15.02.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

29	**Case No.:907/15/82-ALC4/2018**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02364/AM19/	RLA File :09/24/040/00515/AM19/	Lic.No/Date:0910067181 15.02.2019	
	Decision: Deferred for comments of TE.			

30	**Case No.:916/15/82-ALC4/2018**	Party Name:OPTIMUS DRUGS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02373/AM19/	RLA File :09/24/040/00569/AM19/	Lic.No/Date:0910067192 20.02.2019	
	Decision: Deferred for comments of TE.			

31	**Case No.:919/15/82-ALC4/2018**	Party Name:ORTIN LABORATORIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02376/AM19/	RLA File :09/24/040/00573/AM19/	Lic.No/Date:0910067198 21.02.2019	
	Decision: Deferred for comments of TE.			

32	**Case No.:922/15/82-ALC4/2018**	Party Name:GLOBE TROTTERS PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02379/AM19/	RLA File :03/94/040/01015/AM19/	Lic.No/Date:0310827201 21.02.2019	
	Decision: Deferred for comments of TE.			

33	**Case No.:924/15/82-ALC4/2018**	Party Name:INDO AMINES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02381/AM19/	RLA File :03/94/040/00984/AM19/	Lic.No/Date:0310827206 21.02.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm vide its e-mail dated 27.11.2019 has furnished its reply. Deferred for comments of TE.			

34	**Case No.:929/15/82-ALC4/2018**	Party Name:THINQ PHARMA-CRO LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02386/AM19/	RLA File :03/95/040/01186/AM19/	Lic.No/Date:0310827227 22.02.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

35	**Case No.:931/15/82-ALC4/2018**	Party Name:MEHK CHEMICALS PVT. LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Rejected**
	HQ File :01/82/050/02388/AM19/	RLA File :03/95/040/01227/AM19/	Lic.No/Date:0310827242 22.02.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. **7/82-ALC4/2019 dated 06.09.2019,** followed by Reminder on **30.10.2019** and Final Reminder on **18.03.2020**: **(i) Complete 4E with all technical details i.e chemistry, molecular weight, stoichiometric reaction and % of yield on molar basis at every stage.** Hence, the Committee decided to **reject** the case. RA concerned may take further necessary action as per above decision of NC.			

36	**Case No.:932/15/82-ALC4/2018**	Party Name:MEHK CHEMICALS PVT. LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Rejected**
	HQ File :01/82/050/02389/AM19/	RLA File :03/95/040/01209/AM19/	Lic.No/Date:0310827243 22.02.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. **7/82-ALC4/2019 dated 06.09.2019,** followed by Reminder on **30.10.2019** and Final Reminder on **18.03.2020**: **(i) Complete 4E with all technical details i.e chemistry, molecular weight, stoichiometric reaction and % of yield on molar basis at every stage.** Hence, the Committee decided to **reject** the case. RA concerned may take further necessary action as per above decision of NC.			

37	**Case No.:934/15/82-ALC4/2018**	Party Name:ASTRAL STERITECH PVT. LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02391/AM19/	RLA File :34/24/040/00356/AM19/	Lic.No/Date:3410044929 22.02.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm vide its e-mail dated 02.08.2019 has furnished its reply. Deferred for comments of TE.			

38	**Case No.:935/15/82-ALC4/2018**	Party Name:ASTRAL STERITECH PVT. LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02392/AM19/	RLA File :34/24/040/00355/AM19/	Lic.No/Date:3410044930 22.02.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm vide its e-mail dated 02.08.2019 has furnished its reply. Deferred for comments of TE.			

39	**Case No.:936/15/82-ALC4/2018**	Party Name:VISION DRUGS PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02393/AM19/	RLA File :09/24/040/00575/AM19/	Lic.No/Date:0910067217 25.02.2019	
	Decision: Deferred for comments of TE.			

40	**Case No.:1033/15/82-ALC4/2018**	Party Name:SRIAM LABS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02490/AM19/	RLA File :09/24/040/00591/AM19/	Lic.No/Date:0910067219 26.02.2019	
	Decision: Deferred for comments of TE.			

41	**Case No.:1038/15/82-ALC4/2018**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02495/AM19/	RLA File :09/24/040/00530/AM19/	Lic.No/Date:0910067224 27.02.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

42	**Case No.:1039/15/82-ALC4/2018**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02496/AM19/	RLA File :09/24/040/00491/AM19/	Lic.No/Date:0910067225 27.02.2019	
	Decision: Deferred for comments of TE.			

43

Case No.:1041/15/82-ALC4/2018	Party Name:WEXFORD LABORATORIES P LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
HQ File :01/82/050/02498/AM19/	RLA File :07/24/040/00276/AM19/	Lic.No/Date:0710114597 27.02.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	CEFADROXIL 250MG/5ML SUSPENSION 100ML BOTTLE (182.28KG)	36456.000 Number	1	CEFADROXIL MONOHYDRATE COMPACTED-USP	191.34 kg
2	CEFADROXIL 500MG CAPSULES (91.3KG)	182600.000 Number	2	CEFADROXIL MONOHYDRATE PLAIN-USP	93.126 kg

RA concerned may take further necessary action as per above decision of NC.

44	**Case No.:1045/15/82-ALC4/2018**	Party Name:SAVA HEALTHCARE LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/02502/AM19/	RLA File :31/83/040/00183/AM19/	Lic.No/Date:3110067341 01.03.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No	Export Product	Qty.	Sl. No.	Import items	Qty.
1	VETERINARY PRODUCT - SELAFORTE - SELAMECTIN SPOT ON SOLUTION 6% w/v FOR CATS 5.1 TO 7.5 KG STRENGTH 0.75 ML EACH PIPPET CONTENT SELAMECTIN EP 45 MG NET CONTENT IN RP TOTAL 18000 PIPPET	18000.000 Number	1	SELAMECTIN EP	850.5 Gram
2	VETERINARY PRODUCT - SELAFORTE - SELAMECTIN SPOT ON SOLUTION 6% w/v FOR PUPPIES AND KITTENS 2.5. KGS STRENGTH 0.25 ML EACH PIPPET CONTENT SELAMECTIN EP 15 MG NET CONTENT IN RP TOTAL 6000 PIPPET	6000.000 Number	1	SELAMECTIN EP	94.5 Gram
3	VETERINARY PRODUCT - SELAFORTE - SELAMECTIN SPOT ON SOLUTION 12% w/v FOR DOGS 2.6. TO 5 KGS STRENGTH 0.25 ML EACH PIPPET CONTENT SELAMECTIN EP 30 MG NET CONTENT IN RP TOTAL 6000 PIPPET	6000.000 Number	1	SELAMECTIN EP	189.0 Gram
4	VETERINARY PRODUCT - SELAFORTE - SELAMECTIN SPOT ON SOLUTION 12% w/v FOR DOGS 5.1 TO 10 KG STRENGTH 0.50 ML EACH PIPPET CONTENT SELAMECTIN EP 60 MG NET CONTENT IN RP TOTAL 6000 PIPPET	6000.000 Number	1	SELAMECTIN EP	378.0 Gram

RA concerned may take further necessary action as per above decision of NC.

45	**Case No.:1057/15/82-ALC4/2018**	Party Name:CIPLA LIMITED.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02514/AM19/	RLA File :03/94/040/01019/AM19/	Lic.No/Date:0310827414 01.03.2019	
	Decision: Deferred for comments of TE.			

46	**Case No.:143/1/82-ALC4/2019**	Party Name:TINA ORGANICS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02538/AM19/	RLA File :05/24/040/00695/AM19/	Lic.No/Date:0510409855 06.03.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm vide its letter dated 11.03.2020 has furnished its reply. Deferred for comments of TE.			

47

Case No.:149/1/82-ALC4/2019	Party Name:SRIAM LABS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**	
HQ File :01/82/050/02544/AM19/	RLA File :09/24/040/00604/AM19/	Lic.No/Date:0910067252 11.03.2019		

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
ABACAVIR SULFATE (ABC-III)	1 kg	1	2-Azabicylo [2.2.1] hept-5-en-3-one (Vincelactam)	2.50 kg
		2	Sodium borohydride(SBH)	0.48 kg
		3	N-(2-amino-4,6-dichloro-5-pyrimidinyl) Formamide (FADCP)	1.042 kg
		4	L(+) Tartaric acid	1.251 kg
		5	D(-)Tartaric acid	1.30 kg
		6	Cyclopropylamine	0.19 kg

RA concerned may take further necessary action as per above decision of NC.

48	**Case No.:150/1/82-ALC4/2019**	Party Name:ALKALI METALS LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Rejected**
	HQ File :01/82/050/02545/AM19/	RLA File :09/24/040/00561/AM19/	Lic.No/Date:0910067258 11.03.2019	
	Decision: The Committee considered the case as per Agenda and it was noted that the firm still has not furnished the information on following deficiencies raised by NC-3 in its Meeting No. **9/82-ALC4/2019 dated 18.10.2019,** followed by Reminder on **09.12.2019** and Final Reminder on **20.03.2020**: **(i) Complete 4E with all technical details i.e chemistry, molecular weight, stoichiometric reaction and % yield on molar basis at every stage.** Hence, the Committee decided to **reject** the case. RA concerned may take further necessary action as per above decision of NC.			

49	**Case No.:159/1/82-ALC4/2019**	Party Name:EMMENNAR PHARMA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02554/AM19/	RLA File :09/24/040/00600/AM19/	Lic.No/Date:0910067264 12.03.2019	
	Decision: Deferred for comments of TE.			

50	**Case No.:160/1/82-ALC4/2019**	Party Name:ASHISH LIFE SCIENCE PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/02555/AM19/	RLA File :03/94/040/00693/AM19/	Lic.No/Date:0310827639 12.03.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	TYLOSIN TARTRATE POWDER 100%-100GM SACHET (EACH GRAM CONTAINS TYLOSIN TARTRATE 100%) (nett content of exempt material is 20 kgs)	200.000 Number	1	TYLOSIN TARTRATE	235.088 kg
2	TYLOSIN TARTRATE POWDER 100% -500GM SACHET (EACH GRAM CONTAINS TYLOSIN TARTRATE 100%) (nett content of exempt material is 20 kgs)	40.000 Number			
3	TYLOSIN TARTRATE POWDER 100% -1KG JAR (EACH GRAM CONTAINS TYLOSIN TARTRATE 100%) (nett content of exempt material is 20 kgs)	20.000 Number			
4	TYLOSIN TARTRATE POWDER 99% -100GM SACHET (EACH GRAM CONTAINS TYLOSIN TARTRATE 99%) (nett content of exempt material is 9.90kgs)	100.000 Number			
5	TYLOSIN TARTRATE POWDER 99% -500GM SACHET (EACH GRAM CONTAINS TYLOSIN TARTRATE 99%) (nett content of exempt material is 12.375kgs)	25.000 Number			
6	TYLOSIN TARTRATE POWDER 99% -1KG JAR (EACH GRAM CONTAINS TYLOSIN TARTRATE 99%) (nett content of exempt material is 19.80kgs)	20.000 Number			
7	TYLOSIN TARTRATE POWDER 20% -100GM (EACH GRAM CONTAINS TYLOSIN TARTRATE EQ. TO TYLOSIN 20%) (nett content of exempt material is 14.50 kgs)	725.000 Number			

8	TYLOSIN TARTRATE POWDER 20% -500GM (EACH GRAM CONTAINS TYLOSIN TARTRATE EQ. TO TYLOSIN 20%) (nett content of exempt material is 5.00 kgs)	50.000 Number			
9	TYLOSIN TARTRATE POWDER 20% -1KG JAR (EACH GRAM CONTAINS TYLOSIN TARTRATE EQ. TO TYLOSIN 20%) (nett content of exempt material is 5.00 kgs)	25.000 Number			
10	TYLOSIN BOLUS 200MG (EACH BOLUS CONTAINS TYLOSIN 200MG) (nett content of exempt material is 20 kgs)	100000.000 Number			
11	TYLOSIN INJECTION 5%-30 ML (EACH ML CONTAINS TYLOSIN TARTRATE EQ. TO TYLOSIN BASE 50MG) (nett content of exempt material is 15 kgs)	10000.000 Number			
12	TYLOSIN INJECTION 5%-50 ML (EACH ML CONTAINS TYLOSIN TARTRATE EQ. TO TYLOSIN BASE 50MG) (nett content of exempt material is 25 kgs)	10000.000 Number			
13	TYLOSIN INJECTION 5%-100 ML (EACH ML CONTAINS TYLOSIN TARTRATE EQ. TO TYLOSIN BASE 50MG) (nett content of exempt material is 25kgs)	5000.000 Number			

RA concerned may take further necessary action as per above decision of NC.

51	**Case No.:161/1/82-ALC4/2019**	Party Name:OPTRIX LABORATORIES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/02556/AM19/	RLA File :09/24/040/00621/AM19/	Lic.No/Date:0910067270 13.03.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
VELPATASVIR-COPOVIDONE (1:1)	1 kg	1	Methyl [(2S)-1-[(2S,5S)-2-[9-[2-[(2S,4S)-1-[(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,11-dihydroisochromeno[4,3:6,7]naphtha[1,2-d]imidazol-2-yl]-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl)carbamate	0.555 kg

RA concerned may take further necessary action as per above decision of NC.

52	**Case No.:166/1/82-ALC4/2019**	Party Name:ENAL DRUGS PVT LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/02561/AM19/	RLA File :09/24/040/00614/AM19/	Lic.No/Date:0910067274 13.03.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
RABEPRAZOLE SODIUM BP/EP/USP/JP/CP .	1 kg	1	3-METHOXY -1-PROPANOL	0.90 kg

RA concerned may take further necessary action as per above decision of NC.

53	**Case No.:167/1/82-ALC4/2019**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02562/AM19/	RLA File :09/24/040/00612/AM19/	Lic.No/Date:0910067275 13.03.2019	
	Decision: Deferred for comments of TE.			

54	**Case No.:169/1/82-ALC4/2019**	Party Name:RUSAN PHARMA LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02564/AM19/	RLA File :03/95/040/01315/AM19/	Lic.No/Date:0310827685 13.03.2019	
	Decision: Deferred for comments of TE.			

55	**Case No.:170/1/82-ALC4/2019**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02565/AM19/	RLA File :03/94/040/01071/AM19/	Lic.No/Date:0310827686 13.03.2019	
	Decision: Deferred for comments of TE.			

56

Case No.:175/1/82-ALC4/2019	Party Name:MALLADI DRUGS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
HQ File :01/82/050/02570/AM19/	RLA File :04/24/040/00244/AM19/	Lic.No/Date:0410165324 14.03.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
(4S,5R)-(-)-4-Methyl-5-Phenyl-2-Oxazolidinone (Chiral Oxazolidinone)	1 kg	1	Propiophenone	5.98 kg
		2	Diethyl Carbonate	0.95 kg
		3	Heptane	6.82 kg
		4	Toluene	8.90 kg
		5	Iso Propyl Alcohol	11.22 kg
		6	Methyl Isobutyl Ketone	3.11 kg
		7	Acetone	3.56 kg
		8	Causticsoda Flakes	3.11 kg

RA concerned may take further necessary action as per above decision of NC.

57	**Case No.:198/1/82-ALC4/2019**	Party Name:LABORATE PHARMACEUTICAL INDIA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/02593/AM19/	RLA File :33/24/040/00020/AM19/	Lic.No/Date:3310030519 14.03.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Clindamycin Phosphate Cream /Gel 30gm (Clindamycin Phosphate 0.41gm is equivalent to 30 gm Clindamycin) 128.049 Kg consuming in 426830 Tubes/Cream 30gm each	1 Number Tube of 30 gms	1	Clindamycin Phosphate IP/BP/USP A raw material in powder form	364.14 mg

RA concerned may take further necessary action as per above decision of NC.

58	**Case No.:204/1/82-ALC4/2019**	Party Name:DEEPAK PHENOLICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02599/AM19/	RLA File :34/24/040/00353/AM19/	Lic.No/Date:3410044969 14.03.2019	

Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm:

(i) Quantity and commercial value of Co-Product Phenol obtained.
(ii) Percentage yield on molar basis.

59	**Case No.:179/1/82-ALC4/2019**	Party Name:SHANKUS PHARMACEUTICALS	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02574/AM19/	RLA File :08/24/040/00430/AM19/	Lic.No/Date:0810144782 18.03.2019	

Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm:

(i) **Complete chemistry, molecular weight as per Appendix 4E.**

60	**Case No.:181/1/82-ALC4/2019**	Party Name:DINAKARA LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02576/AM19/	RLA File :09/24/040/00571/AM19/	Lic.No/Date:0910067285 18.03.2019	

Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

61	**Case No.:133/6/82-ALC4/2019**	Party Name:ORIENTAL AROMATICS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00359/AM20/	RLA File :03/95/040/01320/AM19/	Lic.No/Date:0310827769 18.03.2019	
	Decision: The Committee considered the case as per agenda in the presence of technical experts and it was noted that the firm vide its letter dated 26.12.2019 has furnished its reply. Deferred for comments of TE.			

62	**Case No.:184/1/82-ALC4/2019**	Party Name:KLJ PLASTICIZERS LIMITED.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/02579/AM19/	RLA File :05/23/040/00562/AM19/	Lic.No/Date:0510409975 19.03.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
DI-BUTYL TEREPHTHALATE (DBTP)	1 kg	1	TEREPHTHALIC ACID	0.350 kg
		2	N-BUTANOL	0.588 kg

RA concerned may take further necessary action as per above decision of NC.

63	**Case No.:185/1/82-ALC4/2019**	Party Name:MANGALAM ORGANICS LIMITED (FORMERLY DUJODWALA	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02580/AM19/	RLA File :03/95/040/00899/AM19/	Lic.No/Date:0310827775 19.03.2019	

Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm:

(i) Manufacturing process furnished is for Pine Oil and not for Camphor.
(ii) Manufacturing details as per Appendix 4E with all technical details, quantity of By Products and their commercial value.

64	**Case No.:187/1/82-ALC4/2019**	Party Name:OPTRIX LABORATORIES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02582/AM19/	RLA File :09/24/040/00619/AM19/	Lic.No/Date:0910067297 19.03.2019	
	Decision: The Committee considered the case as per agenda and it was observed that the **applied inputs do not match with manufacturing process, chemistry, material balance and flow chart.** **In view of above, the Committee decided to call for clarification from the firm.**			

65	**Case No.:188/1/82-ALC4/2019**	Party Name:VASUDHA PHARMA CHEM LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/02583/AM19/	RLA File :09/24/040/00629/AM19/	Lic.No/Date:0910067299 19.03.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
LOSARTAN POTASSIUM (OR) LOSARTAN POTASSIUM USP	1 kg	1	2-Cyano-4-Bromomethyl Biphenyl (BR-OTBN)	0.75 kg
		2	Toluene	1.46 kg
		3	Methanol	2.09 kg
		4	Sodium Boro Hydride	0.048 kg
		5	Sodium Azide	0.38 kg
		6	Activated Carbon"SC40V"	0.100 kg
		7	Iso Propyl Alcohol	0.91 kg
		8	Valeronitrile	0.45 kg
		9	Glycine Technical Grade	0.37 kg
		10	Dimethyl Formamide	0.54 kg

RA concerned may take further necessary action as per above decision of NC.

66	**Case No.:200/1/82-ALC4/2019**	Party Name:AETHER INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02595/AM19/	RLA File :52/24/040/00085/AM19/	Lic.No/Date:5210043000 19.03.2019	
	Decision: Deferred for comments of TE.			

67	**Case No.:205/1/82-ALC4/2019**	Party Name:ALEOR DERMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/02600/AM19/	RLA File :34/24/040/00396/AM19/	Lic.No/Date:3410044985 19.03.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	CLOBETASOL PROPIONATE TOPICAL SOLUTION USP 0.05% 25 ML (net Content of active ingredients - 70.022 gm Plus 62.073 gm for Process Loss / Quality Control Analysis/ Handling Loss/ Bulk Hold Batch)	1 Pack	1	Clobetasol Propionate USP (Micronized)	12.75 mg per pack
2	CLOBETASOL PROPIONATE TOPICAL SOLUTION USP 0.05% 50 ML (net Content of active ingredients - 822.974 gm Plus 587.487 gm for Process Loss / Quality Control Analysis / Handling Loss / Bulk Hold Batch)"	1 Pack	1	Clobetasol Propionate USP (Micronized)	25.50 mg per pack

RA concerned may take further necessary action as per above decision of NC.

68	**Case No.:206/1/82-ALC4/2019**	Party Name:ALEOR DERMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/02601/AM19/	RLA File :34/24/040/00397/AM19/	Lic.No/Date:3410044986 19.03.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	DESONIDE OINTMENT 0.05% - 15 GM (net Content of active ingredients - 338.250 gm Plus 176.534 gm for Process Loss / Quality Control Analysis / Handling Loss / Bulk Hold Batch)	1 Number Tube	1	Desonide USP (Micronized)	7.65 mg
2	DESONIDE OINTMENT 0.05% - 60 GM (net Content of active ingredients - 461.250 gm Plus 224.064 gm for Process Loss / Quality Control Analysis / Handling Loss / Bulk Hold Batch)	1 Number Tube	1	Desonide USP (Micronized)	30.60 mg

RA concerned may take further necessary action as per above decision of NC.

69	**Case No.:210/1/82-ALC4/2019**	Party Name:V.D.H. ORGANICS PVT. LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Rejected**
	HQ File :01/82/050/02605/AM19/	RLA File :05/24/040/00721/AM19/	Lic.No/Date:0510410010 20.03.2019	

Decision: The Committee considered the case as per Agenda and it was noted that the firm still has not furnished the information on following deficiencies raised by NC-3 in its Meeting No. **9/82-ALC4/2019 dated 18.10.2019,** followed by Reminder on **09.12.2019** and Final Reminder on **20.03.2020**:

(i) Complete 4E with all technical details i.e chemistry, molecular weight, stoichiometric reaction and % of yield on molar basis at every stage

Hence, the Committee decided to **reject** the case.

RA concerned may take further necessary action as per above decision of NC.

70	**Case No.:211/1/82-ALC4/2019**	Party Name:PORUS LABORATORIES PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02606/AM19/	RLA File :09/24/040/00633/AM19/	Lic.No/Date:0910067303 20.03.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

71	**Case No.:214/1/82-ALC4/2019**	Party Name:DEEPAK PHENOLICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/02609/AM19/	RLA File :34/24/040/00327/AM19/	Lic.No/Date:3410044990 20.03.2019	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm: **(i) Quantity and commercial value of Co-Product Phenol obtained.** **(ii) Percentage yield on molar basis.**			

72	**Case No.:215/1/82-ALC4/2019**	Party Name:BEST VALUE CHEM PVT. LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/02610/AM19/	RLA File :34/24/040/00389/AM19/	Lic.No/Date:3410044991 22.03.2019	
	Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 1/82-ALC4/2018 , dated 01.05.2018, it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower: RA concerned may take further necessary action as per above decision of NC.			

Export Product	Qty.	Sl.No.	Import items	Qty.
Undecavertol (Kakdinol) (4-Methyl-3-decen-5-ol)	1 kg	1.	Propionaldehyde	0.842 kg
		2.	1-Pentanol/N Amyl Alcohol	0.639 kg

73	**Case No.:216/1/82-ALC4/2019**	Party Name:BEST VALUE CHEM PVT. LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Withdrawn**
	HQ File :01/82/050/02611/AM19/	RLA File :34/24/040/00390/AM19/	Lic.No/Date:3410044992 22.03.2019	
	Decision: The firm vide e-mail dated 02.07.2019 has informed that they had applied for issuance of Advance Authorization under para 4.07 A (self declaration and self ratification) in view of its becoming AEO status holder, but while issuing the subject Advance Authorization, RA inadvertantly indicated Advance Licence issued under para 4.7 of HBP 2015-20, for which they have requested RLA,Vadodara to amend the condition sheet of advance authorization to read as Advance Licence issued under para 4.07 A of HBP Vol. I. The Committee considered the case as per agenda in the presence of technical experts and in light of above e-mail of firm, it wasdecided to **withdraw** the case.			

74	**Case No.:13/1/82-ALC4/2019**	Party Name:DEEPAK NOVOCHEM TECHNOLOGIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00013/AM20/	RLA File :31/83/040/00296/AM19/	Lic.No/Date:3110067362 02.04.2019	
	Decision: The Committee considered the case as per Agenda and it was noted that the firm still has not furnished the information on following deficiencies raised by NC-3 in its Meeting No. **9/82-ALC4/2019 dated 18.10.2019,** followed by Reminder on **09.12.2019** and Final Reminder on **19.03.2020**: **(i) Catalogue of OCP.** **(ii) Certificate of Analysis (CoA) of OCP.** **(iii) Percentage yield on molar basis.** Hence, the Committee decided to **reject** the case. RA concerned may take further necessary action as per above decision of NC.			

75	**Case No.:14/1/82-ALC4/2019**	Party Name:CLEAN SCIENCE AND TECHNOLOGY PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00014/AM20/	RLA File :31/83/040/00299/AM19/	Lic.No/Date:3110067371 04.04.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. **13/82-ALC4/2019 dated 31.01.2020**, followed by Reminder on **18.03.2020**: **(i) Quantity and value of By-Product- Acetic Anhydride.** In view of above, the Committee decided to issue **Final Reminder** to firm to furnish its reply, failing which the case will be rejected.			

76	**Case No.:39/1/82-ALC4/2019**	Party Name:TIDE INDUSTRIES	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00039/AM20/	RLA File :34/24/040/00009/AM20/	Lic.No/Date:3410045044 11.04.2019	
	Decision: The Committee considered the case as per agenda and it was noted that the firm vide its e-mail dated 30.06.2020 has furnished its reply. Deferred for comments of TE.			

77	**Case No.:97/1/82-ALC4/2019**	Party Name:CLEAN SCIENCE AND TECHNOLOGY PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00097/AM20/	RLA File :31/83/040/00013/AM20/	Lic.No/Date:3110067404 01.05.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. **13/82-ALC4/2019 dated 31.01.2020**, followed by Reminder on **18.03.2020**: **(i) Quantity and value of By-Product- Acetic Anhydride.** In view of above, the Committee decided to issue **<u>Final Reminder</u>** to firm to furnish its reply, failing which the case will be rejected.			

78	**Case No.:194/6/82-ALC4/2019**	Party Name:ETERNIS FINE CHEMICALS LIMITED,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00420/AM20/	RLA File :03/94/040/00023/AM20/	Lic.No/Date:0310828815 07.05.2019	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm: **(i) Quantity and Commercial value of distillation residue obtained in manufacturing process.**			

79	**Case No.:140/1/82-ALC4/2019**	Party Name:MALWA OXYGEN & INDUSTRIAL GASES PVT.LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00140/AM20/	RLA File :56/24/040/00035/AM19/	Lic.No/Date:5610005605 09.05.2019	
	Decision: The Committee considered the case as per agenda and it was noted that the firm vide its e-mail dated 24.07.2020 has furnished its reply. Deferred for comments of TE.			

80	**Case No.:141/1/82-ALC4/2019**	Party Name:MALWA OXYGEN & INDUSTRIAL GASES PVT.LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00141/AM20/	RLA File :56/24/040/00034/AM19/	Lic.No/Date:5610005606 09.05.2019	
	Decision: The Committee considered the case as per agenda and it was noted that the firm vide its e-mail dated 24.07.2020 has furnished its reply. Deferred for comments of TE.			

81	**Case No.:283/1/82-ALC4/2019**	Party Name:SALVI CHEMICAL INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Rejected**
	HQ File :01/82/050/00189/AM20/	RLA File :03/95/040/00158/AM20/	Lic.No/Date:0310829176 22.05.2019	
	Decision: The Committee considered the case as per Agenda and it was noted that the firm still has not furnished the information on following deficiencies raised by NC-3 in its Meeting No. **9/82-ALC4/2019 dated 18.10.2019,** followed by Reminder on **09.12.2019** and Final Reminder on **18.03.2020**: **(i) Chemical reaction with molecular weight.** **(ii) Percentage yield on molar basis.** Hence, the Committee decided to **reject** the case. RA concerned may take further necessary action as per above decision of NC.			

82	**Case No.:284/1/82-ALC4/2019**	Party Name:SALVI CHEMICAL INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Rejected**
	HQ File :01/82/050/00190/AM20/	RLA File :03/95/040/00156/AM20/	Lic.No/Date:0310829177 22.05.2019	
	Decision: The Committee considered the case as per Agenda and it was noted that the firm still has not furnished the information on following deficiencies raised by NC-3 in its Meeting No. **9/82-ALC4/2019 dated 18.10.2019,** followed by Reminder on **09.12.2019** and Final Reminder on **18.03.2020**: **(i) Chemical reaction with molecular weight.** **(ii) Percentage yield on molar basis.** Hence, the Committee decided to **reject** the case. RA concerned may take further necessary action as per above decision of NC.			

83	**Case No.:285/1/82-ALC4/2019**	Party Name:SALVI CHEMICAL INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00191/AM20/	RLA File :03/95/040/00157/AM20/	Lic.No/Date:0310829190 22.05.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

84	**Case No.:286/1/82-ALC4/2019**	Party Name:SALVI CHEMICAL INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Rejected**
	HQ File :01/82/050/00192/AM20/	RLA File :03/95/040/00160/AM20/	Lic.No/Date:0310829199 22.05.2019	
	Decision: The Committee considered the case as per Agenda and it was noted that the firm still has not furnished the information on following deficiencies raised by NC-3 in its Meeting No. **9/82-ALC4/2019 dated 18.10.2019,** followed by Reminder on **09.12.2019** and Final Reminder on **18.03.2020**: **(i) Chemical reaction with molecular weight.** **(ii) Percentage yield on molar basis.** Hence, the Committee decided to **reject** the case. RA concerned may take further necessary action as per above decision of NC.			

85	**Case No.:287/1/82-ALC4/2019**	Party Name:SALVI CHEMICAL INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Rejected**
	HQ File :01/82/050/00193/AM20/	RLA File :03/95/040/00161/AM20/	Lic.No/Date:0310829200 22.05.2019	
	Decision: The Committee considered the case as per Agenda and it was noted that the firm still has not furnished the information on following deficiencies raised by NC-3 in its Meeting No. **9/82-ALC4/2019 dated 18.10.2019,** followed by Reminder on **09.12.2019** and Final Reminder on **18.03.2020**: **(i) Chemical reaction with molecular weight.** **(ii) Percentage yield on molar basis.** Hence, the Committee decided to **reject** the case. RA concerned may take further necessary action as per above decision of NC.			

86	**Case No.:288/1/82-ALC4/2019**	Party Name:SALVI CHEMICAL INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Rejected**
	HQ File :01/82/050/00194/AM20/	RLA File :03/95/040/00159/AM20/	Lic.No/Date:0310829205 22.05.2019	
	Decision: The Committee considered the case as per Agenda and it was noted that the firm still has not furnished the information on following deficiencies raised by NC-3 in its Meeting No. **9/82-ALC4/2019 dated 18.10.2019,** followed by Reminder on **09.12.2019** and Final Reminder on **18.03.2020**: **(i) Chemical reaction with molecular weight.** **(ii) Percentage yield on molar basis.** Hence, the Committee decided to **reject** the case. RA concerned may take further necessary action as per above decision of NC.			

87	**Case No.:163/13/82-ALC4/2019**	Party Name:RESONANCESPECIALTIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01006/AM20/	RLA File :03/95/040/00166/AM20/	Lic.No/Date:0310829318 29.05.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

88	**Case No.:320/1/82-ALC4/2019**	Party Name:DEEPAK PHENOLICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00226/AM20/	RLA File :34/24/040/00036/AM20/	Lic.No/Date:3410045179 30.05.2019	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm: **(i) Quantity and commercial value of Co-Product Phenol obtained.** **(ii) Percentage yield on molar basis.**			

89	**Case No.:144/6/82-ALC4/2019**	Party Name:LACTOSE (INDIA) LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00370/AM20/	RLA File :03/95/040/00296/AM20/	Lic.No/Date:0310830184 09.07.2019	
	Decision: The Committee considered the case as per agenda and it was noted that the firm vide its e-mail dated 07.07.2020 has furnished its reply. Deferred for comments of TE.			

90	**Case No.:154/6/82-ALC4/2019**	Party Name:INDO AMINES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00380/AM20/	RLA File :03/94/040/00122/AM20/	Lic.No/Date:0310830244 12.07.2019	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm: **(i) Complete specifications of import item No. 2 - Ni-Catalyst with catalogue of Export Product.** **(ii) Last two years Production & corresponding consumption of different raw materials duly certified by GST.**			

91	**Case No.:203/6/82-ALC4/2019**	Party Name:SONGWON SPECIALTY CHEMICALS INDIA PVT. LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00429/AM20/	RLA File :34/24/040/00069/AM20/	Lic.No/Date:3410045298 18.07.2019	
	Decision: Deferred for comments of TE.			

92	**Case No.:15/7/82-ALC4/2019**	Party Name:GLOBAL CALCIUM PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00510/AM20/	RLA File :07/24/040/00093/AM20/	Lic.No/Date:0710115208 23.07.2019	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm: **(i) Complete technical details as per Appendix 4E.**			

93	**Case No.:229/6/82-ALC4/2019**	Party Name:NISARG BIOSCIENCES PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Rejected**
	HQ File :01/82/050/00455/AM20/	RLA File :09/24/040/00221/AM20/	Lic.No/Date:0910067836 25.07.2019	
	Decision: The Committee considered the case as per Agenda and it was noted that the firm still has not furnished the information on following deficiencies raised by NC-3 in its Meeting No. **9/82-ALC4/2019 dated 18.10.2019,** followed by Reminder on **09.12.2019** and Final Reminder on **18.03.2020**: **(i) Percentage yield on molar basis.** **(ii) Calculation Sheet showing the necessary calculations to arrive at the export quantity.** Hence, the Committee decided to **reject** the case. RA concerned may take further necessary action as per above decision of NC.			

94	**Case No.:248/6/82-ALC4/2019**	Party Name:HUBERGROUP INDIA PRIVATE LIMITED.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00474/AM20/	RLA File :03/94/040/00346/AM20/	Lic.No/Date:0310830713 31.07.2019	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm: (i) **Material balance in terms of 53% solid resin content between import and export taking into account 5% wastage claimed.**			

95	**Case No.:258/6/82-ALC4/2019**	Party Name:NISARG BIOSCIENCES PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Rejected**
	HQ File :01/82/050/00484/AM20/	RLA File :09/24/040/00236/AM20/	Lic.No/Date:0910067858 01.08.2019	
	Decision: The Committee considered the case as per Agenda and it was noted that the firm still has not furnished the information on following deficiencies raised by NC-3 in its Meeting No. **9/82-ALC4/2019 dated 18.10.2019,** followed by Reminder on **09.12.2019** and Final Reminder on **18.03.2020**: **(i) Percentage yield on molar basis.** **(ii) Calculation Sheet showing the necessary calculations to arrive at the export quantity.** Hence, the Committee decided to **reject** the case. RA concerned may take further necessary action as per above decision of NC.			

96	**Case No.:4/7/82-ALC4/2019**	Party Name:KEVA FRAGRANCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00499/AM20/	RLA File :03/94/040/00373/AM20/	Lic.No/Date:0310830887 07.08.2019	
	Decision: Deferred for comments of TE.			

97	**Case No.:25/7/82-ALC4/2019**	Party Name:UNILINK PHARMA PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00520/AM20/	RLA File :04/24/040/00074/AM20/	Lic.No/Date:0410165953 13.08.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
PENICILLIN - V TABLETS PHENOXY METHYL PENICILLIN POTASSIUM BP EQUIVALENT TO PHENOXY METHYL PENICILLIN 250 MG (400000IU)	1 Number Tablet	1	PHENOXY MEHTYL PENICILLIN POTASSIUM BP PHENOXY MEHTYL PENICILLIN POTASSIUM BP	278.00 mg

RA concerned may take further necessary action as per above decision of NC.

98	**Case No.:28/7/82-ALC4/2019**	Party Name:UPL LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00523/AM20/	RLA File :03/95/040/01337/AM19/	Lic.No/Date:0310830995 14.08.2019	

Decision: Deferred for comments of TE.

99	**Case No.:29/7/82-ALC4/2019**	Party Name:ETERNIS FINE CHEMICALS LIMITED,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00524/AM20/	RLA File :03/94/040/00381/AM20/	Lic.No/Date:0310831004 14.08.2019	

Decision: Deferred for comments of TE.

100	**Case No.:33/7/82-ALC4/2019**	Party Name:AETHER INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00528/AM20/	RLA File :52/21/040/00085/AM20/	Lic.No/Date:5210043146 14.08.2019	

Decision: Deferred for comments of TE.

101	**Case No.:34/7/82-ALC4/2019**	Party Name:AETHER INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00529/AM20/	RLA File :52/21/040/00086/AM20/	Lic.No/Date:5210043147 14.08.2019	
	Decision: Deferred for comments of TE.			

102	**Case No.:35/7/82-ALC4/2019**	Party Name:AETHER INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00530/AM20/	RLA File :52/21/040/00061/AM20/	Lic.No/Date:5210043148 14.08.2019	
	Decision: Deferred for comments of TE.			

103	**Case No.:38/7/82-ALC4/2019**	Party Name:FRESENIUS KABI INDIA PRIVATE LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00533/AM20/	RLA File :03/94/040/00397/AM20/	Lic.No/Date:0310831038 16.08.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

104	**Case No.:39/7/82-ALC4/2019**	Party Name:TADIMETY AROMATICS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00534/AM20/	RLA File :07/24/040/00104/AM20/	Lic.No/Date:0710115296 19.08.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

105	**Case No.:40/7/82-ALC4/2019**	Party Name:ORTIN LABORATORIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00535/AM20/	RLA File :09/24/040/00259/AM20/	Lic.No/Date:0910067901 19.08.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

106	**Case No.:44/7/82-ALC4/2019**	Party Name:SWATI MENTHOL & ALLIED CHEMICALS LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00539/AM20/	RLA File :29/24/040/00011/AM20/	Lic.No/Date:2910025423 19.08.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

107	**Case No.:45/7/82-ALC4/2019**	Party Name:SUPERMINT EXPORTS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00540/AM20/	RLA File :29/24/040/00010/AM20/	Lic.No/Date:2910025424 19.08.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

108	**Case No.:48/7/82-ALC4/2019**	Party Name:SRINI PHARMACEUTICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00543/AM20/	RLA File :09/24/040/00269/AM20/	Lic.No/Date:0910067906 20.08.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

109

	Case No.:50/7/82-ALC4/2019	Party Name:DIVIS LABORATORIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00545/AM20/	RLA File :09/24/040/00264/AM20/	Lic.No/Date:0910067908 20.08.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and in line with GST Certificate, it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
NAPROXEN	1 kg	1	DL-NAPROXEN	1.25 kg
		2	N-OCTYL-D-GLUCAMINE	0.09 kg
		3	METHANOL	2.03 kg
		4	ACETIC ACID	0.54 kg
		5	TOLUENE	1.13 kg

RA concerned may take further necessary action as per above decision of NC.

110	**Case No.:51/7/82-ALC4/2019**	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00546/AM20/	RLA File :05/24/040/00291/AM20/	Lic.No/Date:0510411567 20.08.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Ciprofloxacin and Dexamethasone Sterile Otic Suspension 7.5ml (Each ml contains Ciprofloxacin 3mg. & Dexamethasone 1mg (Equivalent to 15750gm Ciprofloxacin and 5250gm Dexamethasone Bulk Drug)	700000.000 Number	1	Ciprofloxacin (Ciprofloxacin Hcl)	18356.62 gms
		2	Dexamethasone USP	5512.50 gms

RA concerned may take further necessary action as per above decision of NC.

111	**Case No.:54/7/82-ALC4/2019**	Party Name:LYRUS LIFE SCIENCES PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00549/AM20/	RLA File :07/24/040/00091/AM20/	Lic.No/Date:0710115309 20.08.2019	

Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

112	**Case No.:56/7/82-ALC4/2019**	Party Name:GLOBAL CALCIUM PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00551/AM20/	RLA File :07/24/040/00107/AM20/	Lic.No/Date:0710115314 21.08.2019	

Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm was asked to furnish following information asked for by NC-3 in its Meeting No. **13/82-ALC4/2019 dated 31.01.2020**, followed by Reminder on **19.03.2020**:

(i) Chemical reaction, molecular weight, stiochometric balance.
(ii) Production / Consumption data duly certified by GST.
(iii) Justification for low yield.

The firm vide its e-mail dated 24.07.2020 has furnished its reply. Technical Expert after examining the reply of firm stated that the reply is not proper as whatever available in the application is again forwarded.

In view of above, the Committee decided to issue **Final Reminder** to firm with the request to furnish its reply strictly as per above points mentioned in earlier DL, failing which the case will be rejected.

113	**Case No.:59/7/82-ALC4/2019**	Party Name:GLOBAL CALCIUM PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00554/AM20/	RLA File :07/24/040/00117/AM20/	Lic.No/Date:0710115318 22.08.2019	
	Decision: The Committee considered the case as per agenda and it was noted that the firm vide its e-mail dated 30.06.2020 has furnished its reply. Deferred for comments of TE.			

114	**Case No.:68/7/82-ALC4/2019**	Party Name:NEOGEN CHEMICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00563/AM20/	RLA File :03/95/040/00310/AM20/	Lic.No/Date:0310831251 27.08.2019	
	Decision: The Committee considered the case as per online agenda in the presence of technical experts and it was noted that the firm still has not furnished the following information asked for by NC-3 in its Meeting No. **13/82-ALC4/2019 dated 31.01.2020**, followed by Reminder on **20.03.2020**: **(i) Justification of lower yield.** **(ii) Quantity and commercial value of By-product –HBr in the process.** In view of above, the Committee decided to issue **<u>Final Reminder</u>** to firm to furnish its reply, failing which the case will be rejected.			

115	**Case No.:71/7/82-ALC4/2019**	Party Name:SYNTHO CHIRALS PVT. LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00566/AM20/	RLA File :09/24/040/00275/AM20/	Lic.No/Date:0910067938 27.08.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

116	**Case No.:72/7/82-ALC4/2019**	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00567/AM20/	RLA File :09/24/040/00274/AM20/	Lic.No/Date:0910067940 27.08.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
CEFUROXIME AXETIL AMORPHOUS	1 kg	1	3-Hydroxycefuroxime (or) Descarbamoyl Cefuroxime Acid	0.963 kg
		2	Acetone	3.691 kg
		3	Carbon Enoanticromos (Activated Carbon)	0.097 kg
		4	Chlorosulfonyl Isocyanate (CSI)	0.53 kg
		5	Cyclohexane (Benzene Free)	1.10 kg
		6	Methanol (Methyl Alcohol)	1.70 kg
		7	N,N- Dimethyl Acetamide	1.62 kg

RA concerned may take further necessary action as per above decision of NC.

117	**Case No.:74/7/82-ALC4/2019**	Party Name:UNICHEM LABORATORIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00569/AM20/	RLA File :03/95/040/00541/AM20/	Lic.No/Date:0310831283 28.08.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	DOXAZOSIN 1 MG TABLETS	1 Number	1	DOXAZOSIN MESYLATE	1.236 mg / 1 mg tablet
2	DOXAZOSIN 2 MG TABLETS	1 Number	1	DOXAZOSIN MESYLATE	2.472 mg / 2 mg tablet
3	DOXAZOSIN 4 MG TABLETS	1 Number	1	DOXAZOSIN MESYLATE	4.945 mg / 4 mg tablet
4	DOXAZOSIN 8 MG TABLETS	1 Number	1	DOXAZOSIN MESYLATE	9.890 mg/ 8 mg tablet

RA concerned may take further necessary action as per above decision of NC.

118	**Case No.:77/7/82-ALC4/2019**	Party Name:HETERO LABS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00572/AM20/	RLA File :09/24/040/00291/AM20/	Lic.No/Date:0910067953 28.08.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
ROSUVASTATIN CALCIUM	1 kg	1	(E)tertbutyl2-(6-(2-(4-(4fluorophenyl) 6isopropyl2(Nmethylsulfonamido) pyrimidin5yl)vinyl)2,2dimethyl1,3dioxan4-yl)acetate (E)-tert-butyl 2-(6-(2-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido) pyrimidin-5-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate	1.30 kg
		2	CALCIUM ACETATE	0.30 kg
		3	C.S. FLAKES	0.16 kg
		4	HYDROCHLORIC ACID	0.24 kg
		5	TOLUENE	2.68 kg
		6	METHANOL	0.64 kg

RA concerned may take further necessary action as per above decision of NC.

119	**Case No.:79/7/82-ALC4/2019**	Party Name:SENTISS PHARMA PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00574/AM20/	RLA File :05/24/040/00292/AM20/	Lic.No/Date:0510411666 28.08.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Tobriss (Tobramycin 0.3%) Eye Drops 5ml Pack	1 Number Pack	1	Tobramycin Sulphate	19.057 mg

RA concerned may take further necessary action as per above decision of NC.

120	**Case No.:131/13/82-ALC4/2019**	Party Name:NECTAR LIFESCIENCES LIMITED,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00974/AM20/	RLA File :22/24/040/00001/AM16/	Lic.No/Date:2210016280 31.10.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Cefpodoxime Proxetil	1 kg	1	7-ACA	0.8378 kg
		2	Methane Sulfonicacid	1.626 kg
		3	Methanol	1.635 kg
		4	Ammonium Hydroxide	2.13 kg
		5	S-2 Benzothiazolyl-2-Amino-2-(methoxyimino)-4-tiazolyl acetate (MAEM)	0.8378 kg
		6	Triethylamine (TEA)	0.260 kg
		7	1-CEIPC	0.55 kg
		8	Sodium Iodide	0.28 kg
		9	Toluene	0.263 kg
		10	N, N-Dimethyl Acetamide	0.665 kg
		11	TMG	0.223 kg
		12	Ethyl acetate	1.842 kg
		13	Sodium thio-sulphate	0.080 kg
		14	Activated carbon	0.100 kg
		15	Acetone	1.863 kg
		16	Ethylenediamine Tetra Acetic Acid Disodium Salt Dihydrate (EDTA)	0.005 kg
		17	Cyclohexane	3.572 kg

RA concerned may take further necessary action as per above decision of NC.

121	**Case No.:1/13/82-ALC4/2019**	Party Name:LINK PHARMA CHEM LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00844/AM20/	RLA File :34/24/040/00248/AM20/	Lic.No/Date:3410045631 20.11.2019	

Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

122	**Case No.:3/13/82-ALC4/2019**	Party Name:SRF LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00846/AM20/	RLA File :05/24/040/00445/AM20/	Lic.No/Date:0510412564 21.11.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

123	**Case No.:4/13/82-ALC4/2019**	Party Name:SRF LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00847/AM20/	RLA File :05/24/040/00471/AM20/	Lic.No/Date:0510412565 21.11.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

124	**Case No.:7/13/82-ALC4/2019**	Party Name:AVIK PHARMACEUTICAL LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00850/AM20/	RLA File :03/94/040/00657/AM20/	Lic.No/Date:0310832928 21.11.2019	
	Decision: Deferred for comments of TE.			

125	**Case No.:8/13/82-ALC4/2019**	Party Name:SWISS PARENTERALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00851/AM20/	RLA File :08/24/040/00195/AM20/	Lic.No/Date:0810146613 21.11.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

126	**Case No.:11/13/82-ALC4/2019**	Party Name:MANGALAM ORGANICS LIMITED FORMERLY DUJODWALA PRODU	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00854/AM20/	RLA File :03/95/040/00790/AM20/	Lic.No/Date:0310832931 21.11.2019	
	Decision: Deferred for comments of TE.			

127	**Case No.:12/13/82-ALC4/2019**	Party Name:LINK PHARMA CHEM LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00855/AM20/	RLA File :34/24/040/00256/AM20/	Lic.No/Date:3410045634 21.11.2019	
	Decision: Deferred for comments of TE.			

128	**Case No.:17/13/82-ALC4/2019**	Party Name:GOVIND LABORATORIES PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00860/AM20/	RLA File :08/24/040/00272/AM20/	Lic.No/Date:0810146634 22.11.2019	
	Decision: Deferred for comments of TE.			

129	**Case No.:22/13/82-ALC4/2019**	Party Name:U K AROMATICS & CHEMICALS	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00865/AM20/	RLA File :03/95/040/00825/AM20/	Lic.No/Date:0310832966 22.11.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	ALPHA AMYL CINNAMIC ALDEHYDE	1 kg	1	N - HEPTALDEHYDE	0.66 kg
2	ALLYL CAPROATE	1 kg	2	CAPROIC ACID	0.86 kg
3	ALLYL HEPTOATE	1 kg	3	N - HEPTANOIC ACID	0.89 kg

RA concerned may take further necessary action as per above decision of NC.

130	**Case No.:18/13/82-ALC4/2019**	Party Name:HETERO LABS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00861/AM20/	RLA File :09/24/040/00431/AM20/	Lic.No/Date:0910068219 25.11.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

131	**Case No.:23/13/82-ALC4/2019**	Party Name:SRF LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00866/AM20/	RLA File :05/24/040/00501/AM20/	Lic.No/Date:0510412619 25.11.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

132	**Case No.:25/13/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00868/AM20/	RLA File :03/94/040/00683/AM20/	Lic.No/Date:0310833016 26.11.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Import items	Qty.
1	FLUCORT N SKIN CREAM 0.025% (Pack Size 15 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 1.210 Kgs.)	322660.000 Packs	FLUOCINOLONE ACETONIDE BP	9.10 kg
2	FLUCORT SKIN CREAM 0.025% (Pack Size 15 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 1.210 Kgs.)	322660.000 Packs		
3	FLUCORT SKIN CREAM 0.025% (Pack Size 10 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 0.605 Kgs.)	242000.000 Packs		
4	FLUCORT SKIN CREAM 0.025% (Pack Size 5 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 1.210 Kgs.)	968000.000 Packs		
5	FLUOCINOLONE CREAM (TDR) ET 0.025% (Pack Size 10 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 0.242 Kgs.)	96800.000 Packs		
6	CYNOZET CREAM 0.025% (Pack Size 5 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 0.242 Kgs.)	193600.000 Packs		
7	CYNOZET CREAM 0.025% (Pack Size 15 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 0.242 Kgs.)	64532.000 Packs		
8	SUPRICORT CREAM 0.025% (Pack Size 5 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 0.726 Kgs.)	580800.000 Packs		
9	SUPRICORT CREAM 0.025% (Pack Size 15 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 0.726 Kgs.)	193596.000 Packs		

10	SUPRICORT CREAM 0.025% (Pack Size 250 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 0.242 Kgs.)	3873.000 Packs		
11	SUPRICORT N CREAM 0.025% (Pack Size 5 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 0.242 Kgs.)	193600.000 Packs		
12	SUPRICORT N CREAM 0.025% (Pack Size 15 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 0.242 Kgs.)	64532.000 Packs		
13	Flucort C Cream 0.01% (Pack Size 15 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 0.095 Kgs)	63332.000 Packs		
14	FLUCORT C OINTMENT 0.025% (Pack Size 15 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 0.605 Kgs.)	161330.000 Packs		
15	GLENCORT GEL 0.025% (Pack Size 5 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 0.452 Kgs.)	361600.000 Packs		
16	GLENCORT GEL 0.025% (Pack Size 30 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 0.484 Kgs.)	64535.000 Packs		
17	FLUCORT MZ SKIN OINTMENT 0.01% (Pack Size 15 gms) (Net Wt.of FLUOCINOLONE ACETONIDE BP is 0.145 Kgs.)	96798.000 Packs		

RA concerned may take further necessary action as per above decision of NC.

133	**Case No.:26/13/82-ALC4/2019**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00869/AM20/	RLA File :09/70/040/00130/AM20/	Lic.No/Date:0910068227 27.11.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

134	**Case No.:31/13/82-ALC4/2019**	Party Name:DEEPAK PHENOLICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00874/AM20/	RLA File :34/24/040/00223/AM20/	Lic.No/Date:3410045650 27.11.2019	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm: **(i) Quantity and commercial value of Co-Product Acetone produced.** **(ii) Percentage yield on molar basis.**			

135	**Case No.:32/13/82-ALC4/2019**	Party Name:DEEPAK PHENOLICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00875/AM20/	RLA File :34/24/040/00205/AM20/	Lic.No/Date:3410045651 27.11.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019. However, the Committee considered the case as per agenda and based on the decision taken in similar cases of the firm, it was decided to call for following information from the firm: **(i) Quantity and commercial value of Co-Product Acetone produced.** **(ii) Percentage yield on molar basis.** **(iii) Complete set of 4.07 application alongwith technical details as per Appendix 4E.**			

136	**Case No.:33/13/82-ALC4/2019**	Party Name:DEEPAK NITRITE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00876/AM20/	RLA File :34/24/040/00240/AM20/	Lic.No/Date:3410045652 27.11.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

137	**Case No.:34/13/82-ALC4/2019**	Party Name:DEEPAK NITRITE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00877/AM20/	RLA File :34/24/040/00239/AM20/	Lic.No/Date:3410045653 27.11.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

138	**Case No.:35/13/82-ALC4/2019**	Party Name:BLISS GVS PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00878/AM20/	RLA File :03/94/040/00681/AM20/	Lic.No/Date:0310833065 28.11.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

139	**Case No.:36/13/82-ALC4/2019**	Party Name:OPTIMUS DRUGS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00879/AM20/	RLA File :09/24/040/00435/AM20/	Lic.No/Date:0910068236 28.11.2019	
	Decision: Deferred for comments of TE.			

140	**Case No.:40/13/82-ALC4/2019**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00883/AM20/	RLA File :03/94/040/00677/AM20/	Lic.No/Date:0310833120 02.12.2019	
	Decision: Deferred for comments of TE.			

141

Case No.:41/13/82-ALC4/2019	Party Name:VIVIMED LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
HQ File :01/82/050/00884/AM20/	RLA File :09/24/040/00373/AM20/	Lic.No/Date:0910068240 02.12.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Ibuprofen Tablets USP - 800mg (Import condition:- Pre-import condition is imposed in case this is unregistered and export obligation should be completed within 12 months from the date of import of each consignment as per Appendix- 4J of FTP 2015-2020.)	1 Number Tablet	1	Pregelatinized Starch	34.75 mg
		2	Sodium Starch Glycolate	46.00 mg
		3	Mg Stearate - Veg Source (Magnesium Stearate)	5.75 mg

RA concerned may take further necessary action as per above decision of NC.

142	**Case No.:42/13/82-ALC4/2019**	Party Name:VIVIMED LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00885/AM20/	RLA File :09/24/040/00374/AM20/	Lic.No/Date:0910068241 02.12.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

143	**Case No.:43/13/82-ALC4/2019**	Party Name:VIVIMED LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00886/AM20/	RLA File :09/24/040/00425/AM20/	Lic.No/Date:0910068242 02.12.2019	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm: **(i) Master Batch formula for 600 mg tablet.**			

144	**Case No.:44/13/82-ALC4/2019**	Party Name:BALAJI AMINES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00887/AM20/	RLA File :31/83/040/00117/AM20/	Lic.No/Date:3110067616 02.12.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

145	**Case No.:132/13/82-ALC4/2019**	Party Name:TRANSPEK INDUSTRY LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00975/AM20/	RLA File :34/24/040/00269/AM20/	Lic.No/Date:3410045672 02.12.2019	
	Decision: The Committee considered the case in the presence of technical experts and in light of e-mail dated 25.02.2020 received from firm, it was decided to defer the case for comments of TE.			

146	**Case No.:46/13/82-ALC4/2019**	Party Name:RUBICON RESEARCH PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00889/AM20/	RLA File :03/95/040/00793/AM20/	Lic.No/Date:0310833193 04.12.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

147	**Case No.:49/13/82-ALC4/2019**	Party Name:VN CREATIVE CHEMICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00892/AM20/	RLA File :03/95/040/00849/AM20/	Lic.No/Date:0310833213 04.12.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

148	**Case No.:54/13/82-ALC4/2019**	Party Name:US AMINO PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00897/AM20/	RLA File :03/95/040/00816/AM20/	Lic.No/Date:0310833244 05.12.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

149	**Case No.:57/13/82-ALC4/2019**	Party Name:INDO AMINES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00900/AM20/	RLA File :03/94/040/00728/AM20/	Lic.No/Date:0310833360 11.12.2019	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 17/82-ALC4/2013 , dated 05.12.2013, it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl.No.	Import items	Qty.
1-Methyl Cyclohexene	1 KG.	1.	Ortho Cresol	1.25 kg

RA concerned may take further necessary action as per above decision of NC.

150	**Case No.:59/13/82-ALC4/2019**	Party Name:M/S HIMALAYAN PRODUCTS & INDUSTRIES CORPN., P.LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00902/AM20/	RLA File :05/24/040/00483/AM20/	Lic.No/Date:0510412862 12.12.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

151	**Case No.:60/13/82-ALC4/2019**	Party Name:VEERAL ADDITIVES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00903/AM20/	RLA File :03/95/040/00847/AM20/	Lic.No/Date:0310833378 12.12.2019	
	Decision: Deferred for comments of TE.			

152	**Case No.:66/13/82-ALC4/2019**	Party Name:AETHER INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00909/AM20/	RLA File :52/24/040/00044/AM20/	Lic.No/Date:5210043258 12.12.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

153	**Case No.:67/13/82-ALC4/2019**	Party Name:ARIHANTANAM LIFECARE PVT. LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00910/AM20/	RLA File :52/24/040/00046/AM20/	Lic.No/Date:5210043259 12.12.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

154	**Case No.:62/13/82-ALC4/2019**	Party Name:CADILA HEALTHCARE LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00905/AM20/	RLA File :08/24/040/00276/AM20/	Lic.No/Date:0810146758 13.12.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	URSODIOL TABLETS USP 250 MG (ACTIVE INGREDIENT : URSODIOL USP (URSODEOXYCHOLIC ACID USP) - NET WT. 1719.700 KGS.)	1 Number	1	URSODIOL USP (URSODEOXYCHOLIC ACID USP)	255 mg
			2	MAGNESIUM STEARATE PH.E/NF/JP	Not shown in the Master Batch Formula
			3	MICROCRYSTALLINE CELLULOSE NF/PH.E (AVICEL PH200)	31.00 mg
			4	SODIUM STARCH GLYCOLATE NF/JP	28.00 mg
			5	POVIDONE USP (PLASDONE K-29/32)	18.00 mg
			6	MICROCRYSTALLINE CELLULOSE NF 101 (COMPRECEL M101D+)	64.00 mg
2	URSODIOL TABLETS USP 500 MG (ACTIVE INGREDIENT : URSODIOL USP (URSODEOXYCHOLIC ACID USP) - NET WT. 3439.300 KGS.)	1 Number	1	URSODIOL USP (URSODEOXYCHOLIC ACID USP)	510 mg
			2	MAGNESIUM STEARATE PH.E/NF/JP	Not shown in the Master Batch Formula
			3	MICROCRYSTALLINE CELLULOSE NF/PH.E (AVICEL PH200)	62.00 mg
			4	SODIUM STARCH GLYCOLATE NF/JP	56.00 mg
			5	POVIDONE USP (PLASDONE K-29/32)	36.00 mg
			6	MICROCRYSTALLINE CELLULOSE NF 101 (COMPRECEL M101D+)	128.00 mg

RA concerned may take further necessary action as per above decision of NC.

155	**Case No.:64/13/82-ALC4/2019**	Party Name:ANTHEA AROMATICS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00907/AM20/	RLA File :03/94/040/00576/AM20/	Lic.No/Date:0310833390 13.12.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

156	**Case No.:65/13/82-ALC4/2019**	Party Name:ASHISH LIFE SCIENCE PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00908/AM20/	RLA File :03/94/040/00662/AM20/	Lic.No/Date:0310833391 13.12.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

157	**Case No.:70/13/82-ALC4/2019**	Party Name:PANACEA BIOTEC LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00913/AM20/	RLA File :05/24/040/00566/AM20/	Lic.No/Date:0510412934 17.12.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

158	**Case No.:76/13/82-ALC4/2019**	Party Name:KLJ PLASTICIZERS LIMITED.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00919/AM20/	RLA File :05/23/040/00363/AM20/	Lic.No/Date:0510412972 19.12.2019	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm: **(i) Molecular weight of export and import items.** **(ii) Stoichiometric balance in terms of molar basis between import and export.**			

159	**Case No.:78/13/82-ALC4/2019**	Party Name:GLENMARK LIFE SCIENCES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00921/AM20/	RLA File :03/94/040/00787/AM20/	Lic.No/Date:0310833584 20.12.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Tadalafil	1 kg	1	(6R,12aR)-Methyl-1,2,3,4-tetrahydro-2-chloroacetyl-1-[3,4 Methylene dioxyphenyl)-9H-pyrido-[3,4-b]indole-3-carboxylate	1.64 kg
		2	Methanol	7.14 kg

RA concerned may take further necessary action as per above decision of NC.

160	**Case No.:79/13/82-ALC4/2019**	Party Name:INDOCOREMEDIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00922/AM20/	RLA File :03/94/040/00780/AM20/	Lic.No/Date:0310833599 23.12.2019	

Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

161	**Case No.:80/13/82-ALC4/2019**	Party Name:FINE ORGANIC INDUSTRIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00923/AM20/	RLA File :03/94/040/00783/AM20/	Lic.No/Date:0310833601 23.12.2019	

Decision: The Committee considered the case as per agenda and it was noted that the firm vide its e-mail dated 18.03.2020 has furnished its reply. Deferred for comments of TE.

162	**Case No.:81/13/82-ALC4/2019**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00924/AM20/	RLA File :09/24/040/00472/AM20/	Lic.No/Date:0910068297 23.12.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

S. No.	Export Product	Qty.
1	Esmolol Hydrochloride in Sodium Chloride Injection 2000 mg per 100ml (20mg per ml) single dose bags	4265.000 Number
2	Esmolol Hydrochloride in Sodium Chloride Injection 2500 mg per 250ml (10mg per ml) single dose bags	7500.000 Number

S. No.	Import Items	Qty.
1	Esmolol Hydrochloride Condition: Pre Import condition is imposed in Additional Condition as per Appendix 4J	28.644 kg
2	Flexible bags	Net to Net with accountability
3	Twist off port stoppers	Net to Net with accountability

RA concerned may take further necessary action as per above decision of NC.

163	**Case No.:84/13/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00927/AM20/	RLA File :03/94/040/00724/AM20/	Lic.No/Date:0310833636 24.12.2019	

Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

164	**Case No.:86/13/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00929/AM20/	RLA File :03/94/040/00790/AM20/	Lic.No/Date:0310833644 24.12.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	THEOPHYLLINE ER TABS 400MG (Pack Size 100 Tabs.) (Net Wt. of THEOPHYLLINE ANHYDROUS USP is 1000.000 Kgs)	25000.000 Number	1	THEOPHYLLINE ANHYDROUS USP	2550.00 kg
2	THEOPHYLLINE ER TABS 600MG (Pack Size 100 Tabs.) (Net Wt. of THEOPHYLLINE ANHYDROUS USP is 1500.000 Kgs)	25000.000 Number			

RA concerned may take further necessary action as per above decision of NC.

165	**Case No.:88/13/82-ALC4/2019**	Party Name:CLARIANT CHEMICALS INDIA LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00931/AM20/	RLA File :03/94/040/00797/AM20/	Lic.No/Date:0310833685 24.12.2019	

Decision: Deferred for comments of TE.

166	**Case No.:91/13/82-ALC4/2019**	Party Name:RADIANT CORPORATION	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00934/AM20/	RLA File :03/95/040/00938/AM20/	Lic.No/Date:0310833719 26.12.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
METHYL PROPYL KETOXIME (MPKO)	1 kg	1	METHYL PROPYL KETONE (MPK) (95%)	1.10 kg
		2	HYDROXYLAMINE SULPHATE (HS)	0.95 kg

RA concerned may take further necessary action as per above decision of NC.

167	**Case No.:92/13/82-ALC4/2019**	Party Name:TADIMETY AROMATICS PVT. LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00935/AM20/	RLA File :07/24/040/00229/AM20/	Lic.No/Date:0710115939 27.12.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

168	**Case No.:93/13/82-ALC4/2019**	Party Name:TADIMETY AROMATICS PVT. LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00936/AM20/	RLA File :07/24/040/00230/AM20/	Lic.No/Date:0710115940 27.12.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

169

Case No.:94/13/82-ALC4/2019	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
HQ File :01/82/050/00937/AM20/	RLA File :05/24/040/00607/AM20/	Lic.No/Date:0510413115 27.12.2019	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Brinzolamide Ophthalmic Suspension, 1%w/v 5ml (Sterile Eye Drops) (BRINOLAR) (Each ml contains Brinzolamide equivalent to Brinzolamide Micronized Sterile 10 mg (Equivalent to 650.000 Gm of Bulk Drug),	13000.000 Number	1	Brinzolamide Micronized Sterile	663 Gram

RA concerned may take further necessary action as per above decision of NC.

170	**Case No.:95/13/82-ALC4/2019**	Party Name:PHALANX LABS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00938/AM20/	RLA File :26/24/040/00013/AM20/	Lic.No/Date:2610012888 27.12.2019	
	Decision: Deferred for comments of TE.			

171	**Case No.:96/13/82-ALC4/2019**	Party Name:STYRAX PHARMA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00939/AM20/	RLA File :26/24/040/00014/AM20/	Lic.No/Date:2610012889 27.12.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

172	**Case No.:97/13/82-ALC4/2019**	Party Name:MAITHRI DRUGS PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00940/AM20/	RLA File :09/24/040/00465/AM20/	Lic.No/Date:0910068306 27.12.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

173	**Case No.:99/13/82-ALC4/2019**	Party Name:DIPS BIOSCIENCE PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00942/AM20/	RLA File :03/94/040/00788/AM20/	Lic.No/Date:0310833754 27.12.2019	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

174	**Case No.:102/13/82-ALC4/2019**	Party Name:CLARIANT CHEMICALS [INDIA] LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00945/AM20/	RLA File :03/94/040/00817/AM20/	Lic.No/Date:0310833771 30.12.2019	
	Decision: Deferred for comments of TE.			

175	**Case No.:104/13/82-ALC4/2019**	Party Name:MENTHA& ALLIED PRODUCTS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00947/AM20/	RLA File :05/24/040/00601/AM20/	Lic.No/Date:0510413159 01.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

176	**Case No.:105/13/82-ALC4/2019**	Party Name:REFLUX ENTERPRISES	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00948/AM20/	RLA File :03/95/040/00931/AM20/	Lic.No/Date:0310833815 01.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

177	**Case No.:107/13/82-ALC4/2019**	Party Name:SRIAM LABS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00950/AM20/	RLA File :09/24/040/00477/AM20/	Lic.No/Date:0910068319 01.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

178	**Case No.:108/13/82-ALC4/2019**	Party Name:PANACEA BIOTEC LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00951/AM20/	RLA File :05/24/040/00619/AM20/	Lic.No/Date:0510413189 02.01.2020	:31.01.2020
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

179	**Case No.:110/13/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00953/AM20/	RLA File :03/94/040/00807/AM20/	Lic.No/Date:0310833861 02.01.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	Hydrocortison Butyrate Cream - Lipophilic 0.1% 45gm (Net. wt. of Hydrocortisone Butyarte Micronized USP is 3.150 Kgs.)	1 Number Pack	1	Hydrocortisone Butyarte Micronized USP	45.90 mg
2	Hydrocortison Butyrate Cream - Lipophilic 0.1% 60gm (Net. wt. of Hydrocortisone Butyarte Micronized USP is 4.200 Kgs.)	1 Number Pack	1	Hydrocortisone Butyarte Micronized USP	61.20 mg

RA concerned may take further necessary action as per above decision of NC.

180	**Case No.:112/13/82-ALC4/2019**	Party Name:TOJO VIKAS INTERNATIONAL PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00955/AM20/	RLA File :05/24/040/00616/AM20/	Lic.No/Date:0510413195 03.01.2020	

Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

181	**Case No.:119/13/82-ALC4/2019**	Party Name:STYRAX LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00962/AM20/	RLA File :26/24/040/00010/AM20/	Lic.No/Date:2610012891 03.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

182	**Case No.:133/13/82-ALC4/2019**	Party Name:INTAS PHARMACEUTICALS LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00976/AM20/	RLA File :08/24/040/00321/AM20/	Lic.No/Date:0810146922 03.01.2020	
	Decision: Deferred for comments of TE.			

183	**Case No.:118/13/82-ALC4/2019**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00961/AM20/	RLA File :09/24/040/00496/AM20/	Lic.No/Date:0910068340 06.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

184	**Case No.:120/13/82-ALC4/2019**	Party Name:BRAWN LABORATORIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00963/AM20/	RLA File :05/23/040/00390/AM20/	Lic.No/Date:0510413216 06.01.2020	
	Decision: Deferred for comments of TE.			

185	**Case No.:121/13/82-ALC4/2019**	Party Name:REYAANSH HEALTHCARE	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00964/AM20/	RLA File :03/95/040/00826/AM20/	Lic.No/Date:0310833938 06.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

186	**Case No.:140/13/82-ALC4/2019**	Party Name:DEEPAK PHENOLICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00983/AM20/	RLA File :34/24/040/00267/AM20/	Lic.No/Date:3410045769 07.01.2020	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm: **(i) Quantity and commercial value of Co-Product Acetone produced.** **(ii) Percentage yield on molar basis.**			

187	**Case No.:141/13/82-ALC4/2019**	Party Name:DEEPAK PHENOLICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00984/AM20/	RLA File :34/24/040/00263/AM20/	Lic.No/Date:3410045770 07.01.2020	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm: **(i) Quantity and commercial value of Co-Product Phenol obtained.** **(ii) Percentage yield on molar basis.**			

188	**Case No.:142/13/82-ALC4/2019**	Party Name:INDO AMINES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00985/AM20/	RLA File :03/94/040/00834/AM20/	Lic.No/Date:0310833988 08.01.2020	
	Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower: Export Product: LAURYL AMINE; Qty.: 1 kg; Sl. No.: 1; Import items: LAURIC ACID; Qty.: 1.48 kg RA concerned may take further necessary action as per above decision of NC.			

189	**Case No.:145/13/82-ALC4/2019**	Party Name:YASHO INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00988/AM20/	RLA File :03/95/040/00991/AM20/	Lic.No/Date:0310834010 08.01.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
ZINC DIBUTYL DITHIOCARBAMATE (ZDBC)	1 kg	1	ZINC OXIDE	0.18 kg
		2	DI-BUTYLAMINE	0.573 kg
		3	CARBON DISULPHIDE	0.338 kg

RA concerned may take further necessary action as per above decision of NC.

190	**Case No.:149/13/82-ALC4/2019**	Party Name:SIGMA LABORATORIES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00992/AM20/	RLA File :03/95/040/00950/AM20/	Lic.No/Date:0310834031 09.01.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
PROBENECID TABLETS-500MG BRAND NAME : PRO-CID / PROBENECID-AFT	1 Number Tablet	1	PROBENECID USP	510.00 mg
Note: Firm will declare export quantity in number of Tablets in line with DML.				

RA concerned may take further necessary action as per above decision of NC.

191	**Case No.:150/13/82-ALC4/2019**	Party Name:TINA ORGANICS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00993/AM20/	RLA File :05/24/040/00633/AM20/	Lic.No/Date:0510413266 09.01.2020	

Decision: Deferred for comments of TE.

192	**Case No.:155/13/82-ALC4/2019**	Party Name:EMMENNAR PHARMA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/00998/AM20/	RLA File :09/24/040/00485/AM20/	Lic.No/Date:0910068366 13.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

193	**Case No.:156/13/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/00999/AM20/	RLA File :03/94/040/00843/AM20/	Lic.No/Date:0310834099 13.01.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Import items	Qty.
1	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 60gm) (Net Wt. of Calcipotriene (Calcipotriol) is 6.00 Gms.)	2000.000 Number	CALCIPOTRIENE (CALCIPOTRIOL)	152.00 Gram
2	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 5gm) (Net Wt. of Calcipotriene (Calcipotriol) is 0.50Gms.)	2000.000 Number		
3	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 120gm) (Net Wt. of Calcipotriene (Calcipotriol) is 12.00Gms.)	2000.000 Number		
4	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 15gm) (Net Wt. of Calcipotriene (Calcipotriol) is 1.50Gms.)	2000.000 Number		
5	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 45gm) (Net Wt. of Calcipotriene (Calcipotriol) is 4.50Gms.)	2000.000 Number		
6	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 30gm) (Net Wt. of Calcipotriene (Calcipotriol) is 3.00Gms.)	2000.000 Number		

7	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 90gm) (Net Wt. of Calcipotriene (Calcipotriol) is 9.00Gms.)	2000.000 Number		
8	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 100gm) (Net Wt. of Calcipotriene (Calcipotriol) is 10.00Gms.)	2000.000 Number		
9	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 5gm) (Net Wt. of Calcipotriene (Calcipotriol) is 1.25Gms.)	5000.000 Number		
10	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 30gm) (Net Wt. of Calcipotriene (Calcipotriol) is 7.50Gms.)	5000.000 Number		
11	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 45gm) (Net Wt. of Calcipotriene (Calcipotriol) is 11.25Gms.)	5000.000 Number		
12	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 60gm) (Net Wt. of Calcipotriene (Calcipotriol) is 15.00Gms.)	5000.000 Number		
13	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 100gm) (Net Wt. of Calcipotriene (Calcipotriol) is 25.00Gms.)	5000.000 Number		
14	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 120gm) (Net Wt. of Calcipotriene (Calcipotriol) is 30.00Gms.)	5000.000 Number		
15	Calcipotriene Ointment 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 50gm) (Net Wt. of Calcipotriene (Calcipotriol) is 12.50Gms.)	5000.000 Number		

RA concerned may take further necessary action as per above decision of NC.

194	**Case No.:157/13/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01000/AM20/	RLA File :03/94/040/00844/AM20/	Lic.No/Date:0310834101 13.01.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Import items	Qty.
1	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 60gm) (Net Wt. of Calcipotriene (Calcipotriol) is 6.00 Gms.)	2000.000 Number	CALCIPOTRIENE (CALCIPOTRIOL)	152.00 Gram
2	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 5gm) (Net Wt. of Calcipotriene (Calcipotriol) is 0.50Gms.)	2000.000 Number		
3	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 120gm) (Net Wt. of Calcipotriene (Calcipotriol) is 12.00Gms.)	2000.000 Number		
4	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 15gm) (Net Wt. of Calcipotriene (Calcipotriol) is 1.50Gms.)	2000.000 Number		
5	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 45gm) (Net Wt. of Calcipotriene (Calcipotriol) is 4.50Gms.)	2000.000 Number		
6	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 30gm) (Net Wt. of Calcipotriene (Calcipotriol) is 3.00Gms.)	2000.000 Number		
7	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 90gm) (Net Wt. of Calcipotriene (Calcipotriol) is 9.00Gms.)	2000.000 Number		
8	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 100gm) (Net Wt. of Calcipotriene (Calcipotriol) is 10.00Gms.)	2000.000 Number		
9	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 5gm) (Net Wt. of Calcipotriene (Calcipotriol) is 1.25Gms.)	5000.000 Number		
10	Calcipotriene Cream 0.005%	5000.000		

	(Calcitrene Cream USP 0.005%) (Pack Size 30gm) (Net Wt. of Calcipotriene (Calcipotriol) is 7.50Gms.)	Number		
11	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 45gm) (Net Wt. of Calcipotriene (Calcipotriol) is 11.25Gms.)	5000.000 Number		
12	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 60gm) (Net Wt. of Calcipotriene (Calcipotriol) is 15.00Gms.)	5000.000 Number		
13	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 100gm) (Net Wt. of Calcipotriene (Calcipotriol) is 25.00Gms.)	5000.000 Number		
14	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 120gm) (Net Wt. of Calcipotriene (Calcipotriol) is 30.00Gms.)	5000.000 Number		
15	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 50gm) (Net Wt. of Calcipotriene (Calcipotriol) is 12.50 Gms.)	5000.000 Number		

RA concerned may take further necessary action as per above decision of NC.

195	**Case No.:161/13/82-ALC4/2019**	Party Name:VIVIN DRUGS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01004/AM20/	RLA File :09/24/040/00484/AM20/	Lic.No/Date:0910068369 14.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

196	**Case No.:166/13/82-ALC4/2019**	Party Name:SHIRDI CHEMICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01009/AM20/	RLA File :03/95/040/01005/AM20/	Lic.No/Date:0310834190 15.01.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
DMBPC OR 4,4-Cyclohexylidene bis 2-methylphenol OR Dimethylbisphenolcyclohexane DMBPC	1 kg	1	Ortho Cresol Cas No. 95-48-7	0.974 kg
		2	3-Mercaptopropionic Acid Minimum 99%	0.025 kg
		3	Dodecyl Benzene Sulphonic Acid Minimum 94%	0.065 kg

RA concerned may take further necessary action as per above decision of NC.

197	**Case No.:167/13/82-ALC4/2019**	Party Name:ARCH PHARMALABS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01010/AM20/	RLA File :03/94/040/00862/AM20/	Lic.No/Date:0310834233 16.01.2020	

Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

198	**Case No.:168/13/82-ALC4/2019**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01011/AM20/	RLA File :03/94/040/00846/AM20/	Lic.No/Date:0310834236 16.01.2020	

Decision: Deferred for comments of TE.

199	**Case No.:169/13/82-ALC4/2019**	Party Name:INNOVARE LABS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01012/AM20/	RLA File :09/24/040/00514/AM20/	Lic.No/Date:0910068370 16.01.2020	

Decision: Deferred for comments of TE.

200	**Case No.:170/13/82-ALC4/2019**	Party Name:DIVIS LABORATORIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01013/AM20/	RLA File :09/24/040/00516/AM20/	Lic.No/Date:0910068375 16.01.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and in line with GST Certificate, it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
NAPROXEN	1 kg	1	DL-NAPROXEN	1.25 kg
		2	N-OCTYL-D-GLUCAMINE	0.09 kg
		3	METHANOL	2.03 kg
		4	ACETIC ACID	0.54 kg
		5	TOLUENE	1.13 kg

RA concerned may take further necessary action as per above decision of NC.

201	**Case No.:173/13/82-ALC4/2019**	Party Name:VHB MEDISCIENCES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01016/AM20/	RLA File :03/95/040/01016/AM20/	Lic.No/Date:0310834259 16.01.2020	

Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

202	**Case No.:171/13/82-ALC4/2019**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01014/AM20/	RLA File :03/94/040/00850/AM20/	Lic.No/Date:0310834275 17.01.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Import items	Qty.
1	Alclometasone Dipropionate USP Cream 0.05% 15gm (Pack Size 15gm) (Net Wt. of Alclometasone Dipropionate USP is 0.675 Kgs.)	90000.000 Packs	Alclometasone Dipropionate USP	5.036 kg
2	Alclometasone Dipropionate USP Cream 0.05% 45gm (Pack Size 45gm) (Net Wt. of Alclometasone Dipropionate USP is 1.058 Kgs.)	47000.000 Packs		
3	Alclometasone Dipropionate USP Cream 0.05% 60gm (Pack Size 60gm) (Net Wt. of Alclometasone Dipropionate USP is 1.440 Kgs.)	48000.000 Packs		
4	Alclometasone Dipropionate Ointment 0.05% 15gm (Pack Size 15gm) (Net Wt. of Alclometasone Dipropionate USP is 0.360 Kgs.)	48000.000 Packs		
5	Alclometasone Dipropionate Ointment 0.05% 45gm (Pack Size 45gm) (Net Wt. of Alclometasone Dipropionate USP is 0.799 Kgs.)	35500.000 Packs		
6	Alclometasone Dipropionate Ointment 0.05% 60gm (Pack Size 60gm) (Net Wt. of Alclometasone Dipropionate USP is 0.600 Kgs.)	20000.000 Packs		

RA concerned may take further necessary action as per above decision of NC.

203	**Case No.:172/13/82-ALC4/2019**	Party Name:ETERNIS FINE CHEMICALS LIMITED,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01015/AM20/	RLA File :03/94/040/00646/AM20/	Lic.No/Date:0310834276 17.01.2020	

Decision: Deferred for comments of TE.

204	**Case No.:174/13/82-ALC4/2019**	Party Name:PIRAMAL ENTERPRISES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01017/AM20/	RLA File :03/95/040/01020/AM20/	Lic.No/Date:0310834270 17.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

205	**Case No.:175/13/82-ALC4/2019**	Party Name:RENOWN PHARMACEUTICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01018/AM20/	RLA File :34/24/040/00326/AM20/	Lic.No/Date:3410045792 17.01.2020	
	Decision: Deferred for comments of TE.			

206	**Case No.:176/13/82-ALC4/2019**	Party Name:DEEPAK PHENOLICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01019/AM20/	RLA File :34/24/040/00304/AM20/	Lic.No/Date:3410045794 17.01.2020	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm: **(i) Quantity and commercial value of Co-Product Acetone produced.** **(ii) Percentage yield on molar basis.**			

207	**Case No.:177/13/82-ALC4/2019**	Party Name:SUPERMINT EXPORTS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01020/AM20/	RLA File :05/24/040/00670/AM20/	Lic.No/Date:0510413367 17.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

208	**Case No.:178/13/82-ALC4/2019**	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01021/AM20/	RLA File :05/24/040/00666/AM20/	Lic.No/Date:0510413372 17.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

209	**Case No.:179/13/82-ALC4/2019**	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01022/AM20/	RLA File :05/24/040/00669/AM20/	Lic.No/Date:0510413373 17.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

210	**Case No.:180/13/82-ALC4/2019**	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01023/AM20/	RLA File :05/24/040/00667/AM20/	Lic.No/Date:0510413374 17.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

211	**Case No.:186/13/82-ALC4/2019**	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01029/AM20/	RLA File :05/24/040/00657/AM20/	Lic.No/Date:0510413378 17.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

212	**Case No.:188/13/82-ALC4/2019**	Party Name:DEEPAK PHENOLICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01031/AM20/	RLA File :34/24/040/00288/AM20/	Lic.No/Date:3410045795 17.01.2020	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm: **(i) Quantity and commercial value of Co-Product Acetone produced.** **(ii) Percentage yield on molar basis.**			

213	**Case No.:189/13/82-ALC4/2019**	Party Name:GLOBAL CALCIUM PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01032/AM20/	RLA File :07/24/040/00245/AM20/	Lic.No/Date:0710116038 17.01.2020	
	Decision: Deferred for comments of TE.			

214	**Case No.:183/13/82-ALC4/2019**	Party Name:ARCH PHARMALABS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01026/AM20/	RLA File :03/94/040/00874/AM20/	Lic.No/Date:0310834314 20.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

215	**Case No.:184/13/82-ALC4/2019**	Party Name:ARCH PHARMALABS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01027/AM20/	RLA File :03/94/040/00875/AM20/	Lic.No/Date:0310834316 20.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

216	**Case No.:185/13/82-ALC4/2019**	Party Name:ARCH PHARMALABS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01028/AM20/	RLA File :03/94/040/00877/AM20/	Lic.No/Date:0310834317 20.01.2020	
	Decision: The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

217	**Case No.:191/13/82-ALC4/2019**	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01034/AM20/	RLA File :09/24/040/00527/AM20/	Lic.No/Date:0910068384 20.01.2020	
	Decision: Deferred for comments of TE.			

218	**Case No.:1/2/82-ALC4/2020**	Party Name:ARCH PHARMALABS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01035/AM20/	RLA File :03/94/040/00888/AM20/	Lic.No/Date:0310834332 20.01.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

219	**Case No.:2/2/82-ALC4/2020**	Party Name:ARCH PHARMALABS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01036/AM20/	RLA File :03/94/040/00890/AM20/	Lic.No/Date:0310834333 20.01.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

220	**Case No.:3/2/82-ALC4/2020**	Party Name:ETERNIS FINE CHEMICALS LIMITED,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01037/AM20/	RLA File :03/94/040/00715/AM20/	Lic.No/Date:0310834342 20.01.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

221	**Case No.:4/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01038/AM20/	RLA File :03/94/040/00872/AM20/	Lic.No/Date:0310834344 20.01.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Import items	Qty.
1	Clotrimazole & Betamethasone Dipropionate Cream USP 1%/0.05% (Pack Size 15gm) (Net Wt. of Clotrimazole USP is 150.00 Kgs.)	1000000.000 Packs	Clotrimazole USP	1071.00 kg
2	Clotrimazole & Betamethasone Dipropionate Cream USP 1%/0.05% (Pack Size 45gm) (Net Wt. of Import Clotrimazole USP is 450.00 Kgs.)	1000000.000 Packs		
3	Clotrimazole Cream USP 1% (Pack Size 15 Grams) (Net Wt. of Clotrimazole USP is 75.00 Kgs.)	500000.000 Packs		
4	Clotrimazole Cream USP 1% (Pack Size 30 Grams) (Net Wt. of Clotrimazole USP is 150.00 Kgs.)	500000.000 Packs		
5	Clotrimazole Cream USP 1% (Pack Size 45 Grams) (Net Wt. of Clotrimazole USP is 225.00 Kgs.)	500000.000 Packs		

RA concerned may take further necessary action as per above decision of NC.

222	**Case No.:5/2/82-ALC4/2020**	Party Name:ARCH PHARMALABS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01039/AM20/	RLA File :03/94/040/00889/AM20/	Lic.No/Date:0310834354 21.01.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

223	**Case No.:6/2/82-ALC4/2020**	Party Name:VETBIOCHEM INDIA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01040/AM20/	RLA File :31/83/040/00138/AM20/	Lic.No/Date:3110067663 21.01.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

224	**Case No.:7/2/82-ALC4/2020**	Party Name:PANACEA BIOTEC LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01041/AM20/	RLA File :05/24/040/00683/AM20/	Lic.No/Date:0510413419 22.01.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

225	**Case No.:8/2/82-ALC4/2020**	Party Name:AQUILA ORGANICS PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01042/AM20/	RLA File :03/94/040/00879/AM20/	Lic.No/Date:0310834406 22.01.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

226	**Case No.:9/2/82-ALC4/2020**	Party Name:LACTOSE (INDIA) LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01043/AM20/	RLA File :03/95/040/01033/AM20/	Lic.No/Date:0310834414 23.01.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

227	**Case No.:10/2/82-ALC4/2020**	Party Name:GLENMARK LIFE SCIENCES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01044/AM20/	RLA File :03/94/040/00902/AM20/	Lic.No/Date:0310834427 23.01.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

228	**Case No.:11/2/82-ALC4/2020**	Party Name:AURA LIFECARE PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01045/AM20/	RLA File :34/24/040/00323/AM20/	Lic.No/Date:3410045804 23.01.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

229	**Case No.:12/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01046/AM20/	RLA File :03/94/040/00906/AM20/	Lic.No/Date:0310834474 24.01.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

230

Case No.:13/2/82-ALC4/2020	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
HQ File :01/82/050/01047/AM20/	RLA File :03/94/040/00893/AM20/	Lic.No/Date:0310834475 24.01.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Import items	Qty.
1	Ursodiol Tablets USP 250mg (Pack Size 100 Tabs.) (Net. wt. of Ursodiol USP is 925.000 Kgs.)	37000.000 Packs	Ursodiol USP	2500.53 kg
2	Ursodiol Tablets USP 500mg (Pack Size 100 Tabs.) (Net. wt. of Ursodiol USP is 1526.50 Kgs.)	30530.000 Packs		

RA concerned may take further necessary action as per above decision of NC.

231	**Case No.:14/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01048/AM20/	RLA File :03/94/040/00861/AM20/	Lic.No/Date:0310834476 24.01.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Import items	Qty.
1	Clobetasol Propionate Foam 0.05% 50gm (Net. wt. of Net. wt. of Clobetasol Propionate USP (Micronized) is 3.750 Kgs.)	150000.000 Packs	CLOBETASOL PROPIONATE USP (MICRONIZED	24.65 kg
2	Clobetasol Propionate Foam 0.05% 100gm (Net. wt. of Clobetasol Propionate USP (Micronized) is 7.500 Kgs.)	150000.000 Packs		
3	Clobetasol Propionate Cream USP 0.05% (Pack Size 15gm)(Net Weight of Clobetasol Propionate USP (Micronized) 0.750 Kgs)	100000.000 Packs		
4	Clobetasol Propionate Cream USP 0.05% (Pack size 30gm)(Net Weight of Clobetasol Propionate USP (Micronized) 0.300 Kgs)	20000.000 Packs		
5	Clobetasol Propionate Cream USP 0.05% (Pack size 45 gm)(Net Weight of Clobetasol Propionate USP (Micronized) 0.450 Kgs)	20000.000 Packs		
6	Clobetasol Propionate Cream USP 0.05% (Pack size 60gm)(Net Weight of Clobetasol Propionate USP (Micronized) 0.600 Kgs)	20000.000 Packs		
7	Clobetasol Propionate Ointment USP 0.05% (Pack size 15gm) (Net Weight of Clobetasol Propionate USP (Micronized) 0.150 Kgs)	20000.000 Packs		
8	Clobetasol Propionate Ointment USP 0.05% (Pack size 30gm) (Net Weight of Clobetasol Propionate USP (Micronized) 0.750 Kgs)	50000.000 Packs		
9	Clobetasol Propionate Ointment USP 0.05% (Pack size 45gm) (Net Weight of Clobetasol Propionate USP (Micronized) 0.900 Kgs)	40000.000 Packs		
10	Clobetasol Propionate Ointment USP 0.05% (Pack size 60gm) (Net Weight of Clobetasol Propionate USP (Micronized) 0.600 Kgs)	20000.000 Packs		

11	Clobetasol Propionate Spray 0.05% (Pack size 59ml) (Net Weight of Clobetasol Propionate USP (Micronized) 1.180 Kgs)	40000.000 Packs		
12	Clobetasol Propionate Spray 0.05% (Pack size 125ml) (Net Weight of Clobetasol Propionate USP (Micronized) 2.500 Kgs)	40000.000 Packs		
13	Clobetasol Prop. Top Sol USP, 0.05% 25ml (Net Weight of Clobetasol Propionate USP (Micronized) 0.625 Kgs)	50000.000 Packs		
14	Clobetasol Prop. Top Sol USP, 0.05% 50ml (Net Weight of Clobetasol Propionate USP (Micronized) 1.000 Kgs)	40000.000 Packs		
15	Clobetasol Pro Shampoo, 0.05 % 118ml (Net Weight of Clobetasol Propionate USP (Micronized) 2.360 Kgs)	40000.000 Packs		
16	Clobetasol Propionate Foam 0.05% 100gm (Net. wt. of Clobetasol Propionate USP (Micronized) is 0.500 Kgs.)	10000.000 Packs		
17	Clobetasol Propionate Foam 0.05% 50gm (Net. wt. of Clobetasol Propionate USP (Micronized) is 0.250 Kgs.)	10000.000 Packs		

RA concerned may take further necessary action as per above decision of NC.

232	**Case No.:15/2/82-ALC4/2020**	Party Name:SWAASA PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01049/AM20/	RLA File :26/24/040/00016/AM20/	Lic.No/Date:2610012902 24.01.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

233	**Case No.:16/2/82-ALC4/2020**	Party Name:AMI LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01050/AM20/	RLA File :34/24/040/00300/AM20/	Lic.No/Date:3410045821 28.01.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

234	**Case No.:17/2/82-ALC4/2020**	Party Name:AMI LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01051/AM20/	RLA File :34/24/040/00301/AM20/	Lic.No/Date:3410045822 28.01.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

235	**Case No.:18/2/82-ALC4/2020**	Party Name:AMI LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01052/AM20/	RLA File :34/24/040/00302/AM20/	Lic.No/Date:3410045823 28.01.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

236	**Case No.:19/2/82-ALC4/2020**	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01053/AM20/	RLA File :09/24/040/00532/AM20/	Lic.No/Date:0910068419 28.01.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

237	**Case No.:20/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01054/AM20/	RLA File :03/94/040/00908/AM20/	Lic.No/Date:0310834502 28.01.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

238	**Case No.:21/2/82-ALC4/2020**	Party Name:SYNTHO CHIRALS PVT. LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01055/AM20/	RLA File :09/24/040/00540/AM20/	Lic.No/Date:0910068421 28.01.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

239	**Case No.:22/2/82-ALC4/2020**	Party Name:STERILE INDIA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01056/AM20/	RLA File :05/24/040/00693/AM20/	Lic.No/Date:0510413470 29.01.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

240	**Case No.:23/2/82-ALC4/2020**	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01057/AM20/	RLA File :05/24/040/00689/AM20/	Lic.No/Date:0510413471 29.01.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

241	**Case No.:24/2/82-ALC4/2020**	Party Name:GENERIC HEALTHCARE PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01058/AM20/	RLA File :31/83/040/00135/AM20/	Lic.No/Date:3110067669 29.01.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

242	**Case No.:25/2/82-ALC4/2020**	Party Name:KRISHNA ANTIOXIDANTS PVT. LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01059/AM20/	RLA File :03/94/040/00924/AM20/	Lic.No/Date:0310834532 29.01.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
CORROSION INHIBITOR (containing NLT 80% Tall Oil Fatty Acid)	1 kg	1	TALL OIL FATTY ACID	0.80 kg
		2	DIETHYLENETRIAMINE (DETA)	0.30 kg

RA concerned may take further necessary action as per above decision of NC.

243	**Case No.:26/2/82-ALC4/2020**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01060/AM20/	RLA File :09/24/040/00545/AM20/	Lic.No/Date:0910068434 31.01.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

244	**Case No.:27/2/82-ALC4/2020**	Party Name:KLJ PLASTICIZERS LIMITED.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01061/AM20/	RLA File :05/23/040/00417/AM20/	Lic.No/Date:0510413496 31.01.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

245	**Case No.:28/2/82-ALC4/2020**	Party Name:SMS LIFESCIENCES INDIA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01062/AM20/	RLA File :09/24/040/00521/AM20/	Lic.No/Date:0910068451 05.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

246	**Case No.:29/2/82-ALC4/2020**	Party Name:S V LABS PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01063/AM20/	RLA File :09/24/040/00558/AM20/	Lic.No/Date:0910068453 05.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

247	**Case No.:30/2/82-ALC4/2020**	Party Name:JODAS EXPOIM PVT.LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01064/AM20/	RLA File :09/24/040/00531/AM20/	Lic.No/Date:0910068454 05.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

248	**Case No.:31/2/82-ALC4/2020**	Party Name:SANDHYAORGANIC CHEMICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status:CaseAdded**
	HQ File :01/82/050/01065/AM20/	RLA File :03/95/040/00985/AM20/	Lic.No/Date:0310834682 06.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

249	**Case No.:32/2/82-ALC4/2020**	Party Name:CLEAN SCIENCE AND TECHNOLOGY PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01066/AM20/	RLA File :31/83/040/00140/AM20/	Lic.No/Date:3110067673 06.02.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

250

	Case No.:33/2/82-ALC4/2020	Party Name:CLEAN SCIENCE AND TECHNOLOGY PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01067/AM20/	RLA File :31/83/040/00141/AM20/	Lic.No/Date:3110067675 06.02.2020	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 6/82-ALC4/2019 dated 16.08.2019, it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Guaiacol	1 kg	1	Phenol	1.012 kg
		2	Methanol	0.39 kg
		3	Hydrogen Peroxide PURITY 60%	0.687 kg
		4	Acetone (Solvent)	0.14 kg

RA may take appropriate action as per the decision of Norms Committee.

251	**Case No.:34/2/82-ALC4/2020**	Party Name:CLEAN SCIENCE AND TECHNOLOGY PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01068/AM20/	RLA File :31/83/040/00143/AM20/	Lic.No/Date:3110067676 06.02.2020	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 6/82-ALC4/2019 dated 16.08.2019, it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
Guaiacol	1 kg	1	Phenol	1.012 kg
		2	Methanol	0.39 kg
		3	Hydrogen Peroxide PURITY 60%	0.687 kg
		4	Acetone (Solvent)	0.14 kg

RA may take appropriate action as per the decision of Norms Committee.

252	**Case No.:35/2/82-ALC4/2020**	Party Name:CLEAN SCIENCE AND TECHNOLOGY PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01069/AM20/	RLA File :31/83/040/00142/AM20/	Lic.No/Date:3110067677 06.02.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

253	**Case No.:36/2/82-ALC4/2020**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01070/AM20/	RLA File :09/24/040/00459/AM20/	Lic.No/Date:0910068458 06.02.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

254	**Case No.:37/2/82-ALC4/2020**	Party Name:ALEOR DERMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01071/AM20/	RLA File :34/24/040/00339/AM20/	Lic.No/Date:3410045849 06.02.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

255	**Case No.:38/2/82-ALC4/2020**	Party Name:ALEOR DERMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01072/AM20/	RLA File :34/24/040/00342/AM20/	Lic.No/Date:3410045850 06.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

256

Case No.:39/2/82-ALC4/2020	Party Name:COVALENTLABORATORIES PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
HQ File :01/82/050/01073/AM20/	RLA File :09/24/040/00563/AM20/	Lic.No/Date:0910068464 07.02.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Ceftriaxone Sodium Sterile (PKD 10 KG IN 20LTRS)	1 kg	1	Ceftriaxone Sodium Non Sterile	1.04 kg
		2	Acetone	1.72 kg
		3	Activated Carbon [Carbon Enoanticromos]	51.66 gms
		4	Aluminium Canisters 20L with inner & Outer Lids	Relevant as per packing policy with accountability

RA concerned may take further necessary action as per above decision of NC.

257	**Case No.:40/2/82-ALC4/2020**	Party Name:MAKSON HEALTH CARE PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01074/AM20/	RLA File :11/24/040/00008/AM20/	Lic.No/Date:1110028682 10.02.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

258	**Case No.:41/2/82-ALC4/2020**	Party Name:MAKSON HEALTH CARE PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01075/AM20/	RLA File :11/24/040/00009/AM20/	Lic.No/Date:1110028683 10.02.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

259	**Case No.:42/2/82-ALC4/2020**	Party Name:PHALANX LABS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01076/AM20/	RLA File :26/24/040/00019/AM20/	Lic.No/Date:2610012904 10.02.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

260	**Case No.:43/2/82-ALC4/2020**	Party Name:MATRIX FINE SCIENCES PVT.LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01077/AM20/	RLA File :03/95/040/01070/AM20/	Lic.No/Date:0310834755 11.02.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

261

Case No.:44/2/82-ALC4/2020	Party Name:PI INDUSTRIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
HQ File :01/82/050/01078/AM20/	RLA File :13/24/040/00196/AM20/	Lic.No/Date:1310049512 11.02.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
3-(((5-(difluoromethoxy)-1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)methyl)thio)-5,5-dimethyl-4,5-dihydroisoxazol	1 kg	1	Glyoxalic acid 50% Min.	0.720 kg
		2	Hydroxylamine Sulphate	0.400 kg
		3	Bromine	1.214 kg
		4	Thiourea	0.252 kg
		5	1-Methyl-3-(trifluoromethyl)-1H pyrazole -5-ol (MTP)	0.566 kg
		6	n-Butyl Acetate	0.643 kg
		7	Acetonitrile	0.923 kg

RA concerned may take further necessary action as per above decision of NC.

262	**Case No.:45/2/82-ALC4/2020**	Party Name:BALAJI AMINES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01079/AM20/	RLA File :31/83/040/00144/AM20/	Lic.No/Date:3110067681 11.02.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

263	**Case No.:46/2/82-ALC4/2020**	Party Name:SRINI PHARMACEUTICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01080/AM20/	RLA File :09/24/040/00536/AM20/	Lic.No/Date:0910068471 12.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

264	**Case No.:47/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01081/AM20/	RLA File :03/94/040/00935/AM20/	Lic.No/Date:0310834799 12.02.2020	

Decision: TheCommittee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Import items	Qty.
1	Lidocaine Ointment USP 5% (Pack Size 35.44gms) (Net Wt.of Lidocaine USP is 221.500 Kgs.)	125000.000 Packs	LIDOCAINE USP	570.18 kg
2	Lidocaine Ointment USP 5% (Pack Size 50gms) (Net Wt.of Lidocaine USP is 337.500 Kgs.)	135000.000 Packs		

RA concerned may take further necessary action as per above decision of NC.

265	**Case No.:48/2/82-ALC4/2020**	Party Name:SHREE GANESH REMEDIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01082/AM20/	RLA File :34/24/040/00333/AM20/	Lic.No/Date:3410045871 13.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

266	**Case No.:49/2/82-ALC4/2020**	Party Name:KOPRAN RESEARCH LABORATORIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01083/AM20/	RLA File :03/94/040/00948/AM20/	Lic.No/Date:0310834835 13.02.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

267	**Case No.:50/2/82-ALC4/2020**	Party Name:KAIRAV CHEMOFARBE INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01084/AM20/	RLA File :03/94/040/00961/AM20/	Lic.No/Date:0310834847 13.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

268	**Case No.:51/2/82-ALC4/2020**	Party Name:KAIRAV CHEMOFARBE INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01085/AM20/	RLA File :03/94/040/00960/AM20/	Lic.No/Date:0310834848 13.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

269	**Case No.:52/2/82-ALC4/2020**	Party Name:GLENMARK LIFE SCIENCES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01086/AM20/	RLA File :03/94/040/00910/AM20/	Lic.No/Date:0310834853 13.02.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
PERINDOPRIL ERBUMINE	1 kg	1	S-(-)-INDOLINE-2-CARBOXYLIC ACID	0.947 kg
		2	L-NORVALINE	1.423 kg
		3	ACETONITRILE	6.345 kg
		4	N,N-CARBONYLDIIMIDAZOLE	0.700 kg
		5	METHYLENE CHLORIDE (MDC)	6.260 kg
		6	SODIUM PYRUVATE	1.42 kg
		7	METHANOL	10.80 kg

RA concerned may take further necessary action as per above decision of NC.

270	**Case No.:53/2/82-ALC4/2020**	Party Name:GLENMARK LIFE SCIENCES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01087/AM20/	RLA File :03/94/040/00940/AM20/	Lic.No/Date:0310834854 13.02.2020	

Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.

271	**Case No.:54/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01088/AM20/	RLA File :03/94/040/00929/AM20/	Lic.No/Date:0310834855 13.02.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Import items	Qty.
1	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 60gm) (Net Wt. of Calcipotriene (Calcipotriol) is 15.00 Gms.)	5000.000 Number	CALCIPOTRIENE (CALCIPOTRIOL)	300.90 Gram
2	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 5gm) (Net Wt. of Calcipotriene (Calcipotriol) is 1.25 Gms.)	5000.000 Number		
3	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 120gm) (Net Wt. of Calcipotriene (Calcipotriol) is 30.00Gms.)	5000.000 Number		
4	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 15gm) (Net Wt. of Calcipotriene (Calcipotriol) is 3.75 Gms.)	5000.000 Number		
5	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 45gm) (Net Wt. of Calcipotriene (Calcipotriol) is 11.25 Gms.)	5000.000 Number		
6	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 30gm) (Net Wt. of Calcipotriene (Calcipotriol) is 7.50 Gms.)	5000.000 Number		
7	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 90gm) (Net Wt. of Calcipotriene (Calcipotriol) is 45.00 Gms.)	10000.000 Number		
8	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 100gm) (Net Wt. of Calcipotriene (Calcipotriol) is 25.00 Gms.)	5000.000 Number		
9	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 5gm) (Net Wt. of Calcipotriene (Calcipotriol) is 2.50 Gms.)	10000.000 Number		

10	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 30gm) (Net Wt. of Calcipotriene (Calcipotriol) is 15.00 Gms.)	10000.000 Number		
11	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 45gm) (Net Wt. of Calcipotriene (Calcipotriol) is 11.25 Gms.)	5000.000 Number		
12	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 60gm) (Net Wt. of Calcipotriene (Calcipotriol) is 30.00 Gms.)	10000.000 Number		
13	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 100gm) (Net Wt. of Calcipotriene (Calcipotriol) is 25.00 Gms.)	5000.000 Number		
14	Calcipotriene Cream 0.005% (Calcitrene Cream USP 0.005%) (Pack Size 120gm) (Net Wt. of Calcipotriene (Calcipotriol) is 60.00 Gms.)	10000.000 Number		
15	Calcipotrene Ointment USP 0.005% (Calcitrene Ointment USP 0.005%) (Pack Size 50gm) (Net Wt. of Calcipotriene (Calcipotriol) is 12.50 Gms.)	5000.000 Number		

RA concerned may take further necessary action as per above decision of NC.

272	**Case No.:55/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01089/AM20/	RLA File :03/94/040/00930/AM20/	Lic.No/Date:0310834856 13.02.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

273	**Case No.:56/2/82-ALC4/2020**	Party Name:BENZO CHEM INDUSTRIES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01090/AM20/	RLA File :03/94/040/00962/AM20/	Lic.No/Date:0310834862 13.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

274	**Case No.:57/2/82-ALC4/2020**	Party Name:YASHO INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01091/AM20/	RLA File :03/95/040/01083/AM20/	Lic.No/Date:0310834867 14.02.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

275	**Case No.:58/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01092/AM20/	RLA File :03/94/040/00971/AM20/	Lic.No/Date:0310834878 17.02.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

276	**Case No.:59/2/82-ALC4/2020**	Party Name:ALTA LABORATORIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01093/AM20/	RLA File :03/94/040/00968/AM20/	Lic.No/Date:0310834879 17.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

277	**Case No.:60/2/82-ALC4/2020**	Party Name:MICRO LABS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01094/AM20/	RLA File :07/24/040/00275/AM20/	Lic.No/Date:0710116125 17.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

278	**Case No.:61/2/82-ALC4/2020**	Party Name:TADIMETY AROMATICS PVT. LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01095/AM20/	RLA File :07/24/040/00276/AM20/	Lic.No/Date:0710116142 18.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

279	**Case No.:65/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01099/AM20/	RLA File :03/94/040/00984/AM20/	Lic.No/Date:0310834920 18.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

280	**Case No.:66/2/82-ALC4/2020**	Party Name:VERGO PHARMA RESEARCH LABORATORIES PVT. LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01100/AM20/	RLA File :03/95/040/01081/AM20/	Lic.No/Date:0310834922 18.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

281	**Case No.:62/2/82-ALC4/2020**	Party Name:BALAJI AMINES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01096/AM20/	RLA File :31/83/040/00151/AM20/	Lic.No/Date:3110067689 19.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

282	**Case No.:63/2/82-ALC4/2020**	Party Name:SUPERMINT EXPORTS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01097/AM20/	RLA File :05/24/040/00729/AM20/	Lic.No/Date:0510413656 19.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

283	**Case No.:64/2/82-ALC4/2020**	Party Name:RAJASTHAN ANTIBIOTICS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01098/AM20/	RLA File :05/24/040/00728/AM20/	Lic.No/Date:0510413657 19.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

284	**Case No.:68/2/82-ALC4/2020**	Party Name:STERILE INDIA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01102/AM20/	RLA File :05/24/040/00730/AM20/	Lic.No/Date:0510413676 20.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

285	**Case No.:67/2/82-ALC4/2020**	Party Name:GITANJALI CHEMICALS PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01101/AM20/	RLA File :03/94/040/00928/AM20/	Lic.No/Date:0310834973 21.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

286	**Case No.:69/2/82-ALC4/2020**	Party Name:ORIENTAL AROMATICS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01103/AM20/	RLA File :03/95/040/01082/AM20/	Lic.No/Date:0310834955 21.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

287	**Case No.:73/2/82-ALC4/2020**	Party Name:SUDEEP PHARMA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01107/AM20/	RLA File :34/24/040/00272/AM20/	Lic.No/Date:3410045894 21.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

288	**Case No.:70/2/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01104/AM20/	RLA File :03/94/040/00970/AM20/	Lic.No/Date:0310835027 24.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

289	**Case No.:71/2/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01105/AM20/	RLA File :03/94/040/00969/AM20/	Lic.No/Date:0310835028 24.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

290	**Case No.:72/2/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status:CaseAdded**
	HQ File :01/82/050/01106/AM20/	RLA File :03/94/040/00980/AM20/	Lic.No/Date:0310835029 24.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

291	**Case No.:74/2/82-ALC4/2020**	Party Name:RECKITT BENCKISER (INDIA) PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01108/AM20/	RLA File :05/24/040/00731/AM20/	Lic.No/Date:0510413690 24.02.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

292	**Case No.:78/2/82-ALC4/2020**	Party Name:J N P PRODUCTS	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01112/AM20/	RLA File :34/24/040/00370/AM20/	Lic.No/Date:3410045901 24.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

293	**Case No.:75/2/82-ALC4/2020**	Party Name:FINE ORGANIC INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01109/AM20/	RLA File :03/94/040/01001/AM20/	Lic.No/Date:0310835056 25.02.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

294	**Case No.:76/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01110/AM20/	RLA File :03/94/040/00992/AM20/	Lic.No/Date:0310835057 25.02.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

295	**Case No.:77/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01111/AM20/	RLA File :03/94/040/01009/AM20/	Lic.No/Date:0310835058 25.02.2020	

Decision: TheCommittee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Import items	Qty.
1	FLUTICASONE LOTION 0.05% (Pack 30 ML) (Net wt. of Fluticasone Propionate USP is 0.525 Kgs.)	35000.000 Packs	Fluticasone Propionate USP	1.607 kg
2	FLUTICASONE LOTION 0.05% (Pack 60 ML) (Net wt. of Fluticasone Propionate USP is 1.050 Kgs.)	35000.000 Packs		

RA concerned may take further necessary action as per above decision of NC.

296	**Case No.:79/2/82-ALC4/2020**	Party Name:MEDREICH LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01113/AM20/	RLA File :07/24/040/00281/AM20/	Lic.No/Date:0710116165 25.02.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

297	**Case No.:80/2/82-ALC4/2020**	Party Name:BALAJI AMINES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01114/AM20/	RLA File :31/83/040/00150/AM20/	Lic.No/Date:3110067697 25.02.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

298	**Case No.:81/2/82-ALC4/2020**	Party Name:DEEPAK PHENOLICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01115/AM20/	RLA File :34/24/040/00359/AM20/	Lic.No/Date:3410045910 25.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019. However, the Committee considered the case as per agenda and based on the decision taken in similar cases of the firm, it was decided to call for following information from the firm: **(i) Quantity and commercial value of Co-Product Acetone produced.** **(ii) Percentage yield on molar basis.** **(iii) Complete set of 4.07 application alongwith technical details as per Appendix 4E.**			

299	**Case No.:82/2/82-ALC4/2020**	Party Name:DEEPAK PHENOLICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01116/AM20/	RLA File :34/24/040/00334/AM20/	Lic.No/Date:3410045911 25.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019. However, the Committee considered the case as per agenda and based on the decision taken in similar cases of the firm, it was decided to call for following information from the firm: **(i) Quantity and commercial value of Co-Product Acetone produced.** **(ii) Percentage yield on molar basis.** **(iii) Complete set of 4.07 application alongwith technical details as per Appendix 4E.**			

300	**Case No.:83/2/82-ALC4/2020**	Party Name:NATURAL AND ESSENTIAL OILS PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01117/AM20/	RLA File :07/24/040/00288/AM20/	Lic.No/Date:0710116169 25.02.2020	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm:			

	(i) **Complete material balance on the basis of purity of import item.**

301	**Case No.:84/2/82-ALC4/2020**	Party Name:PIRAMAL ENTERPRISES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01118/AM20/	RLA File :03/95/040/01121/AM20/	Lic.No/Date:0310835077 26.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

302	**Case No.:85/2/82-ALC4/2020**	Party Name:SATYADIVIS PHARMACEUTICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01119/AM20/	RLA File :09/24/040/00574/AM20/	Lic.No/Date:0910068514 26.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

303	**Case No.:86/2/82-ALC4/2020**	Party Name:SRINI PHARMACEUTICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01120/AM20/	RLA File :09/24/040/00593/AM20/	Lic.No/Date:0910068522 27.02.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

304	**Case No.:87/2/82-ALC4/2020**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01121/AM20/	RLA File :09/24/040/00596/AM20/	Lic.No/Date:0910068530 02.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

305	**Case No.:88/2/82-ALC4/2020**	Party Name:VIVIMED LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01122/AM20/	RLA File :09/24/040/00576/AM20/	Lic.No/Date:0910068533 02.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

306	**Case No.:89/2/82-ALC4/2020**	Party Name:CIPLA LIMITED.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01123/AM20/	RLA File :03/94/040/00991/AM20/	Lic.No/Date:0310835171 03.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

307	**Case No.:90/2/82-ALC4/2020**	Party Name:FDC LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01124/AM20/	RLA File :03/94/040/01023/AM20/	Lic.No/Date:0310835172 03.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

308	**Case No.:91/2/82-ALC4/2020**	Party Name:TAGOOR CHEMICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01125/AM20/	RLA File :09/24/040/00546/AM20/	Lic.No/Date:0910068543 03.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

309	**Case No.:92/2/82-ALC4/2020**	Party Name:TAGOOR CHEMICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01126/AM20/	RLA File :09/24/040/00547/AM20/	Lic.No/Date:0910068544 03.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

310	**Case No.:93/2/82-ALC4/2020**	Party Name:BDR PHARMACEUTICALS INTERNATIONAL PVT. LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01127/AM20/	RLA File :03/94/040/01012/AM20/	Lic.No/Date:0310835222 04.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

311	**Case No.:94/2/82-ALC4/2020**	Party Name:THINQ PHARMA CRO LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01128/AM20/	RLA File :03/95/040/01105/AM20/	Lic.No/Date:0310835265 06.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

312	**Case No.:95/2/82-ALC4/2020**	Party Name:MANGALAM ORGANICS LIMITED FORMERLY DUJODWALA PRODU	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01129/AM20/	RLA File :03/95/040/01078/AM20/	Lic.No/Date:0310835280 06.03.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

313	**Case No.:96/2/82-ALC4/2020**	Party Name:AETHER INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01130/AM20/	RLA File :52/24/040/00068/AM20/	Lic.No/Date:5210043358 06.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

314	**Case No.:97/2/82-ALC4/2020**	Party Name:NEOGEN CHEMICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01131/AM20/	RLA File :03/95/040/01151/AM20/	Lic.No/Date:0310835305 09.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

315	**Case No.:98/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01132/AM20/	RLA File :03/94/040/01018/AM20/	Lic.No/Date:0310835319 09.03.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import Items	Qty.
1	Lithium Carbonate capsule USP 150mg (Pack Size 100 Tabs.) (Net Wt. of Lithium Carbonate USP is 750.000 Kgs)	1 Number	1	Lithium Carbonate USP	153.00 mg
2	Lithium Carbonate capsule USP 300mg (Pack Size 100 Tabs.) (Net Wt. of Lithium Carbonate USP is 1500.000 Kgs)	1 Number	1	Lithium Carbonate USP	306.00 mg
3	Lithium Carbonate capsule USP 300mg (Pack Size 1000 Tabs.) (Net Wt. of Lithium Carbonate USP is 15000.000 Kgs)	1 Number	1	Lithium Carbonate USP	306.00 mg
4	Lithium Carbonate capsule USP 600mg (Pack Size 100 Tabs.) (Net Wt. of Lithium Carbonate USP is 3000.000 Kgs)	1 Number	1	Lithium Carbonate USP	612.00 mg
5	Lithium Carbonate ER Tab USP 300mg (Pack Size 100 Tabs.) (Net Wt. of Lithium Carbonate USP is 1800.000 Kgs)	1 Number	1	Lithium Carbonate USP	306.00 mg
6	Lithium Cabronate ER Tab USP 450MG (Pack Size 100 Tabs.) (Net Wt. of Lithium Carbonate USP is 2475.000 Kgs)	1 Number	1	Lithium Carbonate USP	459.00 mg
7	Lithium Cabronate ER Tab USP 300MG (Pack Size 1000 Tabs.) (Net Wt. of Lithium Carbonate USP is 600.000 Kgs)	1 Number	1	Lithium Carbonate USP	306.00 mg

RA concerned may take further necessary action as per above decision of NC.

316	**Case No.:99/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01133/AM20/	RLA File :03/94/040/01022/AM20/	Lic.No/Date:0310835320 09.03.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Import items	Qty.
1	Mometasone Furoate Ointment 0.10% (Pack 10gms) (Net Wt. of Mometasone Furoate Micronized 0.180 Kgs.)	18000.000 Packs	Mometasone Furoate Micronized	50.287 kg
2	Mometasone Furoate Ointment 0.10% (Pack 15gms) (Net Wt. of Mometasone Furoate Micronized 0.270 Kgs.)	18000.000 Packs		
3	Mometasone Furoate Ointment 0.10% /Momate Ointment 0.10% (Pack 20gms) (Net Wt. of Mometasone Furoate Micronized 0.280 Kgs.)	14000.000 Packs		
4	Mometasone Furoate Ointment 0.10% (Pack 30gms) (Net Wt. of Mometasone Furoate Micronized 3.000 Kgs.)	100000.000 Packs		
5	Mometasone Furoate Ointment 0.10% (pack 45gms) (Net Wt. of Mometasone Furoate Micronized 4.050 Kgs.)	90000.000 Packs		
6	Mometasone Furoate Ointment 0.10% (Pack 50gms) (Net Wt. of Mometasone Furoate Micronized 0.405 Kgs.)	8100.000 Packs		
7	Mometasone Furoate Ointment 0.10% (pack 60gms) (Net Wt. of Mometasone Furoate Micronized 0.570 Kgs.)	9500.000 Packs		
8	Mometasone Furoate Ointment 0.10% (pack 100gms) (Net Wt. of Mometasone Furoate Micronized 1.900 Kgs.)	19000.000 Packs		
9	Mometasone Furoate Tropical Solution USP 0.1% (Lotion) (Pack 30ml) (Net Wt. of Mometasone Furoate Micronized 0.360 Kgs.)	12000.000 Packs		
10	Mometasone Furoate Tropical Solution USP 0.1% (Lotion) (Pack 60ml) (Net Wt. of Mometasone Furoate Micronized 0.396 Kgs.)	6600.000 Packs		
11	Mometasone Furoate Cream 0.1% (Pack 10gms) (Net Wt. of Mometasone Furoate Micronized 0.210 Kgs.)	21000.000 Packs		
12	Mometasone Furoate Cream 0.1% (Pack 15gms) (Net Wt. of Mometasone Furoate Micronized 1.050 Kgs.)	70000.000 Packs		
13	Mometasone Furoate Cream 0.1% (Pack 20gms) (Net Wt. of Mometasone Furoate Micronized 0.100 Kgs.)	5000.000 Packs		

14	Mometasone Furoate Cream 0.1% /Metactiv Cream 0.10% (Pack 30gms) (Net Wt. of Mometasone Furoate Micronized 2.130 Kgs.)	71000.000 Packs		
15	Mometasone Furoate Cream 0.1% (Pack 45gms) (Net Wt. of Mometasone Furoate Micronized 1.800 Kgs.)	40000.000 Packs		
16	Mometasone Furoate Cream 0.1% (Pack 50gms) (Net Wt. of Mometasone Furoate Micronized 3.000 Kgs.)	60000.000 Packs		
17	Mometasone Furoate Cream 0.1% (Pack 60gms) (Net Wt. of Mometasone Furoate Micronized 0.900 Kgs.)	15000.000 Packs		
18	Mometasone Furoate Cream 0.1% (Pack 100gms) (Net Wt. of Mometasone Furoate Micronized 28.700 Kgs.)	287000.000 Packs		

RA concerned may take further necessary action as per above decision of NC.

317	**Case No.:100/2/82-ALC4/2020**	Party Name:SANDHYA ORGANIC CHEMICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01134/AM20/	RLA File :03/95/040/01128/AM20/	Lic.No/Date:0310835301 09.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

318	**Case No.:101/2/82-ALC4/2020**	Party Name:SENTISS PHARMA PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01135/AM20/	RLA File :05/24/040/00758/AM20/	Lic.No/Date:0510413849 12.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

319	**Case No.:102/2/82-ALC4/2020**	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01136/AM20/	RLA File :05/24/040/00749/AM20/	Lic.No/Date:0510413850 12.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

320	**Case No.:103/2/82-ALC4/2020**	Party Name:KEVA FRAGRANCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01137/AM20/	RLA File :03/94/040/01017/AM20/	Lic.No/Date:0310835375 12.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

321	**Case No.:104/2/82-ALC4/2020**	Party Name:ASTEC LIFESCIENCES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01138/AM20/	RLA File :03/94/040/01030/AM20/	Lic.No/Date:0310835376 12.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

322	**Case No.:108/2/82-ALC4/2020**	Party Name:YASH RASAYAN & CHEMICALS	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01142/AM20/	RLA File :34/24/040/00343/AM20/	Lic.No/Date:3410045953 12.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

323	**Case No.:105/2/82-ALC4/2020**	Party Name:SALICYLATES& CHEMICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01139/AM20/	RLA File :09/24/040/00612/AM20/	Lic.No/Date:0910068573 13.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

324	**Case No.:106/2/82-ALC4/2020**	Party Name:SALICYLATES& CHEMICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01140/AM20/	RLA File :09/24/040/00613/AM20/	Lic.No/Date:0910068574 13.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

325	**Case No.:107/2/82-ALC4/2020**	Party Name:SALICYLATES& CHEMICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01141/AM20/	RLA File :09/24/040/00614/AM20/	Lic.No/Date:0910068575 13.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

326	**Case No.:109/2/82-ALC4/2020**	Party Name:YASH RASAYAN & CHEMICALS	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01143/AM20/	RLA File :34/24/040/00389/AM20/	Lic.No/Date:3410045957 13.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

327	**Case No.:110/2/82-ALC4/2020**	Party Name:WEXFORD LABORATORIES P LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01144/AM20/	RLA File :07/24/040/00302/AM20/	Lic.No/Date:0710116263 16.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

328	**Case No.:111/2/82-ALC4/2020**	Party Name:VERGO PHARMA RESEARCH LABORATORIES PVT. LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01145/AM20/	RLA File :03/95/040/01191/AM20/	Lic.No/Date:0310835417 17.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

329	**Case No.:112/2/82-ALC4/2020**	Party Name:ETERNIS FINE CHEMICALS LIMITED,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01146/AM20/	RLA File :03/94/040/00907/AM20/	Lic.No/Date:0310835431 17.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

330	**Case No.:113/2/82-ALC4/2020**	Party Name:ENALTEC LABS PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01147/AM20/	RLA File :03/94/040/01039/AM20/	Lic.No/Date:0310835434 17.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

331	**Case No.:114/2/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01148/AM20/	RLA File :03/94/040/01032/AM20/	Lic.No/Date:0310835439 17.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

332	**Case No.:115/2/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01149/AM20/	RLA File :03/94/040/01033/AM20/	Lic.No/Date:0310835441 17.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

333	**Case No.:116/2/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01150/AM20/	RLA File :03/94/040/01050/AM20/	Lic.No/Date:0310835445 17.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

334	**Case No.:117/2/82-ALC4/2020**	Party Name:KOPRAN RESEARCH LABORATORIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01151/AM20/	RLA File :03/94/040/01052/AM20/	Lic.No/Date:0310835448 17.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

335	**Case No.:118/2/82-ALC4/2020**	Party Name:LEBEN LABORATORIES PVT.LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01152/AM20/	RLA File :03/95/040/01198/AM20/	Lic.No/Date:0310835458 17.03.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

336	**Case No.:119/2/82-ALC4/2020**	Party Name:SRINI PHARMACEUTICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01153/AM20/	RLA File :09/24/040/00619/AM20/	Lic.No/Date:0910068581 17.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

337	**Case No.:120/2/82-ALC4/2020**	Party Name:VEKO CARE PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01154/AM20/	RLA File :31/83/040/00161/AM20/	Lic.No/Date:3110067716 17.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

338	**Case No.:121/2/82-ALC4/2020**	Party Name:SRIAM LABS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01155/AM20/	RLA File :09/24/040/00631/AM20/	Lic.No/Date:0910068585 18.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

339	**Case No.:122/2/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01156/AM20/	RLA File :03/94/040/01042/AM20/	Lic.No/Date:0310835503 19.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

340	**Case No.:123/2/82-ALC4/2020**	Party Name:ORIENTAL AROMATICS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01157/AM20/	RLA File :03/95/040/01108/AM20/	Lic.No/Date:0310835505 19.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

341	**Case No.:124/2/82-ALC4/2020**	Party Name:RECKITT BENCKISER HEALTHCARE INDIA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01158/AM20/	RLA File :05/24/040/00761/AM20/	Lic.No/Date:0510413921 19.03.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Cepacol Extra Strength Lozenges-Sore throat & Cough Mixed Berry	1 Number	1	ISOMALT ST-M	2320.08 mg
		2	FD&C Red No. 40	0.259 mg
		3	Spectracol Dual FD&C Blue No.1	0.001 mg
		4	Benzocaine USP	8.1864 mg
		5	Berry Flavour TAK 041362	8.152 mg
		6	Intensate Masking TAK 041943	4.485 mg

RA concerned may take further necessary action as per above decision of NC.

342	**Case No.:125/2/82-ALC4/2020**	Party Name:ALTA LABORATORIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01159/AM20/	RLA File :03/94/040/01059/AM20/	Lic.No/Date:0310835519 19.03.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

343	**Case No.:126/2/82-ALC4/2020**	Party Name:ALTA LABORATORIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01160/AM20/	RLA File :03/94/040/01060/AM20/	Lic.No/Date:0310835521 19.03.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

344	**Case No.:127/2/82-ALC4/2020**	Party Name:M/S HIMALAYAN PRODUCTS & INDUSTRIES CORPN., P.LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01161/AM20/	RLA File :05/24/040/00774/AM20/	Lic.No/Date:0510413924 19.03.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

345	**Case No.:129/2/82-ALC4/2020**	Party Name:DEEPAK PHENOLICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01163/AM20/	RLA File :34/24/040/00358/AM20/	Lic.No/Date:3410045960 19.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019. However, the Committee considered the case as per agenda and based on the decision taken in similar cases of the firm, it was decided to call for following information from the firm: **(i) Quantity and commercial value of Co-Product Acetone produced.** **(ii) Percentage yield on molar basis.** **(iii) Complete set of 4.07 application alongwith technical details as per Appendix 4E.**			

346	**Case No.:128/2/82-ALC4/2020**	Party Name:SWATI MENTHOL & ALLIED CHEMICALS LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01162/AM20/	RLA File :05/24/040/00781/AM20/	Lic.No/Date:0510413938 20.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

347	**Case No.:132/2/82-ALC4/2020**	Party Name:NEOGEN CHEMICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01166/AM20/	RLA File :03/95/040/01171/AM20/	Lic.No/Date:0310835548 20.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

348	**Case No.:133/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01167/AM20/	RLA File :03/94/040/01065/AM20/	Lic.No/Date:0310835571 20.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

349	**Case No.:134/2/82-ALC4/2020**	Party Name:PRASOL CHEMICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01168/AM20/	RLA File :03/95/040/01230/AM20/	Lic.No/Date:0310835575 20.03.2020	

Decision: The Committee considered the case as per agenda in the presence of Technical Experts and in the light of earlier decision taken by NC in its Meeting No. 1/82-ALC4/2018 , dated 01.05.2018, it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export product	Qty.	Sl. No.	Import items	Qty.
3,3,5, TRIMETHYL CYCLOHEXANONE / DIHYDROISOPHORONE	1 MT	1	ACETONE	2.054 MT

RA may take appropriate action as per the decision of Norms Committee.

350	**Case No.:135/2/82-ALC4/2020**	Party Name:MANGALAM DRUGS AND ORGANICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01169/AM20/	RLA File :03/95/040/01164/AM20/	Lic.No/Date:0310835580 20.03.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

351	**Case No.:136/2/82-ALC4/2020**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01170/AM20/	RLA File :03/95/040/01136/AM20/	Lic.No/Date:0310835545 20.03.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

352	**Case No.:130/2/82-ALC4/2020**	Party Name:ASTRAL STERITECH PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01164/AM20/	RLA File :34/24/040/00406/AM20/	Lic.No/Date:3410045972 24.03.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

353	**Case No.:131/2/82-ALC4/2020**	Party Name:ASTRAL STERITECH PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01165/AM20/	RLA File :34/24/040/00407/AM20/	Lic.No/Date:3410045973 24.03.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

354

Case No.:137/2/82-ALC4/2020	Party Name:CADILA HEALTHCARE LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
HQ File :01/82/050/01171/AM21/	RLA File :08/24/040/00416/AM20/	Lic.No/Date:0810147569 01.04.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
MESALAMINE DELAYED RELEASE TABLETS 1.2 GRAM (ACTIVE INGREDIENT: MESALAMINE USP - NET WEIGHT 88918.56 KGS.)	1 Number	1	MESALAMINE USP	1.224 gram
		2	MAGNESIUM STEARATE PH.E/NF/JP	0.013 gram
		3	SODIUM STARCH GLYCOLATE NF/JP	0.012 gram
		4	HYPEROMELLOSE 15 CPS USP	0.030 gram
		5	TRIETHYL CITRATE NF	0.015 gram
		6	TALC PH.E/USP/JP	0.011 gram
		7	ISOPROPYL ALCOHOL USP	0.50 gram
		8	MICROCRYSTALLINE CELLULOSE NF/PH.E (AVICEL PH200)	0.0130 gram
		9	METHACRYLIC ACID AND METHYL METHACRYLATE COPOLYMER NF	0.0345 gram
		10	METHACRYLIC ACID COPOLYMER NF (EUDRAGIT L 100)	0.0185 gram

RA concerned may take further necessary action as per above decision of NC.

355	**Case No.:138/2/82-ALC4/2020**	Party Name:BHAGWATI INDUSTRIES	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01172/AM21/	RLA File :08/24/040/00417/AM20/	Lic.No/Date:0810147573 03.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

356

	Case No.:139/2/82-ALC4/2020	Party Name:CADILA HEALTHCARE LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01173/AM21/	RLA File :08/24/040/00421/AM20/	Lic.No/Date:0810147575 03.04.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.
1	AMIODARONE HYDROCHLORIDE TABLETS USP 100 MG (ACTIVE INGREDIENT: AMIODARONE HYDROCHLORIDE USP - 297.993 KGS.)	1 Number
2	AMIODARONE HYDROCHLORIDE TABLETS USP 200 MG (ACTIVE INGREDIENT: AMIODARONE HYDROCHLORIDE USP - 9079.416 KGS.)	1 Number
3	AMIODARONE HYDROCHLORIDE TABLETS USP 400 MG (ACTIVE INGREDIENT: AMIODARONE HYDROCHLORIDE USP - 459.972 KGS.)	1 Number

Sl. No.	Import Items	For export of 1 Number Tablet		
		100 mg	200 mg	400 mg
1	AMIODARONE HYDROCHLORIDE USP	102.0 mg	204.0 mg	408.0 mg
2	CORN STARCH NF	21.375 mg	42.75 mg	85.50 mg
3	LACTOSE MONOHYDRATE NF/PH.EU	35.00 mg	70.00 mg	140.00 mg
4	MAGNESIUM STEARATE PH.E/NF/JP	1.25 mg	2.50 mg	5.00 mg
5	POVIDONE USP (K-30)	7.50 mg	15.00 mg	30.00 mg
6	SODIUM STARCH GLYCOLATE NF	9.00 mg	18.00 mg	36.00 mg

RA concerned may take further necessary action as per above decision of NC.

357	**Case No.:140/2/82-ALC4/2020**	Party Name:ATUL LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01174/AM21/	RLA File :08/24/040/00002/AM21/	Lic.No/Date:0810147590 09.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

358	**Case No.:141/2/82-ALC4/2020**	Party Name:PIRAMAL ENTERPRISES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01175/AM21/	RLA File :03/95/040/01215/AM20/	Lic.No/Date:0310835591 11.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

359	**Case No.:142/2/82-ALC4/2020**	Party Name:RECKITT BENCKISER HEALTHCARE INDIA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01176/AM21/	RLA File :05/24/040/00007/AM21/	Lic.No/Date:0510413971 13.04.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

360	**Case No.:143/2/82-ALC4/2020**	Party Name:MANKIND PHARMA LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01177/AM21/	RLA File :05/24/040/00006/AM21/	Lic.No/Date:0510413979 13.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

361	**Case No.:144/2/82-ALC4/2020**	Party Name:SENTISS PHARMA PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01178/AM21/	RLA File :05/24/040/00791/AM20/	Lic.No/Date:0510413989 13.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

362	**Case No.:145/2/82-ALC4/2020**	Party Name:SENTISS PHARMA PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01179/AM21/	RLA File :05/24/040/00792/AM20/	Lic.No/Date:0510413990 13.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

363	**Case No.:146/2/82-ALC4/2020**	Party Name:ASTRAL STERITECH PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01180/AM21/	RLA File :34/24/040/00003/AM21/	Lic.No/Date:3410045982 15.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

364	**Case No.:147/2/82-ALC4/2020**	Party Name:VIVIN DRUGS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01181/AM21/	RLA File :09/24/040/00616/AM20/	Lic.No/Date:0910068611 16.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

365	**Case No.:148/2/82-ALC4/2020**	Party Name:VIVIN DRUGS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01182/AM21/	RLA File :09/24/040/00617/AM20/	Lic.No/Date:0910068612 16.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

366	**Case No.:149/2/82-ALC4/2020**	Party Name:VIVIN DRUGS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01183/AM21/	RLA File :09/24/040/00618/AM20/	Lic.No/Date:0910068613 16.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

367	**Case No.:152/2/82-ALC4/2020**	Party Name:STERILE INDIA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01186/AM21/	RLA File :05/24/040/00004/AM21/	Lic.No/Date:0510414006 16.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

368	**Case No.:153/2/82-ALC4/2020**	Party Name:STERILE INDIA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01187/AM21/	RLA File :05/24/040/00011/AM21/	Lic.No/Date:0510414007 16.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

369	**Case No.:154/2/82-ALC4/2020**	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01188/AM21/	RLA File :05/24/040/00009/AM21/	Lic.No/Date:0510414013 16.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

370	**Case No.:155/2/82-ALC4/2020**	Party Name:GLOBAL CALCIUM PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01189/AM21/	RLA File :07/24/040/00008/AM21/	Lic.No/Date:0710116344 17.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

371

Case No.:163/2/82-ALC4/2020	Party Name:DIVIS LABORATORIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**	
HQ File :01/82/050/01197/AM21/	RLA File :09/24/040/00585/AM20/	Lic.No/Date:0910068647 17.04.2020		

Decision: The Committee considered case as per agenda in the presence of the technical experts and in line with GST Certificate, it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
NAPROXEN	1 kg	1	DL-NAPROXEN	1.25 kg
		2	N-OCTYL-D-GLUCAMINE	0.09 kg
		3	METHANOL	2.03 kg
		4	ACETIC ACID	0.54 kg
		5	TOLUENE	1.13 kg

RA concerned may take further necessary action as per above decision of NC.

372	**Case No.:150/2/82-ALC4/2020**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01184/AM21/	RLA File :03/95/040/01243/AM20/	Lic.No/Date:0310835621 18.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

373	**Case No.:151/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01185/AM21/	RLA File :03/94/040/01064/AM20/	Lic.No/Date:0310835633 18.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

374	**Case No.:156/2/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01190/AM21/	RLA File :03/94/040/01088/AM20/	Lic.No/Date:0310835634 18.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

375	**Case No.:157/2/82-ALC4/2020**	Party Name:MEHTA API PVT LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01191/AM21/	RLA File :03/95/040/01244/AM20/	Lic.No/Date:0310835667 18.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

376	**Case No.:158/2/82-ALC4/2020**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01192/AM21/	RLA File :03/95/040/01036/AM20/	Lic.No/Date:0310835709 19.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

377	**Case No.:159/2/82-ALC4/2020**	Party Name:INDOCO REMEDIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01193/AM21/	RLA File :03/94/040/00007/AM21/	Lic.No/Date:0310835745 20.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

378	**Case No.:160/2/82-ALC4/2020**	Party Name:SHREE BANKEY BEHARI LAL FLAVORS	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01194/AM21/	RLA File :05/24/040/00005/AM21/	Lic.No/Date:0510414033 20.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

379	**Case No.:161/2/82-ALC4/2020**	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01195/AM21/	RLA File :05/24/040/00010/AM21/	Lic.No/Date:0510414034 20.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

380	**Case No.:162/2/82-ALC4/2020**	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Case Added**
	HQ File :01/82/050/01196/AM21/	RLA File :05/24/040/00013/AM21/	Lic.No/Date:0510414035 20.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

381	**Case No.:164/2/82-ALC4/2020**	Party Name:YASHOINDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status:CaseAdded**
	HQ File :01/82/050/01198/AM21/	RLA File :03/95/040/01234/AM20/	Lic.No/Date:0310835751 21.04.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

382	**Case No.:165/2/82-ALC4/2020**	Party Name:YASHO INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01199/AM21/	RLA File :03/95/040/01231/AM20/	Lic.No/Date:0310835753 21.04.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

383	**Case No.:166/2/82-ALC4/2020**	Party Name:PIRAMAL ENTERPRISES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01200/AM21/	RLA File :03/95/040/01217/AM20/	Lic.No/Date:0310835767 21.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

384	**Case No.:167/2/82-ALC4/2020**	Party Name:USV PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01201/AM21/	RLA File :03/95/040/01193/AM20/	Lic.No/Date:0310835770 21.04.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

385	**Case No.:168/2/82-ALC4/2020**	Party Name:JODAS EXPOIM PVT.LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01202/AM21/	RLA File :09/24/040/00027/AM21/	Lic.No/Date:0910068657 21.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

386	**Case No.:169/2/82-ALC4/2020**	Party Name:VERGO PHARMA RESEARCH LABORATORIES PVT. LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01203/AM21/	RLA File :03/95/040/00017/AM21/	Lic.No/Date:0310835789 21.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

387	**Case No.:170/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01204/AM21/	RLA File :03/94/040/01089/AM20/	Lic.No/Date:0310835803 21.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

388	**Case No.:171/2/82-ALC4/2020**	Party Name:ADCOCK INGRAM LTD,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01205/AM21/	RLA File :07/24/040/00011/AM21/	Lic.No/Date:0710116359 23.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

389	**Case No.:172/2/82-ALC4/2020**	Party Name:ADCOCK INGRAM LTD,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01206/AM21/	RLA File :07/24/040/00012/AM21/	Lic.No/Date:0710116360 23.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

390	**Case No.:173/2/82-ALC4/2020**	Party Name:RUBICON RESEARCH PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01207/AM21/	RLA File :03/95/040/01166/AM20/	Lic.No/Date:0310835813 24.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

391	**Case No.:175/2/82-ALC4/2020**	Party Name:ORTIN LABORATORIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01209/AM21/	RLA File :09/24/040/00028/AM21/	Lic.No/Date:0910068670 24.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

392	**Case No.:176/2/82-ALC4/2020**	Party Name:ALPHAMED FORMULATIONS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01210/AM21/	RLA File :09/24/040/00036/AM21/	Lic.No/Date:0910068668 24.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

393	**Case No.:177/2/82-ALC4/2020**	Party Name:SHILPA MEDICARE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01211/AM21/	RLA File :07/24/040/00019/AM21/	Lic.No/Date:0710116370 24.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

394	**Case No.:174/2/82-ALC4/2020**	Party Name:RUBICON RESEARCH PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01208/AM21/	RLA File :03/95/040/00025/AM21/	Lic.No/Date:0310835832 25.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

395	**Case No.:178/2/82-ALC4/2020**	Party Name:KOPRAN RESEARCH LABORATORIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01212/AM21/	RLA File :03/94/040/00017/AM21/	Lic.No/Date:0310835866 25.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

396	**Case No.:179/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01213/AM21/	RLA File :03/94/040/00022/AM21/	Lic.No/Date:0310835878 25.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

397	**Case No.:180/2/82-ALC4/2020**	Party Name:JINDAL DRUGS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01214/AM21/	RLA File :03/94/040/00003/AM21/	Lic.No/Date:0310835903 25.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

398	**Case No.:181/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01215/AM21/	RLA File :03/94/040/00014/AM21/	Lic.No/Date:0310835905 25.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

399	**Case No.:182/2/82-ALC4/2020**	Party Name:JINDAL DRUGS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01216/AM21/	RLA File :03/94/040/00005/AM21/	Lic.No/Date:0310835906 25.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

400	**Case No.:183/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01217/AM21/	RLA File :03/94/040/00013/AM21/	Lic.No/Date:0310835913 25.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

401	**Case No.:184/2/82-ALC4/2020**	Party Name:S KANT CHEMICALS PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01218/AM21/	RLA File :03/95/040/00024/AM21/	Lic.No/Date:0310835937 26.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

402	**Case No.:185/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01219/AM21/	RLA File :03/94/040/00028/AM21/	Lic.No/Date:0310835970 26.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

403	**Case No.:186/2/82-ALC4/2020**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01220/AM21/	RLA File :03/95/040/01109/AM20/	Lic.No/Date:0310835972 26.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

404	**Case No.:187/2/82-ALC4/2020**	Party Name:STERILE INDIA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01221/AM21/	RLA File :05/24/040/00016/AM21/	Lic.No/Date:0510414054 27.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

405	**Case No.:188/2/82-ALC4/2020**	Party Name:STYRAX PHARMA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01222/AM21/	RLA File :09/24/040/00021/AM21/	Lic.No/Date:0910068675 27.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

406	**Case No.:190/2/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01224/AM21/	RLA File :03/94/040/00024/AM21/	Lic.No/Date:0310836017 27.04.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

407	**Case No.:191/2/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01225/AM21/	RLA File :03/94/040/00023/AM21/	Lic.No/Date:0310836018 27.04.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

408	**Case No.:192/2/82-ALC4/2020**	Party Name:CIPLA LIMITED.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01226/AM21/	RLA File :03/94/040/00021/AM21/	Lic.No/Date:0310836020 27.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

409	**Case No.:189/2/82-ALC4/2020**	Party Name:ORTIN LABORATORIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01223/AM21/	RLA File :09/24/040/00584/AM20/	Lic.No/Date:0910068680 28.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

410	**Case No.:193/2/82-ALC4/2020**	Party Name:ARENE LIFE SCIENCES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01227/AM21/	RLA File :09/24/040/00024/AM21/	Lic.No/Date:0910068681 28.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

411	**Case No.:194/2/82-ALC4/2020**	Party Name:BIOLOGICAL E LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01228/AM21/	RLA File :09/24/040/00638/AM20/	Lic.No/Date:0910068684 28.04.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	NOSCAPINE BP/JP/USP	900.000 kg	1	NOSCAPINE CRUDE 95%	1100 kg
2	NOSCAPINE HCL BP/JP/USP (NOSCAPINE HYDROCHLORIDE BP/JP/USP)	100.000 kg			

RA concerned may take further necessary action as per above decision of NC.

412	**Case No.:195/2/82-ALC4/2020**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01229/AM21/	RLA File :09/24/040/00039/AM21/	Lic.No/Date:0910068685 28.04.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

413	**Case No.:196/2/82-ALC4/2020**	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01230/AM21/	RLA File :09/24/040/00017/AM21/	Lic.No/Date:0910068686 28.04.2020	

Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.

414	**Case No.:197/2/82-ALC4/2020**	Party Name:MEDREICH LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01231/AM21/	RLA File :07/24/040/00023/AM21/	Lic.No/Date:0710116385 28.04.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

415	**Case No.:198/2/82-ALC4/2020**	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01232/AM21/	RLA File :09/24/040/00023/AM21/	Lic.No/Date:0910068694 29.04.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
MEROPENEM FOR INJECTION (MEROPENEM STERILE)	1 kg	1	Meropenem Trihydrate (Non Sterile)	0.9583 kg
		2	Aluminium Canister 14 Ltr. (5Kg)	Relevant as per packing policy

RA concerned may take further necessary action as per above decision of NC.

416	**Case No.:199/2/82-ALC4/2020**	Party Name:NEULAND LABORATORIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01233/AM21/	RLA File :09/24/040/00045/AM21/	Lic.No/Date:0910068697 29.04.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

417	**Case No.:200/2/82-ALC4/2020**	Party Name:AMI ORGANICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01234/AM21/	RLA File :52/24/040/00005/AM21/	Lic.No/Date:5210043384 29.04.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

418	**Case No.:201/2/82-ALC4/2020**	Party Name:ALPHAMED FORMULATIONS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01235/AM21/	RLA File :09/24/040/00049/AM21/	Lic.No/Date:0910068698 29.04.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

419	**Case No.:209/2/82-ALC4/2020**	Party Name:CLARIANT CHEMICALS INDIA LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01243/AM21/	RLA File :03/94/040/00031/AM21/	Lic.No/Date:0310836025 29.04.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Dodecyl Aniline (DODAN-IN)	1 kg	1	BRANCH ALKYL BENZENE	0.978 kg

RA concerned may take further necessary action as per above decision of NC.

420	**Case No.:222/2/82-ALC4/2020**	Party Name:SWAASA PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01256/AM21/	RLA File :26/24/040/00001/AM21/	Lic.No/Date:2610012909 29.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

421	**Case No.:202/2/82-ALC4/2020**	Party Name:DEEPAK PHENOLICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01236/AM21/	RLA File :34/24/040/00402/AM20/	Lic.No/Date:3410046032 30.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019. However, the Committee considered the case as per agenda and based on the decision taken in similar cases of the firm, it was decided to call for following information from the firm: **(i) Quantity and commercial value of Co-Product Acetone produced.** **(ii) Percentage yield on molar basis.** **(iii) Complete set of 4.07 application alongwith technical details as per Appendix 4E.**			

422	**Case No.:203/2/82-ALC4/2020**	Party Name:DEEPAK PHENOLICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01237/AM21/	RLA File :34/24/040/00386/AM20/	Lic.No/Date:3410046034 30.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019. However, the Committee considered the case as per agenda and based on the decision taken in similar cases of the firm, it was decided to call for following information from the firm: : **(i) Quantity and commercial value of Co-Product Acetone produced.** **(ii) Percentage yield on molar basis.** **(iii) Complete set of 4.07 application alongwith technical details as per Appendix 4E.**			

423	**Case No.:204/2/82-ALC4/2020**	Party Name:DEEPAK PHENOLICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01238/AM21/	RLA File :34/24/040/00396/AM20/	Lic.No/Date:3410046035 30.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019. However, the Committee considered the case as per agenda and based on the decision taken in similar cases of the firm, it was decided to call for following information from the firm: **(i) Quantity and commercial value of Co-Product Acetone produced.** **(ii) Percentage yield on molar basis.** **(iii) Complete set of 4.07 application alongwith technical details as per Appendix 4E.**			

424	**Case No.:205/2/82-ALC4/2020**	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01239/AM21/	RLA File :05/24/040/00020/AM21/	Lic.No/Date:0510414089 30.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

425	**Case No.:206/2/82-ALC4/2020**	Party Name:GLOBAL CALCIUM PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01240/AM21/	RLA File :07/24/040/00026/AM21/	Lic.No/Date:0710116403 30.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

426	**Case No.:207/2/82-ALC4/2020**	Party Name:GLOBAL CALCIUM PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01241/AM21/	RLA File :07/24/040/00024/AM21/	Lic.No/Date:0710116404 30.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

427	**Case No.:208/2/82-ALC4/2020**	Party Name:GLOBAL CALCIUM PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01242/AM21/	RLA File :07/24/040/00025/AM21/	Lic.No/Date:0710116405 30.04.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

428	**Case No.:210/2/82-ALC4/2020**	Party Name:REACH GLOBAL INDIA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01244/AM21/	RLA File :31/83/040/00002/AM21/	Lic.No/Date:3110067728 01.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

429	**Case No.:211/2/82-ALC4/2020**	Party Name:JODAS EXPOIM PVT.LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01245/AM21/	RLA File :09/24/040/00658/AM20/	Lic.No/Date:0910068709 01.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

430	**Case No.:212/2/82-ALC4/2020**	Party Name:SUVEN PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01246/AM21/	RLA File :09/24/040/00050/AM21/	Lic.No/Date:0910068712 01.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

431	**Case No.:213/2/82-ALC4/2020**	Party Name:SUVEN PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01247/AM21/	RLA File :09/24/040/00051/AM21/	Lic.No/Date:0910068713 01.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

432	**Case No.:214/2/82-ALC4/2020**	Party Name:SUVEN PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01248/AM21/	RLA File :09/24/040/00052/AM21/	Lic.No/Date:0910068714 01.05.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

433	**Case No.:215/2/82-ALC4/2020**	Party Name:OPTRIX LABORATORIES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01249/AM21/	RLA File :09/24/040/00059/AM21/	Lic.No/Date:0910068716 01.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

434	**Case No.:216/2/82-ALC4/2020**	Party Name:FDC LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01250/AM21/	RLA File :03/94/040/00037/AM21/	Lic.No/Date:0310836053 01.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

435	**Case No.:217/2/82-ALC4/2020**	Party Name:KUMAR ORGANIC PRODUCTS LIMITED,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01251/AM21/	RLA File :07/24/040/00030/AM21/	Lic.No/Date:0710116410 01.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

436	**Case No.:218/2/82-ALC4/2020**	Party Name:CIPLA LIMITED.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01252/AM21/	RLA File :03/94/040/00036/AM21/	Lic.No/Date:0310836063 01.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

437	**Case No.:219/2/82-ALC4/2020**	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01253/AM21/	RLA File :05/24/040/00022/AM21/	Lic.No/Date:0510414098 04.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

438	**Case No.:220/2/82-ALC4/2020**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01254/AM21/	RLA File :03/95/040/00020/AM21/	Lic.No/Date:0310836081 04.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

439	**Case No.:221/2/82-ALC4/2020**	Party Name:THINQ PHARMA-CRO LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01255/AM21/	RLA File :03/95/040/00035/AM21/	Lic.No/Date:0310836083 04.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

440	**Case No.:223/2/82-ALC4/2020**	Party Name:PHAROSE REMEDIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01257/AM21/	RLA File :18/24/040/00001/AM21/	Lic.No/Date:1810004344 04.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

441	**Case No.:224/2/82-ALC4/2020**	Party Name:SUVEN PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01258/AM21/	RLA File :09/24/040/00056/AM21/	Lic.No/Date:0910068721 04.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

442	**Case No.:225/2/82-ALC4/2020**	Party Name:JODAS EXPOIM PVT.LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01259/AM21/	RLA File :09/24/040/00061/AM21/	Lic.No/Date:0910068725 04.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

443	**Case No.:228/2/82-ALC4/2020**	Party Name:SENTISS PHARMA PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01262/AM21/	RLA File :05/24/040/00021/AM21/	Lic.No/Date:0510414103 04.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

444	**Case No.:229/2/82-ALC4/2020**	Party Name:SENTISS PHARMA PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01263/AM21/	RLA File :05/24/040/00024/AM21/	Lic.No/Date:0510414104 04.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

445	**Case No.:233/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01267/AM21/	RLA File :03/94/040/00042/AM21/	Lic.No/Date:0310836089 04.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

446	**Case No.:226/2/82-ALC4/2020**	Party Name:ENCEE AROMATICS PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01260/AM21/	RLA File :32/24/040/00002/AM21/	Lic.No/Date:3210079501 05.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

447	**Case No.:234/2/82-ALC4/2020**	Party Name:AARTI INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01268/AM21/	RLA File :03/94/040/00039/AM21/	Lic.No/Date:0310836098 05.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

448	**Case No.:235/2/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01269/AM21/	RLA File :03/94/040/00038/AM21/	Lic.No/Date:0310836099 05.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

449	**Case No.:236/2/82-ALC4/2020**	Party Name:GLENMARK LIFE SCIENCES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01270/AM21/	RLA File :03/94/040/00047/AM21/	Lic.No/Date:0310836118 05.05.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

450	**Case No.:227/2/82-ALC4/2020**	Party Name:SUVEN PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01261/AM21/	RLA File :09/24/040/00065/AM21/	Lic.No/Date:0910068731 06.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

451	**Case No.:230/2/82-ALC4/2020**	Party Name:RECKITT BENCKISER HEALTHCARE INDIA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01264/AM21/	RLA File :05/24/040/00025/AM21/	Lic.No/Date:0510414108 06.05.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

452	**Case No.:231/2/82-ALC4/2020**	Party Name:RECKITT BENCKISER HEALTHCARE INDIA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01265/AM21/	RLA File :05/24/040/00026/AM21/	Lic.No/Date:0510414109 06.05.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

453	**Case No.:232/2/82-ALC4/2020**	Party Name:ADCOCK INGRAM LTD,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01266/AM21/	RLA File :07/24/040/00020/AM21/	Lic.No/Date:0710116421 06.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

454	**Case No.:237/2/82-ALC4/2020**	Party Name:GLOBAL CALCIUM PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01271/AM21/	RLA File :07/24/040/00032/AM21/	Lic.No/Date:0710116423 06.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

455	**Case No.:238/2/82-ALC4/2020**	Party Name:S.KANT HEALTHCARE LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01272/AM21/	RLA File :03/95/040/00715/AM20/	Lic.No/Date:0310836133 07.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

456	**Case No.:239/2/82-ALC4/2020**	Party Name:CADILA HEALTHCARE LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01273/AM21/	RLA File :08/24/040/00391/AM20/	Lic.No/Date:0810147721 08.05.2020	:
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

457	**Case No.:240/2/82-ALC4/2020**	Party Name:SENTISS PHARMA PVT.LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01274/AM21/	RLA File :05/24/040/00029/AM21/	Lic.No/Date:0510414133 08.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

458	**Case No.:241/2/82-ALC4/2020**	Party Name:ACME GENERICS LLP	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01275/AM21/	RLA File :30/24/040/00132/AM20/	Lic.No/Date:3010105166 08.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

459	**Case No.:242/2/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01276/AM21/	RLA File :03/94/040/01058/AM20/	Lic.No/Date:0310836157 11.05.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

460	**Case No.:243/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01277/AM21/	RLA File :03/94/040/00043/AM21/	Lic.No/Date:0310836158 11.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

461	**Case No.:244/2/82-ALC4/2020**	Party Name:CIPLA LIMITED.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01278/AM21/	RLA File :03/94/040/00051/AM21/	Lic.No/Date:0310836159 11.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

462	**Case No.:245/2/82-ALC4/2020**	Party Name:PORUS LABORATORIES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01279/AM21/	RLA File :09/24/040/00063/AM21/	Lic.No/Date:0910068738 11.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

463	**Case No.:246/2/82-ALC4/2020**	Party Name:SAGA LIFESCIENCES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01280/AM21/	RLA File :08/24/040/00018/AM21/	Lic.No/Date:0810147725 11.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

464	**Case No.:247/2/82-ALC4/2020**	Party Name:AMI LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01281/AM21/	RLA File :34/24/040/00015/AM21/	Lic.No/Date:3410046053 11.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

465	**Case No.:248/2/82-ALC4/2020**	Party Name:NEOGEN CHEMICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01282/AM21/	RLA File :03/95/040/00064/AM21/	Lic.No/Date:0310836170 11.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

466	**Case No.:249/2/82-ALC4/2020**	Party Name:SHREE BANKEY BEHARI LAL FLAVORS	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01283/AM21/	RLA File :05/24/040/00039/AM21/	Lic.No/Date:0510414144 11.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

467	**Case No.:250/2/82-ALC4/2020**	Party Name:MEDREICH LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01284/AM21/	RLA File :07/24/040/00037/AM21/	Lic.No/Date:0710116438 11.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

468	**Case No.:251/2/82-ALC4/2020**	Party Name:OPTRIX LABORATORIES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01285/AM21/	RLA File :09/24/040/00064/AM21/	Lic.No/Date:0910068743 12.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

469	**Case No.:252/2/82-ALC4/2020**	Party Name:JODAS EXPOIM PVT.LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01286/AM21/	RLA File :09/24/040/00077/AM21/	Lic.No/Date:0910068744 12.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

470	**Case No.:253/2/82-ALC4/2020**	Party Name:BALAJI AMINES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01287/AM21/	RLA File :31/83/040/00004/AM21/	Lic.No/Date:3110067731 12.05.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

471	**Case No.:254/2/82-ALC4/2020**	Party Name:BALAJI AMINES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01288/AM21/	RLA File :31/83/040/00005/AM21/	Lic.No/Date:3110067732 12.05.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

472	**Case No.:257/2/82-ALC4/2020**	Party Name:RUBICON RESEARCH PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01291/AM21/	RLA File :03/95/040/00062/AM21/	Lic.No/Date:0310836183 13.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

473	**Case No.:258/2/82-ALC4/2020**	Party Name:MATRIX FINE SCIENCES PVT.LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01292/AM21/	RLA File :03/95/040/00056/AM21/	Lic.No/Date:0310836184 13.05.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

474	**Case No.:259/2/82-ALC4/2020**	Party Name:PIRAMAL ENTERPRISES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01293/AM21/	RLA File :03/95/040/00074/AM21/	Lic.No/Date:0310836193 14.05.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Bempedoic Acid and Ezetimibe Fixed Dose Combination Tablets (Net content of Bempedoic Acid 514.8 kgs and Ezetimibe 28.600 kgs in Total Export Qty) (AA for Free of cost material as per Para 4.11 of HBP & Para 4.19 of FTP & RBI Master Circular C-26 - Disallowing remittances for material being supplied free of cost)	1 Number Tablet	1	BEMPEDOIC ACID	184.62 mg
		2	EZETIMIBE	10.235 mg

RA concerned may take further necessary action as per above decision of NC.

475	**Case No.:255/2/82-ALC4/2020**	Party Name:SWISS PARENTERALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01289/AM21/	RLA File :08/24/040/00025/AM21/	Lic.No/Date:0810147772 15.05.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

476	**Case No.:256/2/82-ALC4/2020**	Party Name:SWISS PARENTERALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01290/AM21/	RLA File :08/24/040/00024/AM21/	Lic.No/Date:0810147773 15.05.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

477	**Case No.:260/2/82-ALC4/2020**	Party Name:FINE ORGANIC INDUSTRIES,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01294/AM21/	RLA File :03/94/040/00069/AM21/	Lic.No/Date:0310836203 15.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

478	**Case No.:261/2/82-ALC4/2020**	Party Name:OLIVE HEALTHCARE	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01295/AM21/	RLA File :03/95/040/00069/AM21/	Lic.No/Date:0310836213 15.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

479	**Case No.:262/2/82-ALC4/2020**	Party Name:U K AROMATICS & CHEMICALS	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01296/AM21/	RLA File :03/95/040/00068/AM21/	Lic.No/Date:0310836217 15.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

480	**Case No.:263/2/82-ALC4/2020**	Party Name:ZIM LABORATORIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01297/AM21/	RLA File :03/95/040/00078/AM21/	Lic.No/Date:0310836218 15.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

481	**Case No.:264/2/82-ALC4/2020**	Party Name:FDC LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01298/AM21/	RLA File :03/94/040/00067/AM21/	Lic.No/Date:0310836223 15.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

482	**Case No.:265/2/82-ALC4/2020**	Party Name:NIFTY LABS PVT LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01299/AM21/	RLA File :09/24/040/00084/AM21/	Lic.No/Date:0910068761 18.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

483	**Case No.:266/2/82-ALC4/2020**	Party Name:INNOVARE LABS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01300/AM21/	RLA File :09/24/040/00072/AM21/	Lic.No/Date:0910068763 18.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

484	**Case No.:267/2/82-ALC4/2020**	Party Name:CLEAN SCIENCE AND TECHNOLOGY PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01301/AM21/	RLA File :31/83/040/00006/AM21/	Lic.No/Date:3110067737 18.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

485	**Case No.:268/2/82-ALC4/2020**	Party Name:AVIK PHARMACEUTICAL LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01302/AM21/	RLA File :03/94/040/00055/AM21/	Lic.No/Date:0310836234 18.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

486	**Case No.:273/2/82-ALC4/2020**	Party Name:PI INDUSTRIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01307/AM21/	RLA File :13/24/040/00006/AM21/	Lic.No/Date:1310049574 19.05.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
DICHLOBENTIAZOX TECHNICAL : 3-[(3,4-dichloro-1,2-thiazol-5-yl)methoxy]-1,2-benzothiazole 1,1-dioxide (ICF)	1 kg	1	Succinonitrile	0.550 kg
		2	Acetonitrile	1.50 kg
		3	Saccharin	0.750 kg

RA concerned may take further necessary action as per above decision of NC.

487	**Case No.:274/2/82-ALC4/2020**	Party Name:PI INDUSTRIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01308/AM21/	RLA File :13/24/040/00004/AM21/	Lic.No/Date:1310049576 19.05.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
CCIM Chemical Name: 4-Chloro-5-p-tolylimidazole-2-carbonitrile	1 kg	1	p-methylacetophenone	1.241 kg
		2	Hydroxylamine sulfate	3.530 kg
		3	Glyoxal 40 % Min.	1.403 kg
		4	N-methylpyrrolidone	0.227 kg
		5	Ethylene Dichloride	0.168 kg

RA concerned may take further necessary action as per above decision of NC.

488	**Case No.:275/2/82-ALC4/2020**	Party Name:PI INDUSTRIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01309/AM21/	RLA File :13/24/040/00003/AM21/	Lic.No/Date:1310049577 19.05.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
747- Ether Chemical Name: 2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluroethoxy)methyl)]benzoic acid	1 kg	1	3-Chloro -2-Methyl aniline	0.625 kg
		2	Sodium Nitrite	0.350 kg
		3	Sodium Methyl Mercaptide	1.902 kg
		4	Bromine	0.650 kg
		5	Ethylene Dichloride	0.668 kg
		6	Acetonitrile	0.154 kg
		7	Hydrogen Peroxide	1.00 kg
		8	Trifluoro Ethanol	0.503 kg

RA concerned may take further necessary action as per above decision of NC.

489	**Case No.:276/2/82-ALC4/2020**	Party Name:CLEAN SCIENCE AND TECHNOLOGY PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01310/AM21/	RLA File :31/83/040/00008/AM21/	Lic.No/Date:3110067739 19.05.2020	

Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.

490	**Case No.:277/2/82-ALC4/2020**	Party Name:BALAJI AMINES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01311/AM21/	RLA File :31/83/040/00007/AM21/	Lic.No/Date:3110067740 19.05.2020	

Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.

491	**Case No.:269/2/82-ALC4/2020**	Party Name:KOPRAN RESEARCH LABORATORIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01303/AM21/	RLA File :03/94/040/00062/AM21/	Lic.No/Date:0310836260 20.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

492	**Case No.:270/2/82-ALC4/2020**	Party Name:KOPRAN RESEARCH LABORATORIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01304/AM21/	RLA File :03/94/040/00071/AM21/	Lic.No/Date:0310836264 20.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

493	**Case No.:271/2/82-ALC4/2020**	Party Name:RAJASTHAN ANTIBIOTICS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01305/AM21/	RLA File :05/24/040/00056/AM21/	Lic.No/Date:0510414210 20.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

494	**Case No.:278/2/82-ALC4/2020**	Party Name:KOPRAN RESEARCH LABORATORIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01312/AM21/	RLA File :03/94/040/00077/AM21/	Lic.No/Date:0310836269 20.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

495	**Case No.:279/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01313/AM21/	RLA File :03/94/040/00082/AM21/	Lic.No/Date:0310836283 20.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

496	**Case No.:272/2/82-ALC4/2020**	Party Name:VERVE HUMAN CARE LABORATORIES	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01306/AM21/	RLA File :05/24/040/00014/AM21/	Lic.No/Date:0510414216 21.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

497	**Case No.:280/2/82-ALC4/2020**	Party Name:VEKO CARE PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01314/AM21/	RLA File :31/83/040/00009/AM21/	Lic.No/Date:3110067742 21.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

498	**Case No.:295/2/82-ALC4/2020**	Party Name:DORF KETAL CHEMICALS INDIA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01329/AM21/	RLA File :03/94/040/00085/AM21/	Lic.No/Date:0310836308 21.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

499	**Case No.:281/2/82-ALC4/2020**	Party Name:OPES HEALTH CARE PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01315/AM21/	RLA File :08/24/040/00394/AM20/	Lic.No/Date:0810147815 22.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

500	**Case No.:282/2/82-ALC4/2020**	Party Name:GLOBAL CALCIUM PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01316/AM21/	RLA File :07/24/040/00046/AM21/	Lic.No/Date:0710116483 22.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

501	**Case No.:283/2/82-ALC4/2020**	Party Name:ADCOCK INGRAM LTD,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01317/AM21/	RLA File :07/24/040/00048/AM21/	Lic.No/Date:0710116485 22.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

502	**Case No.:284/2/82-ALC4/2020**	Party Name:ADCOCK INGRAM LTD,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01318/AM21/	RLA File :07/24/040/00049/AM21/	Lic.No/Date:0710116486 22.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

503	**Case No.:286/2/82-ALC4/2020**	Party Name:AMI ORGANICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01320/AM21/	RLA File :52/24/040/00007/AM21/	Lic.No/Date:5210043401 22.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

504

Case No.:285/2/82-ALC4/2020	Party Name:BIOLOGICAL E LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**	
HQ File :01/82/050/01319/AM21/	RLA File :09/24/040/00646/AM20/	Lic.No/Date:0910068792 26.05.2020		

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Sl. No.	Export Product	Qty.	Sl. No.	Import items	Qty.
1	NOSCAPINE BP/JP/USP	900.000 kg	1	NOSCAPINE CRUDE 95%	1100 kg
2	NOSCAPINE HCL BP/JP/USP (NOSCAPINE HYDROCHLORIDE BP/JP/USP)	100.000 kg			

RA concerned may take further necessary action as per above decision of NC.

505

Case No.:287/2/82-ALC4/2020	Party Name:BALAJI SPECIALITY CHEMICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**	
HQ File :01/82/050/01321/AM21/	RLA File :31/83/040/00001/AM21/	Lic.No/Date:3110067744 26.05.2020		
Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.				

506	**Case No.:288/2/82-ALC4/2020**	Party Name:ALPHAMED FORMULATIONS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01322/AM21/	RLA File :09/24/040/00632/AM20/	Lic.No/Date:0910068801 26.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

507	**Case No.:289/2/82-ALC4/2020**	Party Name:NATURAL& ESSENTIAL OILS PVT.LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01323/AM21/	RLA File :07/24/040/00051/AM21/	Lic.No/Date:0710116493 26.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

508	**Case No.:290/2/82-ALC4/2020**	Party Name:NOVEL NUTRIENTS PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01324/AM21/	RLA File :07/24/040/00038/AM21/	Lic.No/Date:0710116503 26.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

509	**Case No.:293/2/82-ALC4/2020**	Party Name:BIOXERA PHARMA PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01327/AM21/	RLA File :03/94/040/00079/AM21/	Lic.No/Date:0310836357 26.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

510	**Case No.:294/2/82-ALC4/2020**	Party Name:NEW ALLIANCE DYE CHEM PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01328/AM21/	RLA File :03/95/040/00081/AM21/	Lic.No/Date:0310836368 26.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

511	**Case No.:291/2/82-ALC4/2020**	Party Name:VERVE HUMAN CARE LABORATORIES	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01325/AM21/	RLA File :05/24/040/00028/AM21/	Lic.No/Date:0510414258 27.05.2020	:
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

512

	Case No.:292/2/82-ALC4/2020	Party Name:DIVIS LABORATORIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
	HQ File :01/82/050/01326/AM21/	RLA File :09/24/040/00123/AM21/	Lic.No/Date:0910068807 27.05.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
NAPROXEN	1 kg	1	DL-NAPROXEN	1.25 kg
		2	N-OCTYL-D-GLUCAMINE	0.09 kg
		3	METHANOL	2.03 kg
		4	ACETIC ACID	0.54 kg
		5	TOLUENE	1.13 kg

RA concerned may take further necessary action as per above decision of NC.

513	**Case No.:296/2/82-ALC4/2020**	Party Name:ALPHAMED FORMULATIONS P LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01330/AM21/	RLA File :09/24/040/00605/AM20/	Lic.No/Date:0910068804 27.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

514	**Case No.:297/2/82-ALC4/2020**	Party Name:VERVE HUMAN CARE LABORATORIES	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01331/AM21/	RLA File :05/24/040/00032/AM21/	Lic.No/Date:0510414268 27.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

515	**Case No.:298/2/82-ALC4/2020**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01332/AM21/	RLA File :09/24/040/00066/AM21/	Lic.No/Date:0910068809 27.05.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

516	**Case No.:301/2/82-ALC4/2020**	Party Name:GLOBAL CALCIUM PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01335/AM21/	RLA File :07/24/040/00053/AM21/	Lic.No/Date:0710116510 27.05.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

517	**Case No.:299/2/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01333/AM21/	RLA File :03/94/040/00107/AM21/	Lic.No/Date:0310836407 28.05.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

518	**Case No.:300/2/82-ALC4/2020**	Party Name:DELTA FINOCHEM PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01334/AM21/	RLA File :03/94/040/00112/AM21/	Lic.No/Date:0310836419 29.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

519	**Case No.:302/2/82-ALC4/2020**	Party Name:SUPERMINT EXPORTS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01336/AM21/	RLA File :05/24/040/00071/AM21/	Lic.No/Date:0510414288 29.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

520	**Case No.:303/2/82-ALC4/2020**	Party Name:SYNNAT PHARMA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01337/AM21/	RLA File :02/24/040/00012/AM21/	Lic.No/Date:0210209889 29.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

521	**Case No.:304/2/82-ALC4/2020**	Party Name:TADIMETY AROMATICS PVT. LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01338/AM21/	RLA File :07/24/040/00054/AM21/	Lic.No/Date:0710116526 29.05.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

522	**Case No.:308/2/82-ALC4/2020**	Party Name:PIRAMAL ENTERPRISES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01342/AM21/	RLA File :03/95/040/00075/AM21/	Lic.No/Date:0310836467 01.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

523	**Case No.:309/2/82-ALC4/2020**	Party Name:CLARIANT INDIA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01343/AM21/	RLA File :03/94/040/00110/AM21/	Lic.No/Date:0310836469 01.06.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

524	**Case No.:305/2/82-ALC4/2020**	Party Name:BROOKS LABORATORIES LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01339/AM21/	RLA File :30/24/040/00010/AM21/	Lic.No/Date:3010105213 02.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

525	**Case No.:306/2/82-ALC4/2020**	Party Name:ALPA LABORATORIES LTD.,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01340/AM21/	RLA File :56/24/040/00004/AM21/	Lic.No/Date:5610005886 03.06.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

526	**Case No.:307/2/82-ALC4/2020**	Party Name:PHAROSE REMEDIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01341/AM21/	RLA File :18/24/040/00002/AM21/	Lic.No/Date:1810004351 03.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

527	**Case No.:310/2/82-ALC4/2020**	Party Name:CLEAN SCIENCE AND TECHNOLOGY PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01344/AM21/	RLA File :31/83/040/00011/AM21/	Lic.No/Date:3110067749 03.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

528	**Case No.:311/2/82-ALC4/2020**	Party Name:VEERAL ADDITIVES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01345/AM21/	RLA File :03/95/040/00112/AM21/	Lic.No/Date:0310836486 04.06.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

529	**Case No.:312/2/82-ALC4/2020**	Party Name:VEERAL ADDITIVES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01346/AM21/	RLA File :03/95/040/00113/AM21/	Lic.No/Date:0310836487 04.06.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

530	**Case No.:313/2/82-ALC4/2020**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01347/AM21/	RLA File :03/95/040/00845/AM20/	Lic.No/Date:0310836493 04.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

531	**Case No.:314/2/82-ALC4/2020**	Party Name:BLISS GVS PHARMA LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01348/AM21/	RLA File :03/94/040/00114/AM21/	Lic.No/Date:0310836511 04.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

532	**Case No.:315/2/82-ALC4/2020**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01349/AM21/	RLA File :03/95/040/01201/AM20/	Lic.No/Date:0310836514 04.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

533	**Case No.:316/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01350/AM21/	RLA File :03/94/040/00130/AM21/	Lic.No/Date:0310836517 04.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

534	**Case No.:317/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01351/AM21/	RLA File :03/94/040/00131/AM21/	Lic.No/Date:0310836518 04.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

535	**Case No.:318/2/82-ALC4/2020**	Party Name:ADCOCK INGRAM LTD,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01352/AM21/	RLA File :07/24/040/00060/AM21/	Lic.No/Date:0710116553 04.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

536	**Case No.:319/2/82-ALC4/2020**	Party Name:SIGMA LABORATORIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01353/AM21/	RLA File :03/95/040/00080/AM21/	Lic.No/Date:0310836524 05.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

537	**Case No.:320/2/82-ALC4/2020**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01354/AM21/	RLA File :09/24/040/00069/AM21/	Lic.No/Date:0910068850 05.06.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

538	**Case No.:321/2/82-ALC4/2020**	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01355/AM21/	RLA File :05/24/040/00082/AM21/	Lic.No/Date:0510414338 05.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

539	**Case No.:322/2/82-ALC4/2020**	Party Name:LUPIN LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01356/AM21/	RLA File :03/95/040/00108/AM21/	Lic.No/Date:0310836552 05.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

540	**Case No.:323/2/82-ALC4/2020**	Party Name:AUROBINDO PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01357/AM21/	RLA File :09/24/040/00131/AM21/	Lic.No/Date:0910068853 08.06.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

541	**Case No.:324/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01358/AM21/	RLA File :03/94/040/00120/AM21/	Lic.No/Date:0310836566 08.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

542	**Case No.:325/2/82-ALC4/2020**	Party Name:GLENMARK LIFE SCIENCES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01359/AM21/	RLA File :03/94/040/00135/AM21/	Lic.No/Date:0310836569 08.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

543	**Case No.:326/2/82-ALC4/2020**	Party Name:KUSUMA PHARMA	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01360/AM21/	RLA File :03/94/040/00115/AM21/	Lic.No/Date:0310836572 08.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

544

Case No.:327/2/82-ALC4/2020	Party Name:PIRAMAL ENTERPRISES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
HQ File :01/82/050/01361/AM21/	RLA File :03/95/040/00132/AM21/	Lic.No/Date:0310836576 08.06.2020	

Decision: TheCommittee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
Bempedoic Acid and Ezetimibe Fixed Dose Combination Tablets Net content of Bempedoic Acid 2403 kgs and Ezetimibe 133.50 kgs in Total Export Qty) (AA for Free of cost material as per Para 4.11 of HBP & Para 4.19 of FTP & RBI Master Circular C-26 - Disallowing remittances for material being supplied free of cost)	1 Number Tablet	1	BEMPEDOIC ACID	184.62 mg
		2	EZETIMIBE	10.235 mg

RA concerned may take further necessary action as per above decision of NC.

545	**Case No.:328/2/82-ALC4/2020**	Party Name:AMI ORGANICS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01362/AM21/	RLA File :52/24/040/00013/AM21/	Lic.No/Date:5210043424 08.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

546	**Case No.:329/2/82-ALC4/2020**	Party Name:AETHER INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01363/AM21/	RLA File :52/24/040/00004/AM21/	Lic.No/Date:5210043426 08.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

547	**Case No.:330/2/82-ALC4/2020**	Party Name:RELIANCE INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01364/AM21/	RLA File :03/95/040/00105/AM21/	Lic.No/Date:0310836584 09.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

548	**Case No.:331/2/82-ALC4/2020**	Party Name:AETHER INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01365/AM21/	RLA File :52/24/040/00003/AM21/	Lic.No/Date:5210043427 09.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

549	**Case No.:332/2/82-ALC4/2020**	Party Name:INDO AMINES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01366/AM21/	RLA File :03/94/040/00141/AM21/	Lic.No/Date:0310836585 09.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

550	**Case No.:333/2/82-ALC4/2020**	Party Name:STENORA PHARMA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01367/AM21/	RLA File :03/95/040/00129/AM21/	Lic.No/Date:0310836598 09.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

551	**Case No.:334/2/82-ALC4/2020**	Party Name:CADILA HEALTHCARE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01368/AM21/	RLA File :08/24/040/00049/AM21/	Lic.No/Date:0810147921 09.06.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

552	**Case No.:335/2/82-ALC4/2020**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01369/AM21/	RLA File :09/24/040/00044/AM21/	Lic.No/Date:0910068857 09.06.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

553	**Case No.:336/2/82-ALC4/2020**	Party Name:OC SPECIALITIES PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01370/AM21/	RLA File :03/95/040/00138/AM21/	Lic.No/Date:0310836618 10.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

554	**Case No.:337/2/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01371/AM21/	RLA File :03/94/040/00143/AM21/	Lic.No/Date:0310836623 10.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

555	**Case No.:338/2/82-ALC4/2020**	Party Name:MANGALAM INTERMIDIATES,	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01372/AM21/	RLA File :52/21/040/00033/AM21/	Lic.No/Date:5210043430 10.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

556	**Case No.:339/2/82-ALC4/2020**	Party Name:STERILE INDIA PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01373/AM21/	RLA File :05/24/040/00078/AM21/	Lic.No/Date:0510414372 11.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

557	**Case No.:340/2/82-ALC4/2020**	Party Name:SUN PHARMACEUTICAL INDUSTRIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01374/AM21/	RLA File :05/24/040/00100/AM21/	Lic.No/Date:0510414377 11.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

558	**Case No.:341/2/82-ALC4/2020**	Party Name:TADIMETY AROMATICS PVT. LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01375/AM21/	RLA File :07/24/040/00067/AM21/	Lic.No/Date:0710116585 11.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

559	**Case No.:342/2/82-ALC4/2020**	Party Name:AARTI DRUGS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01376/AM21/	RLA File :03/94/040/01084/AM20/	Lic.No/Date:0310836635 11.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

560	**Case No.:343/2/82-ALC4/2020**	Party Name:AARTI INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01377/AM21/	RLA File :03/94/040/00119/AM21/	Lic.No/Date:0310836651 12.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

561	**Case No.:344/2/82-ALC4/2020**	Party Name:VANDANA LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01378/AM21/	RLA File :09/24/040/00127/AM21/	Lic.No/Date:0910068863 12.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

562	**Case No.:345/2/82-ALC4/2020**	Party Name:CLEAN SCIENCE AND TECHNOLOGY PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Withdrawn**
	HQ File :01/82/050/01379/AM21/	RLA File :31/83/040/00017/AM21/	Lic.No/Date:3110067760 12.06.2020	
	Decision: The firm vide e-mail dated 24.07.2020 has informed that they are going to surrender the subject advance authorization. The Committee considered the case as per agenda in the presence of technical experts and in light of above e-mail of firm, it was decided to **withdraw** the case.			

563	**Case No.:346/2/82-ALC4/2020**	Party Name:MR CHEMIE INDIA PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01380/AM21/	RLA File :09/24/040/00129/AM21/	Lic.No/Date:0910068864 12.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

564	**Case No.:347/2/82-ALC4/2020**	Party Name:INDOCO REMEDIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01381/AM21/	RLA File :03/94/040/00161/AM21/	Lic.No/Date:0310836661 15.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

565	**Case No.:348/2/82-ALC4/2020**	Party Name:KOPRAN RESEARCH LABORATORIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01382/AM21/	RLA File :03/94/040/00156/AM21/	Lic.No/Date:0310836662 15.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

566	**Case No.:349/2/82-ALC4/2020**	Party Name:TIDE INDUSTRIES	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01383/AM21/	RLA File :34/24/040/00053/AM21/	Lic.No/Date:3410046153 15.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

567	**Case No.:350/2/82-ALC4/2020**	Party Name:FDC LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01384/AM21/	RLA File :03/94/040/00160/AM21/	Lic.No/Date:0310836666 15.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

568	**Case No.:352/2/82-ALC4/2020**	Party Name:AETHER INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01386/AM21/	RLA File :52/24/040/00017/AM21/	Lic.No/Date:5210043441 16.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

569	**Case No.:351/2/82-ALC4/2020**	Party Name:GLENMARK PHARMACEUTICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01385/AM21/	RLA File :03/94/040/00167/AM21/	Lic.No/Date:0310836705 17.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

570	**Case No.:353/2/82-ALC4/2020**	Party Name:BIOLOGICAL E LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01387/AM21/	RLA File :09/24/040/00637/AM20/	Lic.No/Date:0910068881 17.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

571	**Case No.:354/2/82-ALC4/2020**	Party Name:MAKCUR LABORATORIES LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01388/AM21/	RLA File :08/24/040/00062/AM21/	Lic.No/Date:0810147963 17.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

572	**Case No.:355/2/82-ALC4/2020**	Party Name:VERVE HUMAN CARE LABORATORIES	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01389/AM21/	RLA File :05/24/040/00027/AM21/	Lic.No/Date:0510414412 17.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

573	**Case No.:356/2/82-ALC4/2020**	Party Name:VERVE HUMAN CARE LABORATORIES	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01390/AM21/	RLA File :05/24/040/00098/AM21/	Lic.No/Date:0510414419 17.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

574	**Case No.:357/2/82-ALC4/2020**	Party Name:CONVERGENCE CHEMICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01391/AM21/	RLA File :34/24/040/00047/AM21/	Lic.No/Date:3410046157 17.06.2020	
	Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm: **(i) Certificate from independent Chemical Engineer indicating essentiality of this type of Catalyst in Fluorniation Reaction.** **(ii) Whether the Catalyst is used for single charge or can be recharged after regeneration.**			

575	**Case No.:358/2/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01392/AM21/	RLA File :03/94/040/00097/AM21/	Lic.No/Date:0310836716 17.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

576

Case No.:359/2/82-ALC4/2020	Party Name:PI INDUSTRIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Approved**
HQ File :01/82/050/01393/AM21/	RLA File :13/24/040/00015/AM21/	Lic.No/Date:1310049600 17.06.2020	

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to ratify the ad-hoc input output norms under para 4.07 of HBP Vol. I as per details below or as applied by firm whichever is lower:

Export Product	Qty.	Sl. No.	Import items	Qty.
LAKE PALACE (3-[(2,5-Dichloro-4-ethoxyphenyl)-methylsulfonyl]-4,5-dihydro-5,5-dimethylisoxazole)	1 kg	1	Glyoxalic acid 50% Min.	0.755 kg
		2	Hydroxylamine Sulphate	0.435 kg
		3	Bromine	1.387 kg
		4	Thiourea	0.286 kg
		5	Methyl Tertiary Butyl Ether	0.178 kg
		6	Paraformaldehyde	0.576 kg
		7	n-Butyl Acetate	0.857 kg
		8	Acetonitrile	0.923 kg
		9	Iso propyl alcohol	0.225 kg
		10	2, 5-Dichloro Phenol	0.537 kg

RA concerned may take further necessary action as per above decision of NC.

577	**Case No.:360/2/82-ALC4/2020**	Party Name:RA CHEM PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01394/AM21/	RLA File :09/24/040/00169/AM21/	Lic.No/Date:0910068886 18.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

578	**Case No.:361/2/82-ALC4/2020**	Party Name:AURORE LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01395/AM21/	RLA File :09/24/040/00628/AM20/	Lic.No/Date:0910068890 18.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

579	**Case No.:362/2/82-ALC4/2020**	Party Name:J.B. CHEMICALS & PHARMACEUTICALS LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01396/AM21/	RLA File :03/94/040/00172/AM21/	Lic.No/Date:0310836729 18.06.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

580	**Case No.:363/2/82-ALC4/2020**	Party Name:BENZO CHEM INDUSTRIES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01397/AM21/	RLA File :03/94/040/00169/AM21/	Lic.No/Date:0310836740 18.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

581	**Case No.:364/2/82-ALC4/2020**	Party Name:VERGO PHARMA RESEARCH LABORATORIES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01398/AM21/	RLA File :03/95/040/00137/AM21/	Lic.No/Date:0310836741 18.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

582	**Case No.:365/2/82-ALC4/2020**	Party Name:HALDIA PETROCHEMICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01399/AM21/	RLA File :02/24/040/00027/AM21/	Lic.No/Date:0210209928 18.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

583	**Case No.:366/2/82-ALC4/2020**	Party Name:HALDIA PETROCHEMICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01400/AM21/	RLA File :02/24/040/00028/AM21/	Lic.No/Date:0210209929 18.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

584	**Case No.:367/2/82-ALC4/2020**	Party Name:ORTIN LABORATORIES LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01401/AM21/	RLA File :09/24/040/00116/AM21/	Lic.No/Date:0910068892 18.06.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

585	**Case No.:368/2/82-ALC4/2020**	Party Name:CIPLA LIMITED.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01402/AM21/	RLA File :03/94/040/00166/AM21/	Lic.No/Date:0310836755 19.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

586	**Case No.:369/2/82-ALC4/2020**	Party Name:CIPLA LIMITED.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01403/AM21/	RLA File :03/94/040/00176/AM21/	Lic.No/Date:0310836757 19.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

587	**Case No.:370/2/82-ALC4/2020**	Party Name:VERVE HUMAN CARE LABORATORIES	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01404/AM21/	RLA File :05/24/040/00070/AM21/	Lic.No/Date:0510414451 19.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

588	**Case No.:371/2/82-ALC4/2020**	Party Name:AETHER INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01405/AM21/	RLA File :52/24/040/00016/AM21/	Lic.No/Date:5210043443 19.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

589	**Case No.:372/2/82-ALC4/2020**	Party Name:BALAJI SPECIALITY CHEMICALS PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01406/AM21/	RLA File :31/83/040/00021/AM21/	Lic.No/Date:3110067767 22.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

590	**Case No.:373/2/82-ALC4/2020**	Party Name:PIRAMAL ENTERPRISES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01407/AM21/	RLA File :03/95/040/00153/AM21/	Lic.No/Date:0310836784 22.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

591	**Case No.:374/2/82-ALC4/2020**	Party Name:YASHO INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01408/AM21/	RLA File :03/95/040/00168/AM21/	Lic.No/Date:0310836789 22.06.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

592	**Case No.:375/2/82-ALC4/2020**	Party Name:AETHER INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01409/AM21/	RLA File :52/24/040/00018/AM21/	Lic.No/Date:5210043446 23.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

593	**Case No.:376/2/82-ALC4/2020**	Party Name:BIOXERA PHARMA PVT LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01410/AM21/	RLA File :03/94/040/00175/AM21/	Lic.No/Date:0310836812 23.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

594	**Case No.:377/2/82-ALC4/2020**	Party Name:AMI LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01411/AM21/	RLA File :34/24/040/00069/AM21/	Lic.No/Date:3410046168 23.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

595	**Case No.:378/2/82-ALC4/2020**	Party Name:AMI LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01412/AM21/	RLA File :34/24/040/00067/AM21/	Lic.No/Date:3410046169 23.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

596	**Case No.:379/2/82-ALC4/2020**	Party Name:AMI LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01413/AM21/	RLA File :34/24/040/00068/AM21/	Lic.No/Date:3410046170 23.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

597	**Case No.:380/2/82-ALC4/2020**	Party Name:AMI LIFE SCIENCES PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01414/AM21/	RLA File :34/24/040/00066/AM21/	Lic.No/Date:3410046171 23.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

598	**Case No.:381/2/82-ALC4/2020**	Party Name:SONGWON SPECIALTY CHEMICALS INDIA PVT. LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01415/AM21/	RLA File :34/24/040/00060/AM21/	Lic.No/Date:3410046173 23.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

599	**Case No.:382/2/82-ALC4/2020**	Party Name:SONGWON SPECIALTY CHEMICALS INDIA PVT. LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01416/AM21/	RLA File :34/24/040/00064/AM21/	Lic.No/Date:3410046174 23.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

600	**Case No.:383/2/82-ALC4/2020**	Party Name:HALDIA PETROCHEMICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01417/AM21/	RLA File :02/24/040/00030/AM21/	Lic.No/Date:0210209934 23.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

601	**Case No.:384/2/82-ALC4/2020**	Party Name:HALDIA PETROCHEMICALS LTD	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01418/AM21/	RLA File :02/24/040/00031/AM21/	Lic.No/Date:0210209935 23.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

602	**Case No.:385/2/82-ALC4/2020**	Party Name:UPL LTD.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01419/AM21/	RLA File :03/95/040/00134/AM21/	Lic.No/Date:0310836829 23.06.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

603	**Case No.:386/2/82-ALC4/2020**	Party Name:U K AROMATICS & CHEMICALS	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01420/AM21/	RLA File :03/95/040/00181/AM21/	Lic.No/Date:0310836830 23.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

604	**Case No.:387/2/82-ALC4/2020**	Party Name:CLEAN SCIENCE AND TECHNOLOGY PRIVATE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01421/AM21/	RLA File :31/83/040/00022/AM21/	Lic.No/Date:3110067771 24.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

605	**Case No.:388/2/82-ALC4/2020**	Party Name:RONAK CHEMICALS	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01422/AM21/	RLA File :34/24/040/00017/AM21/	Lic.No/Date:3410046180 24.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

606	**Case No.:389/2/82-ALC4/2020**	Party Name:CADILA HEALTHCARE LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01423/AM21/	RLA File :08/24/040/00071/AM21/	Lic.No/Date:0810147995 25.06.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

607	**Case No.:390/2/82-ALC4/2020**	Party Name:CIPLA LIMITED.	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01424/AM21/	RLA File :03/94/040/00193/AM21/	Lic.No/Date:0310836876 25.06.2020	
	Decision: This case appeared for the first time before Norms Committee.The Committee noted that the 4.07 application of subject Advance Authorization is not available. Hence, it was decided to call for a copy of 4.07 application of the subject advance authorization directly from the firm as per Policy Circular No. 23/2015-20, dated 15.05.2019.			

608	**Case No.:391/2/82-ALC4/2020**	Party Name:GLAND PHARMA LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01425/AM21/	RLA File :09/24/040/00138/AM21/	Lic.No/Date:0910068902 25.06.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

609	**Case No.:392/2/82-ALC4/2020**	Party Name:YASHO INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01426/AM21/	RLA File :03/95/040/00182/AM21/	Lic.No/Date:0310836907 26.06.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

610	**Case No.:393/2/82-ALC4/2020**	Party Name:YASHO INDUSTRIES LIMITED	Meet No/Date:2/82-ALC4/2020 10.07.2020	**Status: Deferred**
	HQ File :01/82/050/01427/AM21/	RLA File :03/95/040/00178/AM21/	Lic.No/Date:0310836909 26.06.2020	
	Decision: This case appeared for the first time before Norms Committee. Deferred for comments of TE.			

MANUAL CASES

Case No.	**B- 01**
Meeting No.	**2/AM21**
Date	**24.07.2020**
Firm's Name	**M/s Jubilant Life Sciences Limited, Noida**
HQ F. No.	01/82/050/00061/AM15/DES-III
RLA F. No.	05/23/040/00506/AM14
Advance Authorization No. and Date	**0510382053 dated 18.03.2014**
Subject	**Request of M/s Jubilant Life Sciences Limited, Noida for revision/correction in adhoc norms fixed against Advance Authorization No. 0510382053 dated 18.03.2014**

Decision: The Committee considered the request of firm in the presence of technical experts and based on the best consumption-coefficient of inputs in line with the Production-Consumption Data (CA certified), it was decided to revise the norms as under:

Export Product	Qty.	Sl. No.	Import items	Qty.
Pyridine 2 Aldehyde	1 kg	1	**Alpha Picoline**	**2.64 kg**
		2	Acetic Acid	1.75 kg
		3	Hydrogen Peroxide	2.50 kg
		4	**Caustic Lye**	**0.966 kg**
		5	Selenium dioxide	0.050 kg
		6	**EDC**	**1.10 kg**

Note: Above revised norms may be restricted to only this Advance Authorization for closure and regularization purpose only. No further licence may be issued on repeat basis based on these norms. No fresh import may be allowed against these advance authorizations.

RA concerned may take further necessary action as per above decision of NC.

Case No.	**B- 02**
Meeting No.	**2/AM21**
Date	**24.07.2020**
Firm's Name	**M/s Jubilant Life Sciences Limited, Noida**
HQ F. No.	01/82/050/01038/AM15/DES-III
RLA F. No.	05/23/040/00218/AM15
Advance Authorization No. and Date	0510391491 dated 08.10.2014
Subject	**Request of M/s Jubilant Life Sciences Limited, Noida for fixation of adhoc norms against Advance Authorization No. 0510391491 dated 08.10.2014**

Decision: The Committee considered the request of firm in the presence of technical experts and based on the best consumption-coefficient of inputs in line with the Production-Consumption Data (CA certified), it was decided to revise the norms as under:

Export Product	Qty.	Sl. No.	Import items	Qty.
Pyridine 2 Aldehyde	1 kg	1	**Alpha Picoline**	**2.64 kg**
		2	Acetic Acid	1.75 kg
		3	Hydrogen Peroxide	2.50 kg
		4	**Caustic Lye**	**0.966 kg**
		5	Selenium dioxide	0.050 kg
		6	**EDC**	**1.10 kg**

Note: Above revised norms may be restricted to only this Advance Authorization for closure and regularization purpose only. No further licence may be issued on repeat basis based on these norms. No fresh import may be allowed against these advance authorizations.

RA concerned may take further necessary action as per above decision of NC.

Case No.	**B-03**
Meeting No.	**2/AM21**
Date	**24.07.2020**
Firm's Name	**M/s Jubilant Life Sciences Limited, Noida**
HQ F. No.	01/82/050/00300/AM19/DES-III 01/82/050/00298/AM19/DES-III 01/82/050/00301/AM19/DES-III 01/82/050/00325/AM19/DES-III 01/82/050/00320/AM19/DES-III
RLA F. No.	05/23/040/00459/AM18 05/23/040/00460/AM18 05/23/040/00472/AM18 05/23/040/00495/AM18 05/23/040/00415/AM18
Advance Authorization No. and Date	0510405843 dated 12.03.2018 0510405828 dated 09.03.2018 0510405869 dated 14.03.2018 0510406030 dated 02.04.2018 0510406312 dated 03.05.2018
Subject	**Request of M/s Jubilant Life Sciences Limited, Noida to allow import of Propionaldehyde in respect of adhoc norms fixed against Advance Authorization Nos. 0510405843 dated 12.03.2018; 0510405828 dated 09.03.2018; 0510405869 dated 14.03.2018; 0510406030 dated 02.04.2018 and 0510406312 dated 03.05.2018.**

Decision: The Committee considered the request of firm in the presence of technical experts and it was decided to revise the norms as under:

Export product	Qty.	Sl. No.	Import items	Qty.
Pyridine 98% Min	1 kg	1	Alumino Silicate Catalyst	0.019 kg
		2	Ethyl Alcohol (Denatured)	2.194 kg
		3	**Propionaldehyde**	**0.073 kg**
		4	Methanol	1.41 kg

RA concerned may take further necessary action as per above decision of NC.

Case No.	**B-04**
Meeting No.	**2/AM21**
Date	**24.07.2020**
Firm's Name	**M/s Jubilant Life Sciences Limited, Noida**
HQ F. No.	01/82/050/00594/AM18/DES-III 01/82/050/00674/AM18/DES-III 01/82/050/00963/AM18/DES-III 01/82/050/00650/AM18/DES-III
RLA F. No.	05/23/040/00100/AM18 05/23/040/00134/AM18 05/23/040/00276/AM18 05/23/040/00178/AM18
Advance Authorization No. and Date	0510403698 dated 17.08.2017 0510403700 dated 17.08.2017 0510404542 dated 08.11.2017 0510403838 dated 29.08.2017
Subject	**Request of M/s Jubilant Life Sciences Limited, Noida to allow Import Item No. 4 - Propionaldehyde against Advance Licence Nos. 0510403698 date 17.08.2017, 0510403700 date 17.08.2017, 0510404542 date 08.11.2017, 0510403838 date 29.08.2017, under para 4.07 of HBP 2015-20**

Decision: The Committee considered the request of firm in the presence of technical experts and it was decided to revise the norms as under:

Export product	Qty.	Sl. No.	Import items	Qty.
Piperidine (Min Purity 99%)	1 kg	1	Ruthenium Alumina Catalyst (Ruthenium 5%)	0.00196 kg
		2	Alumina Silicate Catalyst	0.019 kg
		3	Denatured Ethyl Alcohol	2.242 kg
		4	**Propionaldehyde**	**0.075 kg**
		5	Methanol	1.441 kg

RA concerned may take further necessary action as per above decision of NC.

Case No.	B-05
Meeting No.	2/AM21
Date	24.07.2020
Firm's Name	**M/s Jubilant Life Sciences Limited, Noida**
HQ F. No.	01/82/050/02221/AM19/DES-III
RLA F. No.	05/23/040/00302/AM19
Advance Authorization No. and Date	0510409073 dt. 26.12.2018
Subject	**Request of M/s Jubilant Life Sciences Limited, Noida to allow Import Item No. 5 - Propionaldehyde in respect of adhoc norms fixed against Advance Authorization No. 0510409073 dt. 26.12.2018**

Decision: The Committee considered the request of firm in the presence of technical experts and it was decided to revise the norms as under:

Export product	Qty.	Sl. No.	Import items	Qty.
Piperidine (Min Purity 99%)	1 kg	1.	Ruthenium Alumina Catalyst (Ruthenium 5%)	0.00196
		2.	Alumina Silicate Catalyst	0.01896
		3.	Denatured Ethyl Alcohol	2.242
		4.	Methanol	1.441
		5.	**Propionaldehyde**	**0.075 kg**

RA concerned may take further necessary action as per above decision of NC.

Case No.	**B-06**
Meeting No.	**2/AM21**
Date	**24.07.2020**
Firm's Name	**M/s Jubilant Life Sciences Limited, Noida**
HQ F. No.	01/82/050/00302/AM19/DES-III 01/82/050/00326/AM19/DES-III 01/82/050/00327/AM19/DES-III 01/82/050/00759/AM18/DES-III 01/82/050/00146/AM19/DES-III
RLA F. No.	05/23/040/00392/AM18 05/23/040/00496/AM18 05/23/040/00497AM18 05/23/040/00256/AM18 05/23/040/00381/AM18
Advance Authorization No. and Date	0510405866 dated 13.03.2018 0510406033 dated 02.04.2018 0510406032 dated 02.04.2018 0510404483 dated 02.11.2017 0510405723 dated 27.02.2018
Subject	**Request of M/s Jubilant Life Sciences Limited, Noida to allow import of Propionaldehyde in respect of adhoc norms fixed against Advance Authorization Nos. 0510405866 dated 13.03.2018; 0510406033 dated 02.04.2018; 0510406032 dated 02.04.2018; 0510404483 dated 02.11.2017 and 0510405723 dated 27.02.2018**

Decision: The Committee considered the request of firm in the presence of technical experts and it was decided to revise the norms as under:

Export product	Qty.	Sl. No.	Import items	Qty.
Piperidine (Min Purity 99%)	1 kg	1	Ruthenium Alumina Catalyst (Ruthenium 5%)	0.00196 kg
		2	Alumina Silicate Catalyst	0.019 kg
		3	Denatured Ethyl Alcohol	2.242 kg
		4	**Propionaldehyde**	**0.075 kg**
		5	Methanol	1.441 kg

RA concerned may take further necessary action as per above decision of NC.

Case No.	**B-07**
Meeting No.	**2/AM21**
Date	**24.07.2020**
Firm's Name	**M/s Jubilant Life Sciences Limited, Noida**
HQ F. No.	01/82/050/00034/AM20/DES-III 01/82/050/00170/AM20/DES-III
RLA F. No.	05/23/040/00566/AM19 05/23/040/00530/AM19
Advance Authorization No. and Date	**0510410180 dated 09.04.2019** **0510410582 dated 14.05.2019**
Subject	**Request of M/s Jubilant Life Sciences Limited, Noida for revision/correction in adhoc norms fixed against Advance Authorization Nos. 0510410180 dated 09.04.2019 and 0510410582 dated 14.05.2019**

Decision: The Committee considered the request of firm in the presence of technical experts and it was decided to revise the norms as under:

Export product	Qty.	Sl. No.	Import items	Qty.
Piperidine (Min Purity 99%)	1 kg	1	Ruthenium Alumina Catalyst (Ruthenium 5%)	0.00196 kg
		2	Alumina Silicate Catalyst	0.019 kg
		3	Denatured Ethyl Alcohol	2.242 kg
		4	**Propionaldehyde**	**0.075 kg**
		5	Methanol	1.441 kg

RA concerned may take further necessary action as per above decision of NC.

Case No.	**B-08**
Meeting No.	**2/AM21**
Date	**24.07.2020**
Firm's Name	**M/s Jubilant Life Sciences Limited, Noida**
HQ F. No.	01/82/050/02173/AM19/DES-III
RLA F. No.	05/23/040/00243/AM19
Advance Authorization No. and Date	**0510408887 dated 13.12.2018**
Subject	**Request of M/s Jubilant Life Sciences Limited, Noida for revision/correction in adhoc norms fixed against Advance Authorization No. 0510408887 dated 13.12.2018**

Decision: The Committee considered the request of firm in the presence of technical experts and it was decided to revise the norms as under:

Export product	Qty.	Sl. No.	Import items	Qty.
Beta Picoline	1 kg	1	Denatured Ethyl Alcohol	1.121 kg
		2	Propionaldehyde	0.057 kg
		3	Methanol	0.76 kg
		4	Ammonia	0.82 kg
		5	Alumino Silicate Catalyst	0.007 kg
Piperidine (Min Purity 99%)	1 kg	1	Ruthenium Alumina Catalyst (Ruthenium 5 %)	0.00196 kg
		2	Alumina Silicate Catalyst	0.01896 kg
		3	Denatured Ethyl Alcohol	2.242 kg
		4	**Propionaldehyde**	**0.075 kg**
		5	Methanol	1.441 kg

RA concerned may take further necessary action as per above decision of NC.

Case No.	**B-09**
Meeting No.	**2/AM21**
Date	**24.07.2020**
Firm's Name	M/s Satyadeva Pharmaceuticals Pvt. Ltd, Hyderabad
HQ F. No.	01/82/050/01070/AM18/DES-III
RLA F. No.	09/24/040/00337/AM18
Advance Authorization No. and Date	0910065537 dated 05.10.2017
Subject	**Request of M/s Satyadeva Pharmaceuticals Pvt. Ltd, Hyderabad for fixation of adhoc norms against Advance Authorization No. 0910065537 dated 05.10.2017**

Decision: The Committee considered the request of the firm in the presence of technical experts and it was decided to call for following information from the firm:

(i) Import items and quantities actually imported against these exports.
(ii) Complete technical details including chemistry, yields, material balance for each stage.

Case No.	**B- 10**
Meeting No.	**2/AM21**
Date	**24.07.2020**
Firm's Name	M/s Aether Industries Ltd., Surat
HQ F. No.	01/82/050/02615/AM19/DES-III
RLA F. No.	52/24/040/00097/AM19
Advance Authorization No. and Date	5210043009 dated 25.03.2019
Subject	Request of M/s Aether Industries Ltd, Surat for revision/correction in adhoc norms fixed against Advance Authorization No. 5210043009 dated 25.03.2019

Decision: The Committee considered the request of the firm in the presence of technical experts and it was observed that NC inadvertently ratified the norms with the description of Import item No. 2 as **ETHYLENE OXIDE instead of TETRAHYDRO FURAN**.

In view of above, it was decided to revise the norms as under:

Export product	**Qty.**	**Sl. No**	**Import items**	**Qty.**
4-(2-METHOXYETHYL) PHENOL	1 kg	1.	PARA CHLORO PHENOL	**2.42 kg**
		2.	**TETRAHYDRO FURAN**	**1.00 kg**

RA concerned may take further necessary action as per above decision of NC.

Case No.	**B- 11**
Meeting No.	**2/AM21**
Date	**24.07.2020**
Firm's Name	**M/s Oriental Aromatics Ltd., Mumbai**
HQ F. No.	01/82/050/01633/AM19/DES-III
RLA F. No.	03/95/040/00728/AM19
Advance Authorization No. and Date	0310824506 dated 17.10.2018
Subject	**Request of M/s Oriental Aromatics Ltd., Mumbai for correction / revision in the description of Export Product in respect of Advance Authorization No. 0310824506 dated 17.10.2018**

Decision: The Committee considered the request of the firm in the presence of technical experts and it was decided to correct the description of Export Product to read as "**CAMPHOR (USP)"**. Rest of the earlier Minutes of this case would remain the same.

RA concerned may take further necessary action as per above decision of NC.

Case No.	**B-12**
Meeting No.	**2/AM21**
Date	**24.07.2020**
Firm's Name	**M/s Glenmark Pharmaceuticals Ltd, Mumbai**
HQ F. No.	01/82/050/00738/AM20/DES-III
RLA F. No.	03/94/040/00560/AM20
Advance Authorization No. and Date	0310832260 dated 16.10.2019
Subject	**Request of M/s Glenmark Pharmaceuticals Ltd, Mumbai, for revision/correction in adhoc norms fixed against Advance Authorization No. 0310832260 dated 16.10.2019**

Decision: The Committee considered the request of firm in the presence of technical experts and it was decided to revise the norms as under:

Export Product:

1. Desonide Cream 0.05% 15gm (Net Wt. of Desonide USP Micronised (Sicor) is 0.188 Kgs)
2. Desonide Cream 0.05% 60gm (Net Wt. of Desonide USP Micronised (Sicor) is 0.750 Kgs)
3. **Desonide Lotion 0.05% 59ml (Net Wt. of Desonide USP Micronised (Sicor) is 0.738 Kgs)**
4. **Desonide Lotion 0.05% 118ml (Net Wt. of Desonide USP Micronised (Sicor) is 1.475 Kgs)**
5. Desonide Ointment 0.05% 15gm (Net Wt. of Desonide USP Micronised (Sicor) is 0.188 Kgs)
6. Desonide Ointment 0.05% 60gm (Net Wt. of Desonide USP Micronised (Sicor) is 0.750 Kgs)

SI. No.	**Imort Items**	**For the Export of 1 No. Tablet**					
		0.05% 15gm pack	0.05% 60gm pack	**0.05% 59ml pack**	**0.05% 118ml pack**	0.05% 15gm pack	0.05% 60gm pack
1	Desonide USP Micronised (Sicor)	0.00765 gm	0.0306 gm	**0.0301 gm**	**0.0602 gm**	0.00765 gm	0.0306 gm

RA concerned may take further necessary action as per above decision of NC.

Case No.	**B-13**
Meeting No.	**2/AM21**
Date	**24.07.2020**
Firm's Name	**M/s O C Specialities Pvt. Ltd., Mumbai**
HQ F. No.	01/82/050/00564/AM20/DES-III
RLA F. No.	03/95/040/00528/AM20
Advance Authorization No. and Date	0310831252 dated 27.08.2019
Subject	**Request of M/s O C Specialties Pvt Ltd, Mumbai for revision/correction in adhoc norms fixed against Advance Authorization No. 0310831252 dated 27.08.2019**

Decision: The Committee considered the request of firm in the presence of technical experts and it was decided to revise the norms as under:

Export product	**Qty.**	**Sl. No.**	**Import items**	**Qty.**
3-CHLORO-2-HYDRAZINE PYRIDINE (KC-190)	1 kg	1	3 AMINO PYRIDINE	1.30 kg
		2	HYDROGEN PEROXIDE	0.942 kg
		3	SODIUM NITRITE	0.950 kg
		4	**HYDRAZINE HYDRATE (100 %)**	**1.34 kg**

RA concerned may take further necessary action as per above decision of NC.

Case No.	**B-14**
Meeting No.	**2/AM21**
Date	**24.07.2020**
Firm's Name	**M/s India Glycols Limited, New Delhi**
HQ F. No.	01/82/050/00846/AM19/DES-III
RLA F. No.	05/23/040/00485/AM18
Advance Authorization No. and Date	0510405825 dated 09.03.2018
Subject	**Request of M/s India Glycols Limited, New Delhi for enhancement in the quantity of Import Item No. 2 – Silver Catalyst in respect of adhoc norms fixed against Advance Authorization No. 0510405825 dated 09.03.2018**

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to revise the norms as under:

Export product	Qty.	Sl. No.	Import items	Qty.
Mono Ethylene Glycol (MEG)	1 kg	1	Denatured Ethyl Alcohol	1.123 kg
		2	**Silver Catalyst (Activity 17% to 18%)**	**0.000284 kg**
		3	Alumina Catalyst	0.000362 kg

RA concerned may take further necessary action as per above decision of NC.

Case No.	**B-15**
Meeting No.	2/AM21
Date	24.07.2020
Firm's Name	**M/s Shree Ganesh Remedies Pvt. Ltd., Vadodara**
HQ F. No.	01/82/050/00696/AM16/DES-III
RLA F. No.	34/24/040/00295/AM15
Advance Authorization No. and Date	3410040965 dated 16.02.2015
Subject	**Request of M/s Shree Ganesh Remedies Ltd., Vadodara for review of norms fixed against Advance Authorization No. 3410040965 dated 16.02.2015 (Grievance Registration No. DOCOM/E/2020/00340 dated 30.03.2020)**

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to call for following information from the firm:

(i) Complete technical details as per Appendix 4E including percentage of yield, stoichiometric balance and recovery of solvent.

Case No.	**B-16**
Meeting No.	**2/AM21**
Date	**24.07.2020**
Firm's Name	**M/s Jubilant Life Sciences Limited, Noida**
HQ F. No.	01/82/050/00966/AM18/DES-III 01/82/050/00423/AM18/DES-III 01/82/050/01043/AM18/DES-III 01/82/050/00145/AM19/DES-III
RLA F. No.	05/23/040/00323/AM18 05/23/040/00613/AM17 05/23/040/00269/AM18 05/23/040/00430/AM18
Advance Authorization No. and Date	0510404839 dated 11.12.2017 0510402583 dated 16.05.2017 0510404598 dated 14.11.2017 0510405736 dated 27.02.2018
Subject	**Request of M/s Jubilant Life Sciences Limited, Noida to allow Import Item No. 4 - Propionaldehyde against Advance Licence Nos. 0510404839 dated 11.12.2017, 0510402583 dated 16.05.2017, 0510404598 dated 14.11.2017 and 0510405736 dated 27.02.2018, under para 4.7 of HBP 2015-20**

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to revise the norms as under:

For Advance Authorization Nos. 0510404839 dated 11.12.2017, 0510402583 dated 16.05.2017 and 0510404598 dated 14.11.2017

Export product	Qty.	Sl. No.	Import items	Qty.
3 Cyano Pyridine	1 kg	1	Denatured Ethyl Alcohol	2.229 kg
		2	Methanol	1.405 kg
		3	Alumino Silicate Catalyst	0.023 kg
		4	**Propionaldehyde**	**0.069 kg**

For Advance Authorization No. 0510405736 dated 27.02.2018

Export product	Qty.	Sl.No.	Import items	Qty.
Pyridine 98% Min	1 kg	1	Alumino Silicate Catalyst	0.019 kg
		2	Ethyl Alcohol (Denatured)	2.294 kg
		3	Propionaldehyde	0.073 kg
		4	Methanol	1.41 kg
3 Cyano Pyridine	1 kg	5	Denatured Ethyl Alcohol	2.229 kg
		6	Methanol	1.405 kg
		7	Alumino Silicate Catalyst	0.023kg
		8	Propionaldehyde	**0.069 kg**

RA concerned may take further necessary action as per above decision of NC.

Case No.	**B-17**
Meeting No.	**2/AM21**
Date	**24.07.2020**
Firm's Name	**M/s Jubilant Life Sciences Limited, Noida**
HQ F. No.	01/82/050/00303/AM19/DES-III
RLA F. No.	05/23/040/00352/AM18
Advance Authorization No. and Date	0510405865 dated 13.03.2018
Subject	**Request of M/s Jubilant Life Sciences Limited, Noida to allow import of Propionaldehyde in respect of adhoc norms fixed against Advance Authorization No. 0510405865 dated 13.03.2018**

Decision: The Committee considered case as per agenda in the presence of the technical experts and it was decided to revise the norms as under:

Export product	Qty.	Sl. No.	Import items	Qty.
3 Cyano Pyridine	1 kg	1	Denatured Ethyl Alcohol	2.229 kg
		2	Methanol	1.405 kg
		3	Alumino Silicate Catalyst	0.023 kg
		4	**Propionaldehyde**	**0.069 kg**

RA concerned may take further necessary action as per above decision of NC.

Meeting ended with thanks to Chair and participants

*****